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Abstract 
Background: Gastroschisis is a paraumbilical abdominal wall defect through which 
the bowel herniates. The bowel is in direct contact with the amniotic fluid. At birth 
the bowel is often thickened and shortened. The main gastroschisis-related morbidity 
is that of intestinal dysmotility but the mechanism(s) underlying this are poorly 
understood and no treatment advances have occurred since the advent of parenteral 
nutrition. Human studies have shown that the third trimester amniotic fluid of 
gastroschisis pregnancies is proinflammatory. In addition, in animal models of 
gastroschisis and human pathological gut tissue interstitial cells of Cajal (ICC – 
pacemaker cells of the gut) have been found to be decreased in number and immature 
within gastroschisis bowel.  
Hypotheses: Gastroschisis-related intestinal dysfunction (GRID) is secondary to 
deficient, immature bowel wall ICC. 
Aims: My primary aim in this thesis was to investigate the development of ICC in 
gastroschisis utilising genetic animal models and human pathological gut tissue. 
Additionally, I aimed to determine the overall morphology of gastroschisis bowel 
wall, the impact of inflammatory modulation on bowel wall development and the 
impact of clinical antenatal interventions on infant outcomes.  
Methods: Quantitative analysis of bowel wall ICC, enteric neurons and architecture 
were performed utilising genetic animal gastroschisis models and human 
pathological tissue. Modulation of in-utero inflammation was performed through in-
utero injections of IL-8 (pro-inflammatory protein) in a genetic animal gastroschisis 
model. Finally, retrospective clinical data on gastroschisis were collected from three 
paediatric surgical centres to determine whether early delivery or administration of 
maternal antenatal corticosteroids could improve infant morbidity. 
Results: Phenotypic analysis of the Scribble knockout mouse model revealed the 
expressed abdominal wall defect (AWD) to be that of exomphalos rather than 
gastroschisis. Additionally, phenotypic analysis of the aortic carboxypeptidase-like 
protein (ACLP) knockout mouse showed the AWD was not characteristic of 
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gastroschisis as the externalised bowel was free floating within exocoelomic fluid 
and not the amniotic fluid. Bowel wall ICC were architecturally normal but reduced 
in number in AWD fetuses compared to controls. In-utero injection of IL-8 further 
reduced ICC numbers. In contrast, analysis of human pathological gut tissue showed 
no difference in the number or architecture of bowel wall ICC between gastroschisis 
and control tissue. However, the gastroschisis bowel wall was significantly thicker 
than that of controls with evidence of smooth muscle hyperplasia and deficiency of 
α-smooth muscle actin within the longitudinal muscle layer. 
The clinical retrospective data showed that early delivery of gastroschisis fetuses did 
not improve bowel function and was associated with prolonged time to full enteral 
feeds and length of hospital stay. Additionally, there was no evidence that 
administration of maternal antenatal corticosteroids improved time to full enteral 
feeds or length of hospital stay in gastroschisis infants. 
Conclusions: Phenotypic analysis of abdominal wall defects in murine models is 
challenging. However, accurate delineation of the defect anatomy is essential to 
ensure appropriate result reporting and data analysis. The presented data suggests the 
ICC may be less important as the cause of GRID than originally expected. However, 
another potential cause for GRID is bowel wall thickening comprising of smooth 
muscle hyperplasia and possible bowel myopathy for which there are several 
hypothesised triggers. Additionally, the data presented in this thesis do not support 
early delivery of gastroschisis fetuses or the administration of maternal antenatal 
corticosteroids as methods to improve gastroschisis infant outcomes.   
The results of this thesis have generated some important findings and have 
highlighted a number of novel hypotheses for the trigger of GRID. Further research 
on the basis of these findings within an appropriate animal model and through 
prospective non-invasive human studies are required in order to develop a targeted 
antenatal therapy to improve gastroschisis infant bowel function and clinical 
outcomes. 
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Impact Statement 
The research presented in this thesis significantly adds to the scientific literature on 
the pathophysiology of gastroschisis-related intestinal dysfunction (GRID) and has 
been presented at international conferences and published in peer review journals. In 
particular, the data presented contradicts the current literature on the pathophysiology 
of GRID providing evidence for a potential alternative mechanism and reclassifies 
the phenotypic description of two genetic mouse abdominal wall defect models that 
have previously been reported as gastroschisis in the literature. This will enable 
future research to build on this knowledge and potentially help develop novel 
therapies for GRID shortening the time to full enteral feeds, duration of parenteral 
nutrition and length of hospital stay for gastroschisis infants. The clinical data 
generated from the large retrospective cohort studies will help provide guidance to 
clinicians treating women with a gastroschisis pregnancy in fetal medicine centres 
and enable more informed discussions when counselling the expectant parents. 
Methodologically this thesis describes a novel micro-MRI technique for the 
phenotyping of fetal mouse abdominal wall defects, which could be of value for the 
phenotyping of other structural abnormalities of the abdominal wall and also other 
organ systems in fetal genetic mouse models. Additionally, robust cell quantification 
techniques were developed during this research for the analysis of bowel wall 
interstitial cells of Cajal and enteric neurons, which will be of value to other 
researchers within this field and may help standardise cell quantification making data 
more comparable and reproducible.  
This research adds to the literature, which aims to improve gastroschisis infant 
outcomes and the lives of the patient and their families. As the scientific knowledge 
of the cause of GRID grows this brings the scientific and medical community closer 
to helping affected infants to achieve enteral autonomy and leave hospital sooner. 
This will not only improve the health of the infant and reduce the risk of 
complications such as sepsis but will reunite families quicker. Frequently parents 
have to travel long distances or live away from home during their newborns hospital 
stay due to the care required being located in tertiary referral centres that may be a 
long distance from home. A shorter hospital stay will allow families to bond quicker, 
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reduce parental expense of travelling/accommodation and the stress of living apart 
improving the lives of not just the infant but their family too.  
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Chapter 1: Introduction 
1.1 Overview 
The work in this thesis concerns gastroschisis which is a congenital abdominal wall 
defect that results in significant intestinal dysfunction at birth requiring prolonged 
duration of parenteral nutrition and hospital stay. In order to fully consider this 
condition it is important to introduce the normal structure and function of the gut, 
fetal development, clinical aspects of gastroschisis, current understanding of 
gastroschisis-related intestinal dysfunction and animal models of gastroschisis.  
1.2 Normal Function and Structure of the Gut 
1.2.1 Functions of the Gut 
The alimentary tract (mouth, pharynx, oesophagus, stomach, jejunum, ileum, colon, 
rectum and anus) plus the connected accessory secretory organs (salivary glands, 
liver, gall bladder and pancreas) performs multiple coordinated functions in order to 
achieve nutritional absorption, which is essential for survival. Coordinated action of 
voluntary and smooth muscle of the palate and pharynx is required to achieve a safe 
swallow and ingestion of macromolecules. Appropriate stimulation of secretory cells 
and accessory secretory organs releases digestive enzymes, acid and bile into the 
gastrointestinal lumen. Digestion requires effective mixing and prolusion (gut 
peristalsis) of the secretory products and ingested luminal contents in order to enable 
breakdown of the ingested macromolecules. Absorption of the resultant 
micromolecules, electrolytes and water is achieved primarily by the jejunum and 
ileum but also partly by the colon at an extensive brush boarder providing a large 
surface area for absorption. The undigested or non-absorbable luminal contents are 
then eliminated from the body by defaecation. Dysregulation of any of the four 
essential functions (motility, secretion, digestion and absorption) prevents enteral 
autonomy and requires supportive approaches to ensure appropriate nutritional intake 
(Vander et al., 2001).  
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Additionally, the gut houses an extensive microbiome of more than 100 trillion 
microorganisms, which is important for digestion, intestinal motility, intestinal 
development, digestion, synthesis of vitamins, defence against infection, immune 
modulation, brain development and behaviour (Slattery et al., 2016, Lynch and 
Pedersen, 2016). The gut microbiome differs greatly between individuals that begins 
to be seeded in-utero and continues to develop during infancy and childhood 
(Romano-Keeler and Weitkamp, 2015, Tamburini et al., 2016). A steady state is 
thought to be achieved during adolescence, which persists throughout adult life until 
a decline in stability and function of the microbiome occurs in older age (Hollister et 
al., 2015). The composition of the microbiome is thought to be influenced by several 
factors including the environment, diet (including type of feed from birth), genetics, 
mode of delivery, age, medical treatments and early microbial exposure (Consortium 
[Human Microbiome Project Consortium], 2012). Pathological imbalance of the 
microbiome (dysbiosis) can occur at any stage of life and may be the cause or an 
effect of several pathologies (DeGruttola et al., 2016). Dysbiosis has been related to 
an increasing number of intestinal and extra-intestinal diseases including; 
inflammatory bowel disease, irritable bowel syndrome, obesity, diabetes mellitus, 
neuropsychological conditions and allergies (Jandhyala et al., 2015).  
1.2.2 Structure of the Gastrointestinal Tract Wall 
The gastrointestinal tract is a hollow tube which has a similar wall architecture from 
the mid oesophagus to the anus and is composed of four layers from the luminal 
surface outwards; mucosa, submucosa, muscularis externa and serosa (Figure 1-1) 
(Vander et al., 2001).  
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Figure 1-1: General structure of the gastrointestinal tract. Showing (from luminal surface 
outwards) the convoluted mucosal surface, submucosa, muscularis externa composed of the 
inner circular smooth muscle and outer longitudinal smooth muscle between which is the 
myenteric pleux and interstitial cells of Cajal and finally the outermost layer is the serosa. 
The inner mucosal layer provides the interface between the luminal contents and 
entry into the body and is composed of three layers, namely the epithelium, lamina 
propria and muscularis mucosa. The simple columnar epithelium contains exocrine 
(secretory) and endocrine (hormone producing) cells, below which is the lamina 
propria that is composed of connective tissue allowing passage of blood vessels, 
nerves and lymphatic ducts. Separating the mucosa from the underlying tissues is a 
thin layer of muscle called the muscularis mucosa, which provides structural support 
to the mucosa. The mucosal surface of the small intestine (jejunum and ileum) is 
highly specialised for absorption with finger like projections (villi) extending into the 
lumen. The surface membrane of the simple columnar epithelial cells exhibit a brush 
border with further small projections called microvilli (Figure 1-2). The combination 
of villi and microvilli results in an increase in surface area of approximately 600-fold 
over a flat tube. The centre of each intestinal villus contains a blind ending lymphatic 
vessel (lacteal) for absorption of fat and a blood capillary network for absorption of 
water soluble nutrients (Figure 1-2). Finally, the villus crypts located between the 
base of adjacent villi contain stem cells that provide continual replacement of 
epithelial cells resulting in sloughing of disintegrated cells into the gut lumen (Figure 
1-2) (Vander et al., 2001).  
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Figure 1-2: Structure of jejunal and ileal villi, demonstrating simple columnar epithelia with 
microvilli brush border, villus crypts and a central blind ending lymphatic vessel (lacteal) 
and blood capillary network. 
The submucosa is a second layer of connective tissue containing nerves, blood 
vessels and lymphatics, which supply the mucosa and muscularis externa. The 
muscularis externa is composed of two distinct layers of smooth muscle; the inner 
circular and outer longitudinal muscle (Figure 1-1). Contraction of the inner circular 
layer results in narrowing of the lumen whilst the outer longitudinal layer produces 
shortening of the gut tube. In combination, the contraction of these two muscle layers 
provides the mixing and propulsion required for digestion and transit of the intestinal 
content in a rostrocaudal direction. In between the circular and longitudinal smooth 
muscle layers is the extensive myenteric plexus (Figure 1-1) composed of the enteric 
neurons and glial cells, which are closely associated with the interstitial cells of Cajal 
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(ICC, the pacemaker of the gut). The outermost layer of the gut tube is the serosa 
composed of loose connective tissue and coated in mucous preventing friction 
between the intestinal loops during peristalsis. The extracellular matrix, produced by  
myofibroblasts and other mesenchymal cells, is present within all connective tissue 
layers of the bowel wall and provides physical support to the tissue layers and 
transmits information to and from cells in the form of chemical messengers, which 
regulate cell growth, migration and differentiation thus helping to maintain tissue 
homeostasis especially in response to injury (Bonnans et al., 2014). Finally, the 
majority of the gastrointestinal tract is suspended from the posterior abdominal wall 
by a sheet of connective tissue called the mesentery through which the large 
intestinal blood vessels and lymphatics supply the gastrointestinal tract (Vander et 
al., 2001).   
1.2.3 Gut Motility 
To achieve normal motility patterns the gut relies on the close interaction of the 
muscularis externa, enteric neurons and ICC (Bornstein et al., 2004). On ingestion of 
food boluses (postprandial), gut motility involves gastric peristalsis and intestinal 
segmentation to facilitate digestion and absorption of nutrients. Whilst in between 
meals (interdigestive), a cyclical, recurring motility pattern known as the migrating 
motor complex (MMC) ensures clearance of debris, secretions and microbes 
(Deloose et al., 2012).  
Ingestion of a food bolus stimulates the receptive relaxation of the stomach 
increasing the capacity of the stomach from 50ml to 1.5L enabling acceptance of the 
bolus with little increase in gastric pressure. Gastric peristaltic waves ensue 
originating from the gastric body and travelling towards the pyloric sphincter, which 
is initially closed enabling mixing of gastric contents. Relaxation of the pyloric 
sphincter expels the contents (chyme) into the duodenum. Segmentation occurs 
throughout the small intestine with little apparent net distal movement and involves 
contraction of the circular smooth muscle producing division and movement of the 
chyme in both oral and anal directions ensuring mixing and maximal absorption of 
luminal contents (Husebye, 1999).  
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Following completion of nutritional absorption, segmentation stops and the cyclical 
MCC motility pattern takes over, which is regulated by gut hormones, the 
parasympathetic and enteric nervous system. The MMC was first reported in 1969 
and described by the author as the interdigestive “housekeeper” of the small bowel 
(Szurszewski, 1969). Since the original description of the MMC, extensive research 
has been conducted in order to understand the physiological role and 
pathophysiological significance of this intestinal motility pattern, which remains 
incompletely understood (Husebye, 1999, Deloose et al., 2012). The MMC occurs 
during fasting and is composed of 4 phases; phase I is a state of inactivity or 
quiescence, phase II involves random contractions, phase III sudden bursts of 
contractions with maximal amplitude and duration, and phase IV rapid decrease in 
contractions. The MMC is a recurrent event that moves from the stomach to the 
terminal ileum over a period of 2 hours. Distension of the stomach results in 
termination of the MMC in the stomach and upper small bowel whilst presence of 
nutrients within the small intestine terminates MMC patterns throughout the entire 
bowel (Code and Marlett, 1975).  
1.2.4 Intestinal Smooth Muscle  
The muscle layers that make up the muscularis externa are not truly circular or 
longitudinal but helical. Individual smooth muscle cells are interconnected by gap 
junctions providing electrical coupling resulting in depolarisation within one muscle 
area spreading outwards to adjacent sections. Electrical coupling enables coordinated 
contraction of an entire ring of circular muscle rather than small patches ensuring 
effective mixing and propulsion of luminal contents (Vander et al., 2001). The 
muscularis externa has two actions; (1) prolonged tonic contractions to maintain the 
three dimensional shape of the gastrointestinal tract against intraluminal forces 
created by food boluses and (2) short lasting muscle contractions creating force 
generation. In combination these actions enable maintenance of the intraluminal 
volume capacity and propulsion of contents along the gut (Bitar, 2003).  
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1.2.5 Enteric Nervous System 
The enteric nervous system comprises neurons and glial cells (neuronal supporting 
cells) that form a large interconnecting network of cells along the entire bowel 
length. There are two large nerve plexuses: the myenteric plexus, which is located 
between the layers of the muscularis externa and the submucosal plexus (Figure 1-3), 
which is located in the submucosal connective tissue. There are also scattered 
neurons within the mucosa. The enteric nervous system supplies the smooth muscle 
and exocrine glands creating an autonomous nervous system controlling and 
regulating gut motility, secretions, vascular tone and hormone release throughout the 
gut. A stimulus at one part of the bowel is transmitted both cranially and caudally 
along the enteric nervous system, thus stimulus of the upper small intestine may also 
result in an effect in the stomach and lower intestinal tract. Motility is largely 
controlled by the myenteric plexus but in humans the submucosal plexus is also 
thought to be involved (Burns et al., 2009). Additionally, branches of the 
parasympathetic and sympathetic autonomic nervous system synapse with the enteric 
nervous system through which the central nervous system can also modulate motility 
and secretory function of the gastrointestinal tract (Browning and Travagli, 2014). 
The enteric nervous system contains cholinergic and adrenergic neurons as well as 
noncholinergic and nonadrenergic neurons that release neurotransmitters including 
nitric oxide, several neuropeptides and adenosine triphosphate (ATP) (Burns et al., 
2009, Vander et al., 2001).   
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Figure 1-3: A. Schematic of ileum. B. Immuofluorescence image of the myenteric plexus 
(red) and nuclei (blue) showing the interconnecting network of enteric neurons and glial 
cells. 
1.2.6 Interstitial Cells of Cajal 
The interstitial cells of Cajal (ICC) are the pacemaker cells of the gut and are an 
integral part of the motor function of the bowel. They initiate and propagate 
electrical slow waves, which regulate gut peristalsis and mediate neurotransmission 
between the enteric neurons and smooth muscle of the bowel (Burns, 2007). ICC are 
found throughout the entire gastrointestinal tract in several distinct populations with 
different functional roles (Komuro, 2006, Burns et al., 1997). The most essential 
populations are the branching ICC networks associated with the myenteric plexus, 
which generates spontaneous slow rhythmical pacemaker activity (Hirst et al., 2006), 
and the spindle shaped ICC located intramuscularly that propagate electrical 
waveforms throughout the muscle (Huizinga and Chen, 2014).  
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Figure 1-4: A. Schematic of ileum. B. Immuofluorescence image of the ICC (green) 
network at the level of the myenteric plexus and nuclei (blue) showing the branching 
network of ICC. 
ICC were first described by Ramón y Cajal in 1911 (Thuneberg, 1999) and many 
years later were identified by crude histochemical techniques. The advent of electron 
microscopy in the 1960s revealed the ultrastructure of these cells (Rogers and 
Burnstock, 1966), which were found to have gap junctions with smooth muscle cells 
and close associations with nerve terminals consistent with Ramón y Cajal’s original 
functional hypothesis. However, the histochemical techniques lacked cell specificity 
and electron microscopy is time consuming and labour intensive. So it wasn’t until 
the 1990s when ICC were discovered to express the protooncogene c-kit (Maeda et 
al., 1992) that ICC could easily and robustly be studied.  
C-Kit encodes a transmembrane receptor tyrosine that can be manipulated through 
blockade or genetic mutation and is specifically labelled by anti-Kit antibodies 
making ICC readily manipulatable and detectable. Physiological studies have 
identified that binding of membrane-bound stem cell factor to the extracellular Kit 
receptor is required for activation of the intracellular tyrosine kinase domain (Ward 
et al., 1995, Mikkelsen et al., 1998). Blockade with an anti-Kit antibody or disruption 
of Kit function by mutation of the Dominant white spotting (W) locus in animal 
models results in ICC loss, electrical quiescence and loss of bowel motility (Maeda 
et al., 1992). These findings highlight Kit to be an essential pathway in both function 
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and maintenance of ICC and therefore a useful histochemical marker for studying 
ICC development, function and pathology.  
1.3 Overview of Human Embryological and Fetal Development 
1.3.1 Overview of the Embryonic and Fetal Period 
The human embryonic period refers to the first 8 weeks of development from the 
time of fertilisation and has been described in 23 developmental stages (Carnegie 
stages) based on the Carnegie Collection of human embryos (O'Rahilly, 1979). The 
Carnegie stages are based purely on morphological features and are not dependent on 
size or age of the embryo (O'Rahilly, 1979). During the embryonic period the three 
germ layers form (ectoderm, mesoderm and endoderm) from epiblasts (gastrulation) 
followed by establishment of all the organ systems. The embryonic period of 
development is very rapid resulting in 90% of all adult structures being identifiable 
by the end of this period. Hence, the pregnancy is at its most vulnerable from 
teratogenic influences during these first 8 weeks of development due to extensive 
cell divisions, cell migration and cell differentiation, which can result in congenital 
malformations. The remainder of the pregnancy is designated the fetal period during 
which the organs differentiate, grow and become functional (organogenesis) (Sadler, 
2004).    
1.3.2 Terminology of Pregnancy 
Clinically, the term gestational age (GA) is used to indicate the pregnancy duration 
as calculated from the time of the last menstrual period (LMP) and although this 
normally occurs 2 weeks before the start of ovulation, it is a time point that most 
women can remember and serves as a guide to the time of fertilisation. The term 
developmental age indicates pregnancy duration based on calculations from the time 
of fertilisation i.e. approximately 2 weeks less than the GA and is the term used by 
embryologists and developmental biologists. Pregnancy is divided into 3 trimesters; 
the first trimester spans from 1 week GA through to 12 weeks GA, the second from 
13 weeks GA to 27 weeks GA and the third from 28 weeks GA to birth. The 
approximate due date is calculated as 40 weeks from the date of the LMP therefore 
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the actual length of pregnancy is 38 weeks from fertilisation. However, a pregnancy 
is considered to have reached full term from 37 weeks GA onwards. Neonates born 
at less than 37 weeks GA are considered premature.  
1.3.3 The Placenta, Fetal Membranes, Umbilical Cord, and Amniotic Fluid 
The placenta develops from the blastocysts at the time of implantation into the 
maternal endometrium and provides a high surface area for transfer of substances 
between the maternal and fetal blood. The placenta provides gas exchange, waste 
removal, nutrition, immune and endocrine support and a source of stem cells for the 
developing fetus. The embryo’s initial nutrition source is the yolk sac until the 
umbilical cord is formed by week 5 of development when the placenta takes over this 
function. 
The entire fetus is surrounded by 2 membranes, namely the chorionic and amniotic 
membrane. The chorionic membrane lines the placenta (chorion frondosum) and 
uterine wall (chorion leave). The avascular amniotic membrane arises as a single 
sheet of cells covering the dorsal surface of the embryo and gradually enlarges to 
surround the embryo. Initially the two membranes are separated by the exocoelomic 
cavity, which is a fluid-filled space containing an ultra-filtrate of the maternal serum 
and also proteins from the placenta and secondary yolk sac thus aiding the exchange 
of predominantly proteins between mother and fetus (Jauniaux and Gulbis, 2000). By 
the end of the first trimester the exocoelomic cavity is obliterated due to the 
expansion of the amniotic cavity, which becomes the only significant collection of 
extrafetal fluid. Following obliteration of the exocoelomic cavity the chorionic and 
amniotic membranes come into direct contact forming the chorioamniotic membrane. 
At this point the chorionic and amniotic membranes are slightly adherent but can be 
easily separated due to a spongy layer between the membranes. The chorioamniotic 
membrane has dynamic viscoelastic properties providing resilience to rupture and 
fetal protection (Creasy et al., 2009, Winn and Hobbins, 2000).  
The umbilical cord is the vascular connection between the placenta and fetus, which 
develops from the yolk sac and allantois. The cord consists of 3 blood vessels (2 
arteries and 1 vein), which are surrounded by Wharton’s jelly and the amniotic 
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membrane. The umbilical cord blood vessels originate from the placenta at their 
point of exit from the placenta. The amniotic membrane diverges from the 
chorioamniotic membrane bilayer and adheres to the umbilical vessels for their entire 
length. The umbilical cord terminates by inserting centrally on the ventral abdominal 
wall. The umbilical vein continues as the ductus venosus, the umbilical arteries insert 
onto the internal iliac arteries and the amniotic membrane becomes continuous with 
the abdominal wall ectoderm (Bargy and Beaudoin, 2014). 
The composition of amniotic fluid alters throughout pregnancy. Before keratinisation 
of the fetal skin at 25 weeks GA, the amniotic fluid composition is similar to fetal 
plasma and serves as an extension of the extracellular compartment. After 
keratinisation the composition and volume of amniotic fluid is determined by fetal 
urine, secretion of oral and airway fluids, swallowing and chorioamniotic membrane 
absorption (Gilbert and Brace, 1993). Thus in the third trimester of pregnancy there 
is an increase in urea and creatinine and a reduction in sodium, chloride and 
osmolality (Underwood et al., 2005). In addition, evidence suggests that fetal 
defecation is a normal physiological fetal phenomenon occurring sporadically in the 
second trimester and relatively frequently in the third (Ramon y Cajal and Martinez, 
2003, Ciftci et al., 1996) thus introducing bile, enteric enzymes and interleukin-8 
(IL-8) into the amniotic fluid.  
1.4 Development of the Gastrointestinal Tract and Abdominal Wall 
1.4.1 General Development of the Gastrointestinal Tract 
The primitive gut tube comprising the mucosa, mucosal glands and submucosal 
glands develops from the endoderm lining of the yolk sac secondary to 
cephalocaudal and lateral folding of the embryo. During embryo folding the stiff 
axial structures results in the embryo curving ventrally and the endodermal-lined 
yolk cavity ballooning anteriorly creating a three dimensional embryo and the 
primitive gut tube. The mesenteries that suspend the gastrointestinal tract from the 
body cavity are derived from the mesoderm, which wraps around the endodermal gut 
tube giving rise to the structures of the outer gut wall (lamina propria, muscularis 
mucosa, submucosal connective tissue and blood vessels, muscularis externa, ICC, 
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and serosa). Finally, the ectoderm gives rise to the neural crest, from which the 
enteric nervous system is derived.  
Initially the gastrointestinal tract develops as a hollow tube but during the 5th week 
of development the gut wall undergoes multiple proliferations resulting in complete 
blockage of the lumen (solid stage) by week 6 of development. This tissue over the 
course of the next 2 weeks gradually degenerates and reforms a hollow gut tube by 
the end of week 8 of development. This process is called recanalization.  
The entire gut tube extends the length of the embryo and from four weeks 
developmental age three distinct gut segments are apparent (foregut, midgut and 
hindgut) each with a defined blood supply (Figure 1-5). The foregut is supplied by 
the coeliac artery and includes the oesophagus, stomach, upper duodenum, liver, gall 
bladder, bile ducts, trachea and lungs. The midgut is supplied by the superior 
mesenteric artery and includes the lower duodenum, jejunum, ileum, caecum, 
appendix, ascending colon and proximal two thirds of the transverse colon. The 
hindgut is supplied by the inferior mesenteric artery and includes the distal third of 
the transverse colon, descending colon, sigmoid colon, rectum, upper anal canal, 
urogenital sinus. The midgut develops from lateral embryonic folding, which 
‘pinches off’ a segment of the yolk sac and the two compartments remain 
temporarily connected via the vitelline duct. 
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Figure 1-5: Primitive digestive tract showing the developing foregut, midgut and hindgut 
with the respective arterial supply and the vitelline duct, which temporarily contects the gut 
tube to the yolk sac (Gest, 2002). 
During organogenesis the individual gut structures (e.g. oesophagus, stomach, ileum, 
etc.) develop from the gut tube. Structural identity of the gastrointestinal tract occurs 
secondary to the reciprocal interaction between the endoderm and mesoderm 
whereby regionalisation of the endoderm is determined by the overlying mesoderm. 
HOX genes are expressed along the length of the gut mesoderm, which are induced 
as a result of sonic hedgehog expression by the endoderm. Once the mesoderm HOX 
code is expressed it instructs the endoderm to form the appropriate regional structural 
component of the gastrointestinal tract (Sadler, 2004).  
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1.4.2 Ventral Abdominal Wall Closure and Development of the Midgut 
Intestinal Loops 
The closure of the abdominal wall and the development of the intestinal loops are 
inextricably linked (Sadler, 2010). Ventral abdominal wall closure begins during 
gastrulation from the mesodermal folds at week 3 of development. At this time the 
umbilical ring is represented by the circumference of the flat embryo. During week 4 
of development the thorax and abdomen come to be positioned ventrally following 
cephalocaudal and lateral folding of the embryo. Abdominal closure occurs 
following migration of the cephalic, caudal and two lateral mesodermal folds, which 
converge centrally forming the umbilical ring (Brewer and Williams, 2004a).  
The midgut undergoes rapid elongation during the 6th week of development forming 
a primary intestinal loop (Figure 1-6A). This coincides with the expansion of the 
liver and the abdominal cavity becomes temporarily too small to contain the 
intestinal loops. As such, the intestinal loops project through the open umbilical ring 
into the base of the umbilical cord known as physiological herniation. During 
physiological herniation the intestinal loops rotate approximately 90º anticlockwise 
around the axis of the superior mesenteric artery and the intestine continues to 
elongate forming numerous jejunal and ileal coiled loops (Figure 1-6B). The 
intestinal loops begin to return to the abdominal cavity and rotate a further 180º 
(Figure 1-6C). The jejunum returns to the abdomen first and lies on the left side 
(Figure 1-6D) with later returning loops lying more on the right (Figure 1-6E). The 
caecal bud initially returns and lies in the right upper quadrant and later descends 
into the right iliac fossa placing the ascending colon on the right side of the abdomen 
(Figure 1-6D and E). The factors involved in the return of the intestinal loops to the 
abdominal cavity are not fully understood but may be linked to reduced liver growth 
and expansion of the abdominal cavity (Sadler, 2004). Resolution of the 
physiological hernia occurs at around week 10 of development (12 weeks GA) 
resulting in final closure of the abdominal wall (Sadler, 2010). Additionally, by the 
10th week of development the vitelline duct completely obliterates breaking the 
connection between the midgut and yolk sac.  
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Figure 1-6: Physiological herniation and development of the midgut. A. Rapid elongation of 
the primary intestinal loop during the 6
th
 week of development. B. Rotation of the bowel 
during physiological herniation. C. Return and rotation of the intestinal loops into the 
abdominal cavity. D. Initial returning loops lie on the left side of the abdomen. E. Later 
returning loops come to lie on the right side of the abdomen and the caecal bud comes to lie 
in the right iliac fossa. Physiological herniation resolves around 10
th
 week of development 
(Larsen, 1997). 
The initial primary abdominal wall closure is composed of a thin epithelial 
membrane. Proliferation of myoblasts from the myotome enables secondary 
structures to form including the four muscle pairs (rectus abdominis, external 
oblique, internal oblique and transversus abdominis), fascia and skin (Nichol et al., 
2012). The umbilical ring forms the transition zone between the ectoderm of the 
ventral abdominal wall and the amniotic membrane that surrounds the umbilical 
vessels (Bargy and Beaudoin, 2014). Although the gross structural development of 
the ventral abdominal wall is known, little is understood regarding the mechanisms 
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underpinning cell signalling and migration and therefore the causes of abdominal 
wall defects are not fully understood (Sadler, 2004).   
1.4.3 Neuromuscular Development of the Gut 
The gastrointestinal enteric neurons and smooth muscle are both functionally and 
developmentally coordinated. The gut is populated by the enteric neurons by cell 
migration in an oral to anal cell direction, whilst the smooth muscle has a gradient of 
maturation along the gut again in an oral to anal direction. In contrast, the ICC do not 
appear to develop in a migratory fashion. The enteric neurons develop from the 
neural crest, which is a transient population of cells appearing between the ectoderm 
and dorsal neural tube during early embryo development. The migrating neural crest-
derived precursors of the enteric nervous system are seen within the midgut by week 
5 of development and the entire gut is colonized by week 7 of development (Wallace 
and Burns, 2005). Initially the migrating cells form the myenteric plexus and then 
migrate centripetally to form the submucosal plexus 2-3 days after establishment of 
the myenteric plexus. The gastrointestinal smooth muscle develops from the 
mesoderm and appears, as identified by smooth muscle actin antibody staining, in the 
oesophagus by week 8 of development and the hindgut by week 11 of development. 
The smooth muscle layers are well defined throughout the gut by week 14 of 
development. The ICC are also derived from the mesoderm and appear in the 
muscularis externa of the midgut during weeks 7-9 of development and are more 
distinct by week 11 of development (Burns et al., 2009, Wallace and Burns, 2005). 
The ICC associated with the myenteric ganglia are the first of the ICC populations to 
develop and become a continuous network throughout the entire gut by week 17 of 
development. By week 14 of development the gut has a relatively mature appearance 
in terms of the presence of defined muscle layers, enteric neurons and myenteric 
ICC, although the remaining ICC populations continue to develop throughout fetal 
life and into the newborn period. The intramuscular ICC appear by 36 weeks 
gestational age and the deep muscular plexus appears during the early neonatal 
period. This continued development of ICC during fetal life could explain why 
functional recordings of premature neonates show immature ileal motility (Faussone-
Pellegrini et al., 2007). 
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1.5 Human Congenital Anomalies 
1.5.1 Overview of Congenital Anomalies 
Congenital anomalies develop in-utero before birth and are also known as congenital 
defects or malformations. The term encompasses: (1) Structural defects, which result 
from disruption of body wall folding or organogenesis during the embryonic or fetal 
stage of development creating anatomical abnormalities of structures such as the 
heart, liver, abdominal wall, spinal cord, etc. Frequently the cause of these defects is 
unknown; (2) Functional anomalies are conditions that impact on organ or system 
function and are often genetically inherited including metabolic (glycogen storage 
disease, Lesch-Nyhan syndrome) and haematological disorders (Sickle cell, 
thalassaemia); (3) Chromosomal anomalies, including chromosomal duplication 
(Down’s, Patau’s and Edward’s syndromes), chromosomal deletion (Turner’s) and 
missing, extra or irregular portions of chromosomal DNA (Wolf-Hirschhorn 
syndrome, Charcot-Marie-Tooth disease type 1A).  
Improvements in antenatal ultrasound and developments of new diagnostic 
techniques have enabled many congenital anomalies to be detected during the 
antenatal period. Early detection enables appropriate antenatal counselling, 
monitoring and clinical management, delivery planning and arrangements for 
postnatal management or equally the option for termination. However, other 
congenital anomalies may not be detectable until birth or if symptoms or signs of the 
condition are not evident at birth then later in life (childhood or adulthood). 
In the UK two antenatal ultrasound scans are performed routinely. A first trimester 
dating/screening ultrasound scan at 11 to 14 weeks GA, which determines the 
gestational age of the pregnancy and the risk of chromosomal anomalies such as 
Down’s syndrome. Additionally, it is possible to detect abdominal wall defects at 
this stage. A second trimester anomaly ultrasound scan at 18 to 20 weeks GA is 
performed to systematically review the structural development of the fetus in order to 
detect the presence of any sonographically evident structural defects. A significant 
number of structural anomalies can be detected at this stage including abdominal 
wall defects, heart defects, spina bifida, cleft lip and palate and congenital 
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diaphragmatic hernia (Todros et al., 2001). Further monitoring scans are performed if 
the fetus is found to have a structural defect.  
Screening for chromosomal anomalies (Down’s syndrome, Patau’s and Edwards) is 
performed at the 12 to 13 weeks GA dating/screening scan. Those with a high risk of 
such conditions are offered the opportunity to undergo chorionic villus sampling (a 
sample of chorionic villus is removed from the placenta under ultrasound guidance) 
between the 11
th
 and 14
th
 weeks GA or amniocentesis (a sample of amniotic fluid is 
removed under ultrasound guidance) between the 15
th
 to 20
th
 weeks GA to confirm 
the fetal chromosomal and genetic profile (Alfirevic et al., 2003). However, both 
these procedures are invasive and carry risks to the pregnancy (Akolekar et al., 2015, 
Alfirevic et al., 2003). As such, a new technique has been developed to detect ‘cell-
free fetal DNA’ from a maternal blood sample. This non-invasive test can detect fetal 
DNA circulating within the maternal blood and determine the fetal chromosome 
(including sex) and genetic profile from 10 weeks GA onwards (Barrett et al., 2011).  
The aetiology of many structural defects remains unknown but common causes and 
risk factors include genetic or chromosomal factors, parental consanguinity, maternal 
infections, maternal nutritional status, environmental factors (such as chemicals, 
recreational drugs, medications, pesticides and radiation), young maternal age and 
low socioeconomic status (Brent, 2004, Hobbs et al., 2014, Vrijheid et al., 2000). 
Preventative measures in the peri-conception period have reduced the incidence of 
certain structural conditions such as spina bifida (Burren et al., 2008, Williams et al., 
2015) and advances in modern medicine have significantly reduced infant morbidity 
and mortality from many congenital anomalies in developed countries. However, 
worldwide birth anomalies remain a leading cause of infant death and it is estimated 
that 276 000 neonates (infants under 28 days of age) die each year (WHO, 2014). 
1.5.2 Congenital Ventral Abdominal Wall Defects 
Congenital ventral abdominal wall defects are structural anomalies that involve 
failed closure of the ventral body wall. The most common abdominal wall defects are 
gastroschisis (4.4/10,000 live births) (Kilby, 2006) and exomphalos (2.5/10,000 live 
births) (Weber et al., 2002) but also includes other rare conditions namely bladder 
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exstrophy (1:30,000-50,000 live births) (Ben-Chaim et al., 1996) and body stalk 
anomaly (0.4 to 3.2:100,000 live births and universally fatal) (Bugge, 2012). The 
pathogenesis of abdominal wall defects remains controversial. Exomphalos is largely 
considered to develop secondary to failed return of the bowel following 
physiological herniation (Sadler, 2010) and body stalk anomaly is thought to be due 
to either an early rupture of the amnion and direct mechanical pressure on the 
developing fetus (Paul et al., 2001) or a germinal disk abnormality preventing body 
wall folding (Lockwood et al., 1986). However, there are multiple hypotheses for the 
pathogenesis of both gastroschisis and bladder exstrophy with no overarching 
consensus (Sadler, 2010, K et al., 2015). 
Gastroschisis (Figure 1-7A) exhibits a relatively small paraumbilical, full thickness 
defect (approximately 1 to 2cm wide) that usually lies to the right of the umbilicus 
(Sadler, 2010) through which most of the bowel and occasionally other organs 
herniate. The bowel has no covering membrane and therefore lies in direct contact 
with the amniotic fluid. Frequently at birth the bowel appears thickened and inflamed 
and 10-15% of gastroschisis infants also have concomitant intestinal pathologies 
(Carnaghan et al., 2014, Bradnock et al., 2011) including atresia, stenosis, 
perforation and necrosis. However, concomitant extra-abdominal malformations or 
chromosomal abnormalities are rare. 
In contrast, exomphalos (Figure 1-7B) exhibits a ventral abdominal wall defect 
disrupting the umbilical ring ranging in severity from minor (<5 cm) to major (>5 
cm) (Carnaghan et al., 2009, Groves et al., 2006). The abdominal viscera including 
bowel and frequently liver herniates into the base of the umbilical cord. The viscera 
are characteristically contained within a membranous sac composed of the amniotic 
membrane at the base of the umbilical cord, which protects the viscera from the 
amniotic fluid. Exomphalos is commonly associated with extra-abdominal anomalies 
including structural defects of the heart, diaphragm and limbs, pulmonary hypoplasia 
and metabolic and chromosomal disorders. However, at birth the bowel function is 
normal and exomphalos is rarely associated with concomitant intestinal pathology 
(Vachharajani et al., 2009, Carnaghan et al., 2009). Finally, exomphalos also rarely 
occurs as part of a syndrome called pentalogy of Cantrell exhibiting 5 key features; 
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exomphalos, cleft sternum, ectopia cordis (externalised heart), diaphragmatic hernia 
(anterior diaphragmatic deficiency) and cardiac defects.   
A body stalk anomaly is also known as limb-body wall complex involving 
malformation of the abdomen, thorax and usually limbs. This complex, lethal 
condition involves varying degrees of failed ventral wall closure, which may be 
located centrally or to one side of the torso and can result in externalisation of both 
thoracic and abdominal viscera into an amnioperitoneal membrane. During in-utero 
development a proportion of the fetus lies outside of the amniotic cavity within the 
exocoelomic cavity, there is incomplete fusion of the amnion to the chorion and a 
short or absent umbilical cord. Finally other structural defects include limb 
deformities, scoliosis (curvature of the spine) and malformations of the anorectal 
canal and genitourinary tract (Bugge, 2012). 
Bladder exstrophy (Figure 1-7C) involves failed closure of the inferior ventral 
abdominal wall and splitting of the anterior bladder wall and urethra resulting in an 
exposed bladder plate. Classically exstrophy exhibits a low lying umbilicus, diastasis 
of the pubic symphysis, abnormal genitalia and anorectal malformation. Males 
exhibit severe epispadias and in females a bifid clitoris and vaginal ectopia (K et al., 
2015).  
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Figure 1-7: Types of survivable congenital ventral abdominal wall defects. A. Gastroschisis 
showing a ventral abdominal wall defect to the right of the umbilicus and externalised gut 
without a covering membrane. B. Exomphalos showing a large central abdominal wall defect 
with gut herniating into the base of the umbilical cord providing a protective membrane. C. 
Bladder exstrophy showing a lower midline central abdominal wall defect exposing the 
bladder plate and associated epispadias (Coran et al., 2012). 
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1.5.3 Congenital Gastrointestinal Defects 
The majority of congenital gastrointestinal defects involve disruption of luminal 
continuity including atresia (complete occlusion of the lumen, Figure 1-8A), stenosis 
(narrowing of the lumen, Figure 1-8B) and perforation. Atresia and stenosis of the 
jejunum, ileum and colon are thought to occur secondary to an in-utero vascular 
accident such as external bowel wall compression or a 
vasoconstrictive/thromboembolic event resulting in bowel necrosis and tissue 
resorption (atresia) or scarring (stenosis) (Koga et al., 1975, Louw and Barnard, 
1955).  This is in contrast to duodenal atresias, which are thought to develop 
secondary to failed recanalisation of the primitive gut tube (Sadler, 2004). Isolated 
intestinal perforation (Figure 1-8C) can occur due to a focal attenuation of the 
muscularis externa, which may be caused by focal outer bowel wall necrosis (Lai et 
al., 2014, Izraeli et al., 1992).  
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Figure 1-8: Schematic representation of gastrointestinal pathologies. A. Atresia depicting 
blind ending proximal and distal bowel. B. Stenosis depicting narrowed bowel lumen. C. 
Perforation depicting a hole in the bowel wall. 
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Other congenital defects include duplication cysts, Meckel’s diverticulum, intestinal 
malrotation, intestinal aganglionosis and anorectal malformations. Duplication cysts 
form following incomplete recanalization of the primitive gut tube resulting in 
parallel intestinal lumens, which can result in stenosis and obstruction of the primary 
gastrointestinal lumen. Meckel’s diverticulum results from incomplete resorption of 
the vitelline duct during fetal development and ranges in size from a patent duct 
between the midgut and umbilicus to a fibrous cord connecting the midgut to the 
umbilicus. Intestinal malrotation or non-rotation is abnormal rotation and fixation of 
the bowel during organogenesis of the midgut. The condition includes a narrow 
mesenteric attachment to the posterior abdominal wall around which the gut can 
twist resulting in a midgut volvulus causing bowel necrosis secondary to mesenteric 
vessel obstruction. Intestinal aganglionosis, also known as Hirschsprung’s disease, 
results from failure of the enteric neural crest cells to migrate from mouth to anus 
during fetal development. The length of the aganglionosis varies from being a short 
1cm segment affecting the rectum to a long segment affecting the entire colon and 
occasionally the terminal ileum. In all instances the aganglionosis is continuous with 
no skip lesions. Anorectal malformations encompass a broad spectrum of anomalies 
in which the distal hindgut fails to develop a normal anal opening within the centre 
of the anal sphincter complex. Frequently there is an imperforate anus and the 
intestine terminates with a fistulous connection to the perineum or genitourinary 
tract. Severity of these defects ranges from a mildly displaced anal opening with an 
excellent functional prognosis to imperforate anus associated with deficient sphincter 
and pelvis musculature, genitourinary defects and also spinal anomalies resulting in 
poor functional outcome (Davenport and Pierro, 2009).  
1.6 Gastroschisis  
1.6.1 Overview and Characteristic Features  
Gastroschisis is a relatively small paraumbilical ventral abdominal wall defect that 
typically lies to the right (in 95% of cases) of the umbilical cord (Sadler, 2010, 
Hombalkar et al., 2015). The umbilical cord forms normally consisting of 3 blood 
vessels (2 arteries and 1 vein) covered by Wharton’s jelly and the amniotic 
membrane (Bargy and Beaudoin, 2014). The full thickness gastroschisis abdominal 
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wall defect is positioned between the umbilical cord insertion and the right lateral 
ventral wall fold disrupting the continuation of the amniotic membrane with the 
abdominal wall ectoderm at this point. As such, the externalised abdominal contents 
lie free floating within the amniotic cavity without a covering membrane placing the 
viscera in direct contact with the amniotic fluid. The eviscerated organs usually 
include most of the small and large bowel but can also include stomach, spleen, 
bladder, gonads, uterus and very rarely the liver (McClellan et al., 2011, Mousty et 
al., 2012). Frequently at birth the bowel appears thickened, inflamed and matted, 
which is thought to be due to the abnormal exposure of the serosal surface to the 
irritant amniotic fluid or constriction at a tight abdominal wall defect (Langer et al., 
1989). Figure 1-9 and Figure 1-10 schematically depicts the gastroschisis defect. 
 
Figure 1-9: Schematic illustration of an in-utero gastroschisis fetus. 
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Figure 1-10: Schematic illustration of the gastroschisis abdominal wall defect in transverse 
section. 
1.6.2 Concomitant Congenital Defects 
Gastroschisis is not usually associated with any extra-abdominal congenital 
malformations, chromosomal or genetic defects. However, concomitant congenital 
intestinal pathologies occur in 10-15% of gastroschisis infants (Carnaghan et al., 
2014, Bradnock et al., 2011, Bergholz et al., 2014) including atresia, stenosis, 
perforation and necrosis. It is thought these pathologies develop secondary to 
disruption of the mesenteric vascular supply (Louw and Barnard, 1955) either due to 
an intrinsic vasoconstrictive/thromboembolic event (Hoyme et al., 1990) or external 
compression at a tight abdominal wall defect (Carnaghan et al., 2009, Houben et al., 
2009). The terms simple and complex gastroschisis are used to delineate between 
those infants who do and do not have concomitant intestinal pathologies. Simple 
gastroschisis refers to infants who have otherwise healthy, intact, continuous bowel 
(includes patients with bowel inflammation), whilst complex gastroschisis refers to 
patients with compromised (ischaemic or necrotic), non-continuous (atresia or 
perforated bowel) or narrowed (stenotic) bowel and is associated with higher 
morbidity and mortality rates (Mousty et al., 2012). In all cases of gastroschisis the 
bowel is malrotated due to the failed return of the bowel to the abdominal cavity 
during fetal development. However, individuals affected by gastroschisis are not at 
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risk of volvulus following corrective surgery due to the significant amount of serosal 
inflammation and bowel matting present at birth, which prevents free movement of 
the intestinal loops and therefore rotation around a narrow mesenteric pedicle. 
Finally, gastroschisis is associated with undescended testes, which occurs in 
approximately 30-40% of boys with gastroschisis of which 50% will descend 
spontaneously and the remainder require orchidopexy (Yardley et al., 2012, Lawson 
and de La Hunt, 2001, Hill and Durham, 2011).  
1.6.3 Pathogenesis  
The pathogenesis of gastroschisis remains controversial and the point during 
embryogenesis at which gastroschisis develops is unknown. The earliest routine 
antenatal ultrasound for pregnant women occurs at 11 to 14 weeks GA when 
gastroschisis is easily detectable. However, studies have reported gastroschisis to be 
present concomitantly with physiological herniation (Byrne and Feldkamp, 2008, 
Tibboel et al., 1986), which would suggest the defect may develop prior to 
physiological herniation, which develops from 8 weeks GA and resolves by 12 
weeks gestation (Sadler and Feldkamp, 2008). Several developmental theories have 
been suggested (Sadler, 2010) including: (i) regression of the right umbilical vein 
causing abnormal apoptosis (deVries, 1980); (ii) disruption of the 
omphalomesenteric artery resulting in necrosis at the umbilical cord insertion 
(Hoyme et al., 1981); (iii) failure of the ventral lateral folds to fuse in the midline 
(Duhamel, 1963) secondary to delayed right sided abdominal wall closure (Miller, 
1982); (iv) failure of the umbilical cord to attach to the umbilical ring (Rittler et al., 
2013); (v) damage and subsequent rupture of the amniotic membrane at the base of 
the umbilical cord (Shaw, 1975, Bargy and Beaudoin, 2014), and (vi) escape of the 
yolk sac (Stevenson et al., 2009).  
The vascular theories were suggested due to the high association of gastroschisis 
with concomitant intestinal pathologies (atresia, stenosis, perforation and necrosis). 
However, the vascular theories suggested are not supported embryologically or 
anatomically. Firstly, the right umbilical vein transports blood from the placenta to 
the fetus and does not supply the anterior body wall (Sadler and Rasmussen, 2010). 
Secondly, the omphalomesenteric artery supplies the yolk sac not the abdominal 
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wall. Therefore disruption to either of these vessels would be unlikely to cause 
abnormal apoptosis or necrosis of the abdominal wall. Finally, the abdominal wall is 
supplied by intersegmental arteries arising from the aorta that anastomose 
extensively providing a rich blood supply to the abdominal wall (Moore and Dalley, 
1999).  
Hence, an embryological cause is more likely. Research in chick embryos has shown 
asymmetry in cell proliferation of the lateral ventral folds with the right side lagging 
behind the left (Miller, 1982). Additionally, a human embryo study describes the 
amniotic membrane covering the right side of the umbilical cord base to be thinner 
than the left and suggests rupture of this thin area during physiological herniation 
causes gastroschisis (Bargy and Beaudoin, 2014). Hence, the gastroschisis defect 
may result from failed right lateral fold development, failed umbilical cord insertion 
or a combination of the two.  
1.6.4 Aetiology, Incidence and Risk Factors 
Failed abdominal wall closure in gastroschisis is unlikely to have a single gene 
aetiology as the defect largely occurs in isolation and is very rarely associated with 
any defined genetic conditions. Additionally, unlike other congenital abnormalities 
the incidence of gastroschisis has almost doubled in the UK from 2.5/10,000 live 
births in 1994 to 4.4/10,000 in 2004 (Kilby, 2006). This increased incidence is not an 
isolated phenomena to the UK but has also been observed worldwide (Reid et al., 
2003, Kirby et al., 2013, Loane et al., 2011, Suita et al., 2000) with marked regional 
variation (Castilla et al., 2008, Root et al., 2009) and race specific differences 
(Castilla et al., 2008, Tan et al., 2008) suggesting an environmental contribution is 
likely. Attention has fallen on a number of factors known to be associated with an 
increased risk of gastroschisis; namely poor maternal diet, low socioeconomic status, 
unemployment and maternal smoking (Feldkamp et al., 2011, Lam and Torfs, 2006, 
Rasmussen and Frias, 2008). To date the strongest epidemiological factor found to be 
associated with an increased risk of gastroschisis is young maternal age (Gill et al., 
2012, Rankin et al., 1999, Tan et al., 1996). Recent studies have also revealed a 
possible association between maternal peri-conceptional folic acid supplementation 
and the risk of developing gastroschisis. One study found that omission of maternal 
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peri-conceptional folic acid supplementation was associated with an increased risk of 
gastroschisis (David et al., 2014) and another showed that increased duration of peri-
conceptional folic acid reduced the risk of gastroschisis (Paranjothy et al., 2012). 
Drug abuse was hypothesised to be a risk factor due to its vasoactive effects and 
possible links with intestinal atresia (Hoyme et al., 1990) but a study that performed 
analysis of hair taken from women with gastroschisis pregnancies has shown that 
neither smoking nor recreational drug use were significantly associated with 
gastroschisis incidence after adjusting for maternal age (David et al., 2014).  
1.6.5 Mortality 
In 1943 the first successful primary surgical gastroschisis closure (full reduction of 
the abdominal viscera and closure of the abdominal wall defect at the time of birth) 
was described by Watkins (Watkins, 1943). Prior to this gastroschisis was 
universally fatal. Although primary abdominal wall closure was possible the 
mortality rate remained significant and was reported to be as high as 90%. The main 
causes of death were; (i) failure to achieve primary abdominal wall closure due to 
viscero-abdominal disproportion in which the abdominal compartment is too small to 
accommodate the externalised viscera preventing abdominal closure; (ii) respiratory 
insufficiencies and abdominal compartment syndrome due to high abdominal 
pressures secondary to a tight abdominal wall closure or (iii) prolonged gastroschisis-
related intestinal dysfunction preventing enteral feeding resulting in malnutrition and 
death. However, in the late 1960s the mortality rate dramatically dropped for two 
reasons: (1) the development of a surgical procedure to achieve stage reduction of the 
externalised viscera into the abdomen followed by abdominal wall closure (Schuster, 
1967) and (2) the advent of safe total parenteral nutrition enabling the provision of 
nutritional requirements intravenously until the infant can achieve full enteral 
autonomy (Dudrick and Palesty, 2011). Over the past 4 decades the outcome for 
gastroschisis infants in high-income countries has significantly improved and the 
mortality rate is currently reported to be between 3-10% of live born gastroschisis 
neonates (Bradnock et al., 2011, McClellan et al., 2011, Kassa and Lilja, 2011, 
Skarsgard et al., 2008). Deaths in high-income countries are associated with complex 
gastroschisis (particularly bowel necrosis), prolonged hospitalisation and long-term 
parenteral nutrition (PN) resulting in sepsis, liver failure or inability to gain central 
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venous access for the provision of PN (Erdogan et al., 2012, Bradnock et al., 2011, 
Rodrigues et al., 2006). However, it is also important to note that low income 
countries continue to experience high mortality rates of >90% due to the lack of 
prenatal diagnosis, tertiary centre care and provision of PN (Wesonga et al., 2016). 
1.6.6 Morbidity 
The focus for gastroschisis clinical management and research in high-income 
countries has now shifted from reducing mortality to improving infant morbidity. 
The most frequent gastroschisis-related morbidity is that of intestinal dysfunction 
resulting in a significant delay in attainment of full enteral feeding and enteral 
autonomy. A UK national one-year cohort study reported the median time to full 
enteral feeds in simple gastroschisis was 24 days (range 3->365) (Bradnock et al., 
2011) whilst infants with complex gastroschisis it was 47 days (range 30->365) and 
50% of gastroschisis infants are categorised as having type 2 intestinal failure 
requiring >28 days of PN (Bradnock et al., 2011). As such, infants with gastroschisis 
require prolonged periods of PN, which carries significant risks (van Manen et al., 
2013) of sepsis secondary to central line infection (Roberts and Gollow, 1990, Gray 
et al., 1994), cholestatic liver dysfunction (Jolin-Dahel et al., 2013) and growth 
restriction. A retrospective study revealed neonates with an abdominal wall defect 
(gastroschisis or exomphalos) lost on average 0.07 (p<0.0001) weight Z-scores per 
week of PN and 0.08 (p<0.001) head circumference Z-scores per week of PN 
(Carnaghan et al., 2012) (Appendix 2). Protracted hospital stays also carry risks of 
hospital acquired infections (Sekar, 2010), prevents parental bonding due to 
separation from the family and places an increased burden on neonatal cots. 
Additionally, the rising incidence of gastroschisis between 1996 to 2005 increased 
the cost to the NHS by approximately £11.4 million (Keys et al., 2008).  
Otherwise gastroschisis infants rarely exhibit concomitant abnormalities or 
pathologies and due to the small abdominal wall defect generally do not exhibit signs 
of pulmonary hypoplasia unlike exomphalos in which a strong association has been 
shown between increasing exomphalos defect size and severity of pulmonary 
hypoplasia. A study investigating lung development in a rabbit surgical gastroschisis 
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model showed no demonstrable effects on lung growth or maturation in the 
gastroschisis group compared to controls (Biard et al., 2004). 
Infants with complex gastroschisis experience the highest level of morbidity. Those 
who lose significant lengths of bowel for reasons including; (1) in-utero closed 
gastroschisis (vanishing gastroschisis) resulting in loss of all the externalised bowel 
prior to birth (Dennison, 2016), (2) bowel necrosis requiring extensive bowel 
resection or (3) multiple intestinal atresias resulting in significant bowel loss, may 
never achieve full enteral autonomy and require life-long PN and in some cases a 
small bowel transplant. 
1.6.7 Clinical Management of Gastroschisis 
The clinical management of gastroschisis is divided into antenatal and postnatal. 
Although the treatment principles are universal, antenatal and postnatal management 
protocols vary between centres. Antenatally the emphasis is on diagnosis, fetal 
monitoring, identifying fetal distress, counselling and optimising timing and location 
of delivery. Fetal interventional strategies have been trialled to improve postnatal 
outcomes for gastroschisis infants but none are used routinely and are covered in 
section 1.8 Clinical Therapeutic Strategies Trialled in Humans to Improve GRID. 
Immediate postnatal management addresses cardiorespiratory stabilisation, fluid 
resuscitation, care of externalised abdominal viscera, gastric decompression and safe 
transfer to a neonatal intensive care unit (NICU) with paediatric surgical cover. The 
aims for ongoing care are to return the externalised viscera to the abdomen, close the 
abdominal wall defect and provide nutritional support until autonomous enteral 
feeding is achieved.  
1.6.7.1 Antenatal Management of Gastroschisis 
1.6.7.1.1 Antenatal Diagnosis and Monitoring 
Gastroschisis is usually diagnosed during the 11 to 14 week antenatal dating scan 
when the bowel loops are seen floating in the amniotic fluid. Elevated levels of alpha 
fetoprotein in maternal serum are also frequently found during the second trimester 
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(routinely performed to screen for open spina bifida and trisomy 21) and raises 
suspicion for gastroschisis (Palomaki et al., 1988, Saller et al., 1994). Following 
detection of a gastroschisis defect the pregnant woman is referred to a tertiary fetal 
medicine centre. Gastroschisis fetuses are serially monitored by antenatal ultrasound 
due to the relatively high risk of intrauterine fetal death (South et al., 2013, Meyer et 
al., 2015). Usually monitoring occurs at 4-weekly intervals until 30 weeks GA, 2-
weekly intervals between 30 and 34 weeks and once weekly after 34 weeks GA. 
However, there is no formal consensus on antenatal monitoring strategies between 
fetal medicine centres mainly due to a paucity of evidence associating antenatal 
sonographic findings with fetal/infant outcomes and in turn management of 
gastroschisis (Overton et al., 2012, Amin et al., 2018).  
Generally ultrasound monitoring encompasses potential causes of intrauterine fetal 
death including cardiovascular compromise, umbilical cord compression, 
oligohydramnios, mesenteric vasculature compromise, intrauterine growth restriction 
and bowel compromise (South et al., 2013). As such, fetal monitoring usually 
includes; (1) fetal biophysical profile, which entails sonographic assessment of fetal 
movement, tone, breathing and amniotic fluid index (to detect oligohydramnios and 
polyhydramnios) and cardiotocography to assess fetal heart rate (nonstress test), (2) 
fetal growth given gastroschisis neonates are frequently small for GA, (3) umbilical 
and mesenteric Doppler’s, (4) bowel thickness, diameter and appearance and (5) 
stomach position and diameter (Lepigeon et al., 2014). Oligohydramnios complicates 
25% of gastroschisis pregnancies (Towers and Carr, 2008) and on rare occasions of 
severe oligohydramnios in the preterm period intrapartum amnioinfusion with 
warmed saline has been performed (Dommergues et al., 1996, Sapin et al., 2000). 
The aim of the procedure is to restore the amniotic fluid volume, prolonging 
pregnancy and reduce the risk of bowel damage, umbilical vessel compression, 
pulmonary hypoplasia and fetal death. Early induction of labour or emergency 
caesarean section is frequently performed if there is evidence of fetal distress which 
includes a concerning biophysical profile, severe intrauterine growth restriction 
(IUGR), poor umbilical or mesenteric Doppler’s, an abnormal fetal heart rate trace, 
severe oligohydramnios or occasionally due to marked bowel dilatation raising 
concerns of significant and potentially life threatening bowel compromise (Baud et 
al., 2013, Carnaghan et al., 2016, Carnaghan et al., 2014, Lepigeon et al., 2014).      
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However, it is important to note that sonographic findings have limitations. IUGR is 
generally over-estimated in gastroschisis as antenatal estimates of birth weight rely 
upon ultrasound measurements of fetal abdominal circumference which in 
gastroschisis fetuses is difficult to measure and frequently inaccurate because of the 
externalised abdominal viscera (Mirza et al., 2015, Payne et al., 2011). Studies 
measuring pulsatility and systolic/diastolic ratio in the superior mesenteric artery and 
its branches and the umbilical artery show no differences in Doppler findings 
between good and poor infant outcome groups (Abuhamad et al., 1997, Stuber et al., 
2016). However, the literature suggests that the presence and degree of bowel 
dilatation may be predictive of complex gastroschisis (Huh et al., 2010, Houben et 
al., 2009, Ghionzoli et al., 2012, Nick et al., 2006) and is investigated further in 
Chapter 9.   
Amniotic fluid is known to be pro-inflammatory with elevated neutrophils, 
mononuclear cells, interleukin-8, interleukin-6, total protein and ferritin levels 
(Morrison et al., 1998, Burc et al., 2004, Guibourdenche et al., 2006). However, 
amniocentesis is not routinely performed as currently no specific amniotic fluid 
biomarker has been robustly identified to inform antenatal management of 
fetal/infant outcomes and gastroschisis is not usually associated with genetic or 
chromosomal anomalies (Mastroiacovo et al., 2007, Lepigeon et al., 2014).  
Finally, during the antenatal period expectant parents are counselled by a paediatric 
surgeon who provides information on the gastroschisis diagnosis, the antenatal and 
neonatal management, potential bowel complications and possible duration of 
admission for their baby. However, counselling cannot provide an accurate 
prognostic picture given the lack of antenatal ultrasound/Doppler markers or 
amniotic fluid biomarkers that accurately predict postnatal gastroschisis outcomes 
(Overcash et al., 2014).  
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1.6.7.1.2 Clinical Observational Study to Determine if Amniotic Fluid, Maternal 
Blood or Fetal Cord Blood Biomarkers Correlate with Gastroschisis 
Outcomes 
In order to add to the published literature linking antenatal biomarkers with infant 
outcomes I performed an antenatal clinical prospective observational study over an 
18 month period. The aim was to determine if an amniotic fluid, maternal blood or 
fetal cord blood biomarker could be identified that predicted postnatal gastroschisis 
outcomes. The study was designed to recruit 30 normal and 30 gastroschisis 
pregnancies from University College London Hospital/Great Ormond Street Hospital 
and King’s College Hospital. In both groups the following samples were collected; 
amniotic fluid at time of induction of labour or caesarean section, maternal blood 
prior to delivery and fetal cord blood after delivery. The amniotic fluid was to be 
analysed using ELISA, proteomic biomarker discovery, mass spectrometry and 
biochemical techniques to measure inflammatory, digestive and biochemical 
components in amniotic fluid. The maternal and fetal cord blood was to be analysed 
using biochemical and flow cytometry to identify evidence of inflammation and 
biochemical components.  
Additionally the following was performed within the gastroschisis group only; serial 
antenatal bowel wall thickness measurements at the time of routine antenatal 
ultrasound monitoring, a photograph of the externalised bowel taken at the time of 
delivery to document the macroscopic inflammatory appearance of the bowel, serial 
collection of stool postnatally to test for inflammatory proteins such as calprotectin 
and analyse the faecal microbiome and finally collection of prospective antenatal and 
postnatal clinical outcome data (Table 1-1).  
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 Control Gastroschisis 
Amniotic fluid   
Maternal blood prior to delivery   
Fetal cord blood post delivery   
Serial measurement of bowel wall thickness 
by antenatal ultrasound 
X  
Photograph of externalised bowel at time of 
delivery  
X  
Serial postnatal stool collection X  
Collection of clinical data  X  
Table 1-1: Specimens collected within the control and gastroschisis study groups. 
Potential biomarkers were then to be correlated with neonatal outcomes. Time to full 
enteral feeds was the primary outcome measure and used as a surrogate measure for 
postnatal gut function. Although previous studies have examined the amniotic fluid 
profile in gastroschisis, there have been limited attempts to correlate with postnatal 
outcomes, and as such there was no data on which to base a power calculation 
therefore this was to be a pilot study. During the 18 month period, 22 gastroschisis 
patients were seen in the study hospitals fetal medicine departments (11 University 
College Hospital London, 11 King’s College Hospital) and although 11 patients 
consented to the study it was only possible to collect specimens in 3 patients due to 6 
spontaneous deliveries preventing sample collection, 1 patient withdrew consent and 
1 fetal death at 34 weeks (Table 1-2). Unfortunately due to this low number of 
collected gastroschisis samples it was not possible to complete the study and the data 
is not further discussed in this document. 
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University College 
London Hospital 
King’s College 
Hospital 
Total number of gastroschisis 
pregnancies 
11 11 
   
Consent for study given 3 8 
Specimens successfully collected 2 1 
Early spontaneous delivery  0 6 
Withdrew consent 0 1 
Fetal death 1 0 
Table 1-2: Breakdown of gastroschisis patient recruitment at University College London 
Hospital and King’s College Hospital fetal medicine centres. 
1.6.7.1.3 Timing and Mode of Delivery  
Following reports suggesting in-utero loss of fetuses with gastroschisis can occur in 
the late term period (>39 weeks GA) (Burge and Ade-Ajayi, 1997, Crawford et al., 
1992) gastroschisis fetuses are usually planned to be delivered no later than 37 to 38 
weeks GA (Baud et al., 2013, Carnaghan et al., 2014, Lepigeon et al., 2014). 
Previously, the mode of delivery has been a contentious issue with fears that vaginal 
delivery may cause trauma or ischaemia to the externalised bowel and exposure to 
vaginal bacterial flora may also be detrimental to the eviscerated unprotected bowel. 
However, multiple studies have shown no association between mode of delivery and 
neonatal outcome suggesting vaginal delivery to be safe (Abdel-Latif et al., 2008, 
How et al., 2000, Salihu et al., 2004). Therefore gastroschisis fetuses are routinely 
delivered vaginally by induction of labour at 37 to 38 weeks GA unless fetal or 
maternal concerns necessitate earlier delivery and/or delivery by caesarean section. 
Routinely inducing pregnancies before the due date provides the additional benefit of 
controlling the location of the birth enabling delivery to occur in a tertiary centre 
with paediatric surgical cover preventing the need for inter-hospital transfer, which 
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may have a detrimental effect on neonatal outcomes (Dalton et al., 2016). However, 
frequently women with gastroschisis pregnancies develop spontaneous labour prior 
to 37 weeks GA likely due to the pro-inflammatory amniotic fluid environment 
(Morrison et al., 1998) associated with gastroschisis and therefore the place of 
delivery cannot always be controlled. At the time of induction or onset of labour the 
perinatal team informs the neonatologist and the paediatric surgeons of the 
impending birth. Delivery of a gastroschisis fetus is considered a high risk birth 
requiring the neonatal team to be present throughout the latter stages of labour. 
1.6.7.2 Neonatal and Surgical Management of Gastroschisis 
1.6.7.2.1 Immediate Postnatal Management  
Following delivery the gastroschisis neonate is assessed (as per Advance Paediatric 
Life Support protocols) and stabilised on the labour ward by the neonatal team. If 
respiratory support is required then endotracheal intubation is performed early to 
avoid prolonged bag-mask ventilation and prevent over distension of the stomach 
and bowel. A nasogastric tube (NGT) is placed and left on free drainage to aid 
decompression of the bowel. Inspection of the bowel is performed to identify areas 
of discoloration suggestive of vascular compromise to the bowel. Simple manoeuvres 
to straighten the bowel and remove kinking of the vascular pedicle are performed to 
improve the blood supply. The bowel is placed centrally on the abdomen, supported 
by a doughnut ring made from wet gauze and wrapped in position using non-sterile 
transparent cling film, which maintains the position of the bowel, reduces fluid loss, 
helps maintain body temperature and enables direct visualisation of the bowel. The 
bowel is checked regularly for signs of ischaemia and if required the cling film is 
repositioned to aid bowel perfusion and an urgent surgical review obtained. Venous 
access is obtained and blood taken for cultures and routine surgical tests (full blood 
count, blood group and cross-match, biochemistry, venous gas and clotting). 
Externalised viscera results in significant serous fluid loss and therefore fluid 
resuscitation is commenced in the form of bolus, maintenance and replacement fluids 
as per hospital policy. IV antibiotics are initiated as per local hospital policy. When 
stable the neonate is transferred to the NICU or transported by ambulance to another 
hospital with paediatric surgical cover.  
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1.6.7.3 Surgical Management 
The surgical review is usually carried out on admission to NICU unless there are 
concerns regarding the vascular supply to the bowel in which case the neonate is 
reviewed on the labour ward. The neonate is examined to assess the vascular 
condition of the bowel, presence of concomitant structural intestinal pathologies, 
degree of bowel wall inflammation, the size of the defect ring and presence of extra-
gastrointestinal malformations. This assessment identifies those neonates who 
require urgent surgery due to compromised vascular supply to the bowel and informs 
the most appropriate method for reducing the externalised viscera into the abdomen 
and subsequent closure of the abdominal wall defect.   
Neonates with ischaemic bowel in whom perfusion fails to improve with simple 
bowel repositioning require urgent surgical intervention. Ischaemia can be caused by 
mesenteric compression at a small defect ring also known as ‘closing gastroschisis’ 
(Houben et al., 2009) requiring immediate widening of the defect to prevent necrosis 
of the bowel. The procedure is performed on NICU under local anaesthetic and 
involves a horizontal full thickness incision at the 9 o’clock position following which 
the bowel is observed for vascular improvement. If necrotic bowel is present then 
urgent bowel resection is required.   
The method by which the abdominal viscera are routinely returned to the abdominal 
cavity and the abdominal wall subsequently closed is an area of controversy. Closure 
methods include bedside or surgical, primary or delayed closure. Surgical centres and 
individual surgeons usually have a preferred method of closure and initiate this 
within 24 hours of the neonate’s birth. Deviation from this preferred method may 
occur if there is evidence of concomitant intestinal pathologies requiring urgent 
surgery or there is significant viscero-abdominal disproportion preventing primary 
closure of the abdominal wall defect (Stanger et al., 2014).  
Primary closure is immediate reduction of the viscera and repair of the defect within 
24 hours of birth. Primary closure is conventionally performed under general 
anaesthesia with the fascial (connective tissue) edges of the defect being closed using 
sutures or on occasions with the aid of a prosthetic patch. If reduction of the viscera 
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into the abdomen is not possible then a custom made silo is fashioned using silicone 
sheeting or a saline infusion bag and sutured to the fascial edges. Over a series of 7 
to 14 days the viscera are reduced into the abdomen by decreasing the volume of the 
silo. Once the viscera are fully reduced secondary fascial closure of the abdominal 
wall is performed under general anaesthetic. Other techniques have been developed, 
which achieve visceral reduction and abdominal wall closure without anaesthesia. 
Primary closure can be performed at the cotside in selected infants with gentle 
manual reduction of the viscera and abdominal wall closure achieved by covering the 
defect with the umbilical cord securing the cord in place using Steri Strips, glue 
and/or Tegaderm (plastic closure). Delayed secondary closure can be achieved at the 
cotside using a preformed silo, which is a silicone bag with a spring-loaded opening. 
The externalised viscera are gently placed into the silo and the spring-loaded opening 
manoeuvred through the defect where it rests on the inside of the abdominal wall 
providing traction for the silo to be reduced in volume as previously described.  
Secondary closure is then performed either at the cotside with a plastic closure or 
under general anaesthetic with a fascial sutured closure. Studies have shown that the 
use of a preformed silo reduces the need for ventilation. However, the method of 
visceral reduction and abdominal wall closure has no impact on the infant mortality 
or morbidity including time to full enteral feeds (ENT) and length of hospital stay 
(LOS) (Charlesworth et al., 2014, Kunz et al., 2013).  
1.6.7.3.1 Post-Procedure Management 
Post-procedure the neonate is at risk of respiratory embarrassment, abdominal 
compartment syndrome and ongoing fluid loss. Abdominal wall closure (primary or 
secondary) under tension can result in diaphragmatic splinting and respiratory 
compromise requiring a period of paralysis and ventilation post procedure. Equally 
some neonates with small abdominal girth undergoing staged silo reduction will also 
require a period of paralysis to aid return of the viscera into the abdomen. All 
neonates require monitoring for signs of abdominal compartment syndrome, which 
can occur following abdominal closure or silo reduction due to reduction of 
externalised viscera into a small non-compliant abdomen (viscero-abdominal 
disproportion) resulting in increased abdominal pressure. Raised intra-abdominal 
pressure can compress and impede the mesenteric blood flow resulting in bowel 
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ischaemia and ultimately bowel necrosis (Stanger et al., 2014). Additionally, it can 
cause compression of other major vessels leading to renal impairment or lower limb 
ischaemia. Treatment involves abdominal decompression in the form of reopening a 
closed abdominal wall followed by application of a silo or releasing tension on a silo 
that is already present. Fluid management can be complex due a number of 
insensible fluid losses including; evaporative losses secondary to prolonged exposure 
of the bowel serosa during abdominal wall closure or silo application, continued third 
space intra-abdominal or intra-silo fluid loss post-procedure and large bilious NGT 
aspirates or vomiting due to post-procedure bowel ileus and gastroschisis-related 
intestinal dysfunction. Fluid management may be further hampered by impaired 
monitoring due to decreased urine output secondary to raised intra-abdominal 
pressure.  
1.6.7.3.2 Nutritional Management 
Gastroschisis-related intestinal dysfunction is a very frequent problem for 
gastroschisis infants and refers to prolonged intestinal dysmotility resulting in large 
volume bilious NGT aspirates, bilious vomiting, lack of stooling and the inability to 
tolerate enteral feeding. Infants require alternative nutritional and fluid support until 
full enteral feeding is attained, which can take weeks sometimes months to achieve. 
The infant’s nutritional and baseline fluid requirements are met through the 
administration of parenteral nutrition (PN) via central venous access (usually a 
longline). Gastric losses in the form of NGT aspirates and vomits are replaced 
millilitre for millilitre with 0.9% normal saline with added potassium chloride to 
ensure hydration and electrolyte balance. Initially the infant is kept nil by mouth until 
the gastric losses become minimal and non-bile stained suggesting improved gut 
motility enabling small volume enteral feeds to be introduced via the NGT. Enteral 
feed volumes are slowly increased over several days, weeks or sometimes months. 
Often increasing the volume of feed results in bilious vomiting requiring the feed 
volume to be reduced and maintained for a few days at a lower volume before being 
increased again. During this period the volume of PN is titrated against the volume of 
enteral intake. The protocol for increasing feed volumes varies between centres and 
is dependent on local policies and surgeon/neonatology preference. If enteral feeding 
cannot be initiated within 6 weeks investigations for atresia or stenosis should be 
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undertaken. Careful management of the central venous access is essential to reduce 
the risk of infection and preserve access sites, which is particularly important for 
infants with prolonged gut dysmotility who may require long-term or life-long PN. 
1.6.7.3.3 Implications of Complex Gastroschisis 
Complex gastroschisis is associated with increased mortality and morbidity with an 
increased risk of; prolonged gastroschisis-related intestinal dysfunction, home PN, 
longer hospital stay, sepsis, short bowel syndrome and necrotizing enterocolitis 
(Bergholz et al., 2014). Neonates who require an extensive bowel resection for 
necrosis or multiple atresias are at significant risk of developing short bowel 
syndrome, which is a malabsorption disorder secondary to insufficient small bowel 
absorptive surface area. These neonates are reliant on life-long PN in order to meet 
their nutritional needs and may require complex surgery including a bowel 
transplant. The identification of reliable antenatal ultrasound markers to detect 
complex gastroschisis would provide a more accurate prognostic picture, guide 
antenatal counselling and inform antenatal and postnatal management (Overcash et 
al., 2014). 
1.7 Current Understanding of Gastroschisis-Related Intestinal 
Dysfunction 
Gastroschisis-related intestinal dysfunction (GRID) is a temporary gut dysmotility 
disorder, which causes significant infant morbidity. At birth bilious vomiting and 
vomiting after feeds indicates a functional bowel obstruction that is hypothesised to 
be secondary to dysmotility affecting both peristalsis and the MMC, although, gut 
motility studies have never been formally investigated clinically in gastroschisis 
infants to confirm this hypothesis. However, with time normal feeding is eventually 
established in most cases of gastroschisis allowing the infant to live a normal life. 
Infants with complex gastroschisis are more likely to experience prolonged GRID 
and in some cases may never attain full enteral autonomy. The mechanism(s) 
underpinning GRID remain poorly understood. As such, there have been no advances 
in developing a therapy that will reduce the severity of GRID and in turn improve gut 
function. Therefore, this is an area of significant research interest and if a therapy 
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that improves gut function were to be developed it would considerably improve 
gastroschisis outcomes.  
1.7.1 Gastroschisis versus Exomphalos: Gut Function and Anatomy 
Gastroschisis and exomphalos have important differences in postnatal intestinal 
function and anatomical features. Gastroschisis is associated with significant 
postnatal intestinal dysfunction and 10-15% of neonates are classed as complex due 
to concomitant bowel pathology (Carnaghan et al., 2014, Bradnock et al., 2011). 
Whereas exomphalos neonates usually have normal intestinal function and 
concomitant bowel pathology is rare (Vachharajani et al., 2009). Important 
anatomical differences between gastroschisis and exomphalos include; presence or 
absence of a protective membranous sac over the externalised viscera, the size of the 
abdominal wall defect and presence or absence of liver herniation. In gastroschisis 
the externalised bowel has no membrane coverage and lies in direct contact with the 
amniotic fluid, the defect is usually small approximately 1 to 2cm wide and the liver 
is very rarely externalised. In exomphalos the herniated bowel is contained within the 
amniotic membrane at the base of the umbilical cord protecting the bowel from the 
amniotic fluid. Additionally, the size of the exomphalos defect can range in size from 
a minor (<5 cm but still larger than usually seen in gastroschisis) defect with no liver 
herniation to a major (>5 cm) defect with extensive liver herniation (Carnaghan et 
al., 2009, Groves et al., 2006). Given these differences it has been hypothesised that 
in gastroschisis the abnormal exposure of the bowel serosal surface to amniotic fluid 
during fetal development (Tibboel et al., 1986) or compression/constriction of the 
bowel as it herniates through the tight ventral wall defect (Shah et al., 2012, Langer 
et al., 1989) could be the cause of GRID. 
1.7.2 Gastroschisis Antenatal Bowel Morphological Changes and Amniotic 
Fluid Composition 
An observational study mapped the antenatal morphological changes of gastroschisis 
bowel from 26 human embryos and fetuses exhibiting gastroschisis ranging from 
approximately 8 weeks GA to full term. The study revealed that although the defect 
occurs early, progressive changes to the bowel wall only occurred after the 30th 
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week of gestation consisting of bowel wall inflammation and progressive fibrosis 
(Tibboel et al., 1986). These findings correspond with the significant changes in 
amniotic fluid composition that occur in the third trimester (as previously described) 
including increases in urea, creatinine, bile acids, enteric enzymes and IL-8 and 
reduction in sodium, chloride and osmolality (Underwood et al., 2005). Therefore, 
the development of bowel inflammation from 30 weeks gestation could be due to the 
accumulation of potentially noxious substance in the amniotic fluid during the third 
trimester to which the bowel is directly exposed.  
1.7.3 Amniotic Fluid and Fetal Inflammatory Markers 
The morphological changes described by Tibboel et al. suggest an inflammatory 
process is associated with gastroschisis. Two studies have demonstrated the amniotic 
fluid in gastroschisis pregnancies to be in a pro-inflammatory state. The first 
collected amniotic fluid at the time of caesarean section from 10 pregnant women 
with a gastroschisis fetus and 10 pregnant women with a healthy fetus. Within the 
gastroschisis cohort there was an elevation in neutrophils, mononuclear cells and 
interleukin-8 (pro-inflammatory cytokine) compared to the healthy controls 
(Morrison et al., 1998). In addition, the CD15 mononuclear cell population was 
found to exhibit markedly elevated CD11b markers revealing these cells to be in an 
activated state (Morrison et al., 1998). The second study compared amniotic fluid 
specimens collected by amniocentesis for karyotyping between 15 and 32 weeks GA 
from 41 women with gastroschisis fetuses and 93 age-matched controls. This study 
revealed elevation of amniotic total protein, IL-6, IL-8 and ferritin levels with 
significantly higher amniotic fluid cell counts in gastroschisis pregnancies compared 
to controls (Guibourdenche et al., 2006). Finally, another study investigated the 
presence of systemic fetal inflammation through comparison of fetal cord blood 
lymphocytes collected from 21 gastroschisis pregnancies and 20 healthy controls. 
This study revealed gastroschisis fetal cord blood to have significantly higher 
numbers of effector memory CD8 and CD4 T-cells and terminally differentiated 
effector memory CD8 T-cells compared to controls, indicating the presence of T-cell 
activation (Frascoli et al., 2013). These studies suggest that inflammation could be 
involved in the pathophysiology of GRID.  
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1.7.4 Bowel Wall Thickening  
As described by Tibboel et al., 1986, at birth gastroschisis bowel frequently appears 
thickened and inflamed. Surgical animal models of gastroschisis including chick 
(Api et al., 2001, Olguner et al., 2006, Yu et al., 2004), rat (Correia-Pinto et al., 
2002, Hakguder et al., 2011, Bittencourt et al., 2006), rabbit (Guo et al., 1995) and 
lamb (Srinathan et al., 1995) have demonstrated increased thickening of the bowel 
wall including serosal and smooth muscle layers of gastroschisis bowel compared to 
controls (Table 1-3). Manipulation of the amniotic fluid inflammatory environment 
in these surgical models has led to altering degrees of bowel wall thickening. Intra-
amniotic administration of meconium, which contains numerous products from the 
digestive tract including IL-8 a neutrophil chemotaxin (de Beaufort et al., 1998), in 
chick and rat surgical gastroschisis models revealed an increase in bowel wall 
thickness (Api et al., 2001, Correia-Pinto et al., 2002). Dilution of meconium through 
induction of fetal diuresis by intra-amniotic injection of furosemide in a rat surgical 
gastroschisis model (Hakguder et al., 2011) showed reduction in serosal thickening. 
Additionally, reduction of in-utero inflammation by  intra-amniotic injection of urine 
trypsin inhibitor (an IL-8 inhibitor) in a chick surgical model (Olguner et al., 2006) 
and intra-amniotic dexamethasone in chick and rabbit surgical gastroschisis models 
has shown a reduction in gastroschisis bowel wall thickness (Yu et al., 2004, Guo et 
al., 1995). These data suggest that remodelling of bowel smooth muscle and serosa 
resulting in bowel wall thickening may be induced by inflammation. Furthermore, 
increased levels of transforming growth factor-beta 3 (TGF-β3), which is known to 
cause organ dysfunction through alterations in smooth muscle, have been found in 
human gastroschisis gut compared to controls (Moore-Olufemi et al., 2015) and may 
be a mediator of gastroschisis bowel wall thickening.   
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Table 1-3: Summary of bowel wall morphology findings within animal gastroschisis 
models. GS = gastroschisis, AF = amniotic fluid. 
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1.7.5 Deficiency of the Interstitial Cells of Cajal  
Investigations in animal gastroschisis models and resected human gut specimens 
have also implicated deficiency of the bowel wall interstitial cells of Cajal (ICC) as 
the cause of GRID, which could form the target for an antenatal therapy.  
Animal studies in chick (Vargun et al., 2007), rat (Auber et al., 2013, Midrio et al., 
2004), and lamb (Krebs et al., 2014) surgical gastroschisis models and also the  aortic 
carboxypeptidase-like protein (ACLP) knockout genetic gastroschisis mouse model 
(Danzer et al., 2010) have suggested architecturally immature and reduced number of 
bowel wall ICC are present in gastroschisis (Table 1-4). Additionally, two studies 
(Auber et al., 2013, Danzer et al., 2010) compared both eviscerated and non-
eviscerated gastroschisis fetal bowel with control fetal bowel. Both studies reported 
the eviscerated small bowel to exhibit architecturally immature and reduced number 
of ICC compared to controls, whilst the non-eviscerated bowel exhibited the same 
architecture and ICC numbers as that of controls. Suggesting ICC development is 
only impaired in the eviscerated bowel of gastroschisis.  
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Table 1-4: Summary of ICC findings within animal gastroschisis models. GS = 
gastroschisis, IHC = immunohistochemistry. 
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Fetal interventions to try and improve ICC development have been trialled in animal 
models (Table 1-4). Vargun et al., 2007 investigated whether fetal intervention with 
amnio-allantoic exchange or bicarbonate infusion in a chick surgical gastroschisis 
model would improve ICC development. The aim of amnio-allantoic exchange was 
to remove and replace the potentially noxious amniotic fluid and the bicarbonate 
infusion to buffer the amniotic fluid preventing the normal function of any enzymes 
that may be present in the amniotic fluid from intestinal waste products. This study 
showed there was still a significant reduction in ICC numbers in the bicarbonate 
infusion group compared to controls but no significant difference in ICC numbers in 
the amnio-allantoic exchange group compared to controls. Suggesting amnio-
allantoic exchange lessens the noxious effect of amniotic fluid on the exposed bowel 
improving ICC development. Also, Krebs et al., 2014 attempted to cover the 
externalised bowel in-utero in surgically created gastroschisis lamb fetuses in order 
to protect the bowel from amniotic fluid exposure. The procedure achieved full 
coverage in 2 gastroschisis lambs and partial coverage in 5 gastroschisis lambs. 
However, none of the coverings remained in place until the end of pregnancy due to 
dislocation during late pregnancy. Even so the paper reported in the full coverage 
group the number of ICC to be the same as controls. However, there was a reduction 
in ICC numbers compared to controls in the partial coverage group. These results 
suggest that direct exposure of the bowel wall to amniotic fluid may be the cause of 
ICC deficiency but given the small numbers in each group little more can be 
interrupted from the results.  
It is important to note that all these animal studies have methodological limitations. 
The studies used tissue from randomly selected sections of small intestine 
(eviscerated small intestine in gastroschisis fetuses), which therefore may include a 
mixture of jejunum and ileum and may not be directly comparable. Cross-sectioned 
bowel was used in all the studies but given the small stature of the experimental 
animals used the bowel was equally very small and on assessment of the published 
images of the cross-sectioned tissue it is very difficult to identify ICC cell bodies or 
discern the ICC branching architecture. Therefore based on these images it appears 
difficult to accurately assess ICC architecture or robustly quantify cell numbers using 
this tissue preparation method. All but one paper performed either semi-quantitative 
(e.g. cell grading system of sparse: 0-2 cells, few: 3-7 cells, moderate: 8-12 cells and 
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many:  >12 cells (Danzer et al., 2010)) or qualitative (e.g. cell grading system of 1 
for mature, 2 for moderately mature and 3 for very mature (Auber et al., 2013)) 
methods for quantifying ICC (which could result in bias) instead of a robust 
quantitative method. Also, the field of views used to quantify cells from were 
randomly oriented thereby including a varying area of bowel wall within each image. 
Due to these limitations the results of these studies need to be interrupted with 
caution 
Within the human literature there are 2 published studies investigating ICC 
development in gastroschisis infants. The first study (Midrio et al., 2008) 
qualitatively analysed ICC at two time points in a single case of human gastroschisis. 
The first was at birth following bowel resection and stoma formation for bowel 
necrosis and the second at one month of age when partial enteral feeding was 
tolerated enabling stoma closure. At birth the ICC were described to be decreased in 
number and immature. However, at one month the ICC were observed to have 
formed groups and many were differentiated (Midrio et al., 2008) implying ICC 
numbers and function recovered over time. Finally, during the experimental period of 
this PhD thesis a larger human archival gastroschisis gut study was published (Zani-
Ruttenstock et al., 2015). Bowel specimens were analysed using a quantitative 
method from 12 gastroschisis patients that had stoma formation (time point 1) and 
then stoma reversal (time point 2). ICC numbers were compared against non-
gastroschisis infants who had stoma formation for necrotising enterocolitis, ileal 
atresia and malrotation/volvulus. The authors showed that there was no difference in 
ICC numbers between gastroschisis and controls at time point 1 but there were 
significantly more ICC in the control group at time point 2. Concluding within the 
gastroschisis group, that there was no ICC improvement or recovery during the study 
period and ICC modulation may be beneficial in the treatment of GRID.  
These studies also have limitations, which are; inclusion of resection margins with 
severely inflamed abnormal tissue due to inclusion of conditions such as necrotising 
enterocolitis or stoma reversal which could adversely affect ICC numbers giving 
spurious results, quantification from randomly orientated fields of view thereby 
including a varying area of bowel wall within each image and in the first study a 
qualitative ICC assessment with no comparison to control bowel.  
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Finally, anti-CD117 (antibody to the c-Kit receptor tyrosine kinase present on ICC) 
was used in all the studies and is the most commonly used marker for ICC 
histological assessment. However, this only provides evidence of the presence of c-
Kit receptor tyrosine kinase and the absence or fluctuations in staining doesn’t prove 
absence of the cell. The most robust way of analysing the presence and architecture 
of ICC is by electron microscopy (Tamada and Kiyama, 2015), which although 
provides highly detailed images is an expensive, time consuming and difficult 
method of microscopy and is infrequently used. One of the above animal studies 
(Midrio et al., 2004) also used electron microscopy for the qualitative assessment of 
ICC in eviscerated gastroschisis bowel. This study reported that in the less-damaged 
gastroschisis bowel loops some cells with features that resembled ICC were 
identified on electron microscopy but in the more damaged gastroschisis bowel loops 
no cells with features of ICC could be recognised confirming ICC deficiency may be 
the cause of GRID.  
1.7.6 ICC Plasticity and Response to Inflammation 
Studies have shown ICC to exhibit inherent plasticity resulting in phenotypic change 
and loss of function under certain unfavourable conditions. For example, in one 
study (Torihashi et al., 1999) blockade of Kit receptors resulted in ICC loss which 
was not accounted for by apoptosis assays but analysis with electron microscopy 
revealed remaining ICC had developed features of smooth-muscle cells. 
Additionally, loss of ICC have been reported in inflammatory bowel conditions 
including inflammatory bowel disease and necrotising enterocolitis (Burns, 2007) 
suggesting ICC phenotypic change occurs secondary to inflammation. Furthermore, 
another study has shown that ICC regenerate following removal of unfavourable 
conditions. This study induced gut inflammation in adult mice with Trichinella 
spiralis which led to damaged ICC processes between cells and desynchronous 
electrical activity at 1–15 days post infection. However, after 60 days and resolution 
of gut inflammation the ICC architecture and electrical signals returned to normal 
(Der et al., 2000). This research shows that bowel inflammation can result in 
phenotypic change of ICC and loss of function and this could be the mechanism 
underpinning GRID and a potential antenatal therapeutic target. 
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1.8 Clinical Therapeutic Strategies Trialled in Humans to Improve 
GRID 
1.8.1 Amnioexchange 
Amnioexchange was proposed as a method for diluting and removing potentially 
harmful biochemical and inflammatory products from the third trimester amniotic 
fluid of gastroschisis pregnancies. Animal experiments have reported potentially 
beneficial effects on bowel wall development following amnioexchange. In chick 
(Vargun et al., 2007, Sencan et al., 2002, Aktug et al., 1998a, Aktug et al., 1998b) 
and rabbit (Ashrafi et al., 2008) surgical gastroschisis models, improvements in the 
appearance of macroscopic intestinal damage (peal, matting and adhesions between 
bowel loops), microscopic bowel wall thickness and ICC numbers have been 
reported. Whilst dilution of the amniotic fluid through diuresis stimulated by 
furosemide in a rat surgical model of gastroschisis has also shown reduced serosal 
thickness (Hakguder et al., 2011).  
In humans amnioexchange involves the removal of amniotic fluid by amniocentesis 
and replacement of the fluid with warm normal saline on a weekly or twice weekly 
basis during the third trimester. Studies have reported mixed results with some 
showing a benefit in neonatal outcomes including shorter time to full enteral feeds 
and length of hospital stay (Luton et al., 1999, Luton et al., 2003) and others showing 
no improvement in neonatal outcomes or change in the biochemical or inflammatory 
status of the amniotic fluid (Midrio et al., 2007). This is likely due to the rapid 24 
hour turnover of amniotic fluid (Underwood et al., 2005). A randomised controlled 
trial investigating the effect of amnioexchange was undertaken in France. The 
preliminary results were reported at the 11
th
 World Congress in Fetal Medicine, 
2012, which concluded that so far the results showed no clinical improvement with 
amnioexchange and the procedure may be associated with an increased risk of 
stillbirth (Khalil, 2012). The study was later stopped prior to completion due to 
clinically significant iatrogenic complications including infections and increased rate 
of intra-uterine death. However, the final outcome results of the study are yet to be 
published.  
  
92 
 
A similar procedure called amnioinfusion has also been suggested, whereby warmed 
saline is instilled via amniocentesis to increase the amniotic fluid volume and reduce 
the concentration of potentially noxious substances. However, animal research 
investigating infusion of saline or sterile water has shown no improvement in bowel 
wall development (Bittencourt et al., 2006, Yu et al., 2004). Additionally, in the 
general population clinical studies have been performed to investigate the use of 
serial amnioinfusion in cases of preterm premature rupture of membranes with severe 
oligohydramnios but safety and efficacy data for this intervention is still lacking 
(Van Teeffelen et al., 2013).  As such, amnioinfusion is not performed routinely in 
gastroschisis pregnancies and is only performed on rare occasions in the presence of 
preterm severe oligohydramnios in an attempt to prevent fetal distress and death 
(Sapin et al., 2000, Dommergues et al., 1996).  
1.8.2 Early Delivery  
Planned early delivery of gastroschisis fetuses aims to reduce the duration of bowel 
exposure to the potentially deleterious third trimester amniotic fluid and in turn 
reduce the degree of gut inflammation and therefore severity of GRID. Currently, 
many centres electively deliver gastroschisis fetuses at 37 to 38 weeks GA due to 
concerns relating to unexpected fetal death in later gestation (Burge and Ade-Ajayi, 
1997, Crawford et al., 1992, david et al., 2008). However, some surgeons suggest 
that delivery at less than 37 weeks and even as early as 34 weeks GA would improve 
gut function after birth. A number of studies, the majority of which contain small 
numbers of patients, present conflicting evidence both for (Gelas et al., 2008, Moir et 
al., 2004) and against (Charlesworth et al., 2007, Logghe et al., 2005) delivery at less 
than 37 weeks GA. Given the inconclusive nature of the data standard practice 
continues to be delivery at 37 to 38 weeks GA in most centres.  
1.8.3 Fetoscopic Surgery 
Fetal surgery was developed for defects that cause secondary, progressive damage to 
the fetus resulting in severe morbidity or death. The aim of intervention was to 
ultimately improve infant outcomes and prevent fetal demise (Laberge, 1986). Three 
main types of intervention exist: (1) percutaneous fetal therapy involves placing a 
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needle or catheter in-utero and performing a procedure under 
sonographic/endoscopic guidance, (2) fetoscopic surgery is similar to other forms of 
minimally invasive surgery such as laparoscopic or thoracoscopic surgery and 
utilises small incisions, trocars, specially designed instruments and direct 
visualisation using a fetoscope and additional guidance from ultrasound, and (3) 
open fetal surgery whereby hysterotomy is performed, the fetus is exteriorised and 
operated on directly.  
Fetal surgery is becoming more common place for conditions such as severe 
congenital diaphragmatic hernia (Van der Veeken et al., 2018) and 
myelomeningocele (Adzick et al., 2011, Moldenhauer and Adzick, 2017). In the case 
of diaphragmatic hernia severe lung hypoplasia can lead to significant postnatal 
morbidity and mortality due to severe lung hypoplasia. The aim of fetal surgery is 
not to repair the primary diaphragmatic defect (initial attempts to do this by open 
fetal surgery led to suboptimal outcomes (Harrison et al., 1990)) but to improve lung 
development. As such fetal endoluminal tracheal occlusion (FETO) was developed 
secondary to lessons learned from tracheal atresia whereby the fetus develops larger 
than normal lungs due to the accumulation of lung secretions causing lung stretch 
and in turn increased lung proliferation. FETO is performed by a percutaneous 
technique under sonographic and endoscopic guidance in which a latex balloon is 
endoscopically positioned in the trachea and inflated. Prior to birth the balloon is 
removed (plug-unplug sequence) to enable balanced development of both type I and 
type II pneumocytes. Clinically the procedure is offered routinely to right-sided 
defects and an International randomised control trial is ongoing to assess the benefit 
of FETO in severe and moderate left sided defects (Van der Veeken et al., 2018).  
Invasive fetal intervention for gastroschisis (other than amnioexchange) has not been 
performed clinically in humans but has been trialled in fetal lambs with surgically 
created gastroschisis. Attempts to achieve safe fetoscopic primary repair of the 
abdominal wall defect in fetal lambs was found not to be possible due to viscero-
abdominal disproportion preventing safe return of the externalised viscera into the 
abdominal cavity (Bergholz et al., 2012, Kohl et al., 2009). As such, similar to fetal 
intervention for congenital diaphragmatic hernia where the aim is to improve lung 
development, fetal interventions in gastroschisis that aim to improve gut 
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development are potentially more appropriate. Two fetoscopic techniques that have 
been trialled in fetal lambs include defect widening (Kohl et al., 2009) and coverage 
of the externalised viscera.  Defect widening is based on the hypothesis that bowel 
compression at a tight abdominal wall defect is the cause of GRID and severe bowel 
compression could lead to necrosis and bowel loss. The aim of decompression is to 
improve gut development and in turn postnatal gut function in the less severe cases 
and bowel salvage in the most severe cases. Although the procedure has been shown 
to be technically possible (Kohl et al., 2009) it has not been used clinically due to the 
lack of evidence supporting extrinsic bowel compression as the cause of GRID or 
robust sonographic antenatal makers to detect fetuses that may benefit from this 
procedure for example those with impending bowel necrosis secondary to a closing 
gastroschisis defect. Coverage of the externalised viscera is based on the hypothesis 
that exposure of the bowel to amniotic fluid causes GRID and therefore protecting 
the eviscerated bowel would improve bowel development. Studies have shown it is 
possible fetoscopically to cover the bowel with a synthetic or biological sheet to 
protect the bowel from the potentially noxious amniotic fluid (Roelofs et al., 2013, 
Krebs et al., 2014) but safety and efficacy of the procedure have yet to be proven and 
therefore it has not been performed clinically in humans.   
1.8.4 Postnatal Prokinetics 
It had been postulated that postnatal prokinetics could stimulate bowel function. As 
such, a double blind randomised controlled trial was conducted to investigate 
whether enteral erythromycin (a smooth muscle motilin receptor agonist, which 
induces intense intestinal motor activity similar to phase III migrating motor 
complexes) would reduce the time to achieve ENT. However, the trial showed no 
improvement in postnatal outcomes and concluded that GRID was likely secondary 
to gastrointestinal damage that was not amenable to stimulus by a prokinetic (Curry 
et al., 2004). These findings suggest that an antenatal therapeutic approach to 
improve GRID may be more beneficial.  
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1.9 Animal Models  
1.9.1 Overview of Animal Research 
Animal models are used to mimic human pathology in order to enable a better 
understanding of the aetiology, pathophysiology and outcomes of such conditions. 
Animal models enable researchers to perform experiments that are not possible in 
humans and may yield essential information, which could be used to prevent or 
improve therapeutic options for the investigated pathology. Additionally, they enable 
new therapeutic strategies to be tested before use in human trials. In order to fully 
understand the pathophysiological mechanisms underlying GRID and to enable 
investigation of new therapies to improve postnatal gut function the use of a 
gastroschisis animal model is essential.  
The Animals (Scientific Procedures) Act 1986 is in place to regulate the use of 
animals for research in the UK. The Act applies to any research that could cause 
pain, suffering, distress or lasting harm to an animal. It ensures that research is 
performed in a humane and safe way with as minimal suffering as possible to the 
animal. The Act stipulates that in order for results to be relevant to the human disease 
it is essential to refine the animal model to ensure that the induced condition most 
closely resembles the human condition with respect to structural and functional 
characteristics (Klocke et al., 2007). Poorly designed animal models can lead to 
misleading data resulting in inaccurate physiological assumptions or theories (Chu et 
al., 2002, Klocke et al., 2007). Furthermore, extrapolation of such data to humans 
can be misleading (Casals et al., 2011). Several gastroschisis animal models have 
been described but none have been accepted as the definitive model that most 
reliably mimics the features of the human disease. 
1.9.2 Types of Animal Models 
Rodent models are frequently used in medical research because they share many 
biological similarities to humans and develop disease over the span of days or weeks 
rather than months or years. Additionally, they have short gestational periods and 
large litter sizes which are invaluable for researching congenitally acquired diseases. 
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Other commonly used animals include zebrafish, chicks, hamsters, guinea pigs, 
rabbits and sheep and very rarely dogs and primates.   
There are four types of animal model: induced, spontaneous, negative and orphan. 
Induced models are experimentally created. Spontaneous models involve animals 
that naturally develop a condition similar to human pathology. Negative models 
involve specific conditions that inhibit growth or a reaction to specific stimulus as a 
mechanism to understand physiology. Orphan models are pathologies that occur 
naturally in animals but have not been identified in humans (Casals et al., 2011). A 
gastroschisis animal model falls into the category of an induced model as 
gastroschisis is not known to occur naturally in animals such as chick, mouse, rat, 
rabbit and sheep, which are the most frequently utilised animals for basic science 
research. 
1.9.3 Induced Models of Human Pathology 
Induced models are usually created by surgical creation, genetic manipulation or 
chemical induction. 
1.9.3.1 Surgical Animal Models 
Surgically created models involve a surgical procedure to induce a human pathology 
in an animal. In cardiovascular or ischaemic disease this frequently involves the 
constriction of blood vessels, which can be achieved by a variety of methods 
including banding, ligation or blockage (Casals et al., 2011, Klocke et al., 2007, 
Louw and Barnard, 1955). In the case of structural malformations, such as 
gastroschisis, this involves the surgical creation of an abdominal wall defect that 
mimics the human condition at an appropriate time point in the animals’ life cycle 
(Langer et al., 1989).  
1.9.3.2 Genetically Modified Animal Models 
Genetic manipulation of animals involves adding, changing or removing targeted 
DNA sequences. Mice are most widely used for this application as advancements in 
genomic techniques have made manipulation of the murine genome relatively simple 
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enabling creation of phenotypes that are analogous to human pathology. The 
International Mouse Knockout Consortium aims to manipulate all protein-encoding 
genes in mouse embryonic stem cells using gene trapping and gene targeting 
techniques (Collins et al., 2007). As a result, some conditions now have known target 
genes, for example, investigations into the molecular mechanisms of 
craniorachischisis are focussed around loop-tail and circletail (Murdoch, 2003) gene 
manipulation. Whilst other conditions, such as gastroschisis, have no known genetic 
cause/link and rely upon incidental phenotype recognition during genetic model 
creation for other reasons (Murdoch, 2003, Layne et al., 2001).  
1.9.3.3 Chemically Induced Animal Models 
Chemical induction involves delivering a substance to an animal by ingestion or 
injection or removing a substance from an animals’ diet in order to mimic the human 
condition. This manipulation may involve either wild type or genetically modified 
animals. For example, to create coronary atherosclerosis wild type rats are fed a high 
fat/cholesterol diet (Wilson and Hartroft, 1970) whilst dietary folate restriction to 
pregnant dams induces neural tube defects (NTD) in splotch embryos (Burren et al., 
2008). Gastroschisis like defects can be created in animal fetuses with the use of 
several teratogens ( Table 1-5) (Van Dorp et al., 2010, McBride et al., 1982, Sukra et 
al., 1976, Fisher and Sawyer, 1980, Padmanabhan, 1998, Szabo et al., 1978, Gutova 
et al., 1971, Beauchemin et al., 1984, Samarawickrama and Webb, 1981, Hoffman 
and Moore, 1979, Singh, 2003, Yan and Hales, 2006, Pampfer and Streffer, 1988, 
Quemelo et al., 2007). However the incidence of gastroschisis like defects in these 
models is low and is frequently associated with significant concomitant 
malformations that could confound results. As such, chemically induced 
gastroschisis mutants will not be further discussed here.  
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Study Teratogen Animal Incidence of 
Gastroschisis 
Like Defect 
Concomitant Defects 
McBride et 
al., 1982 
Scopolamine 
hydrobromide (100µg, 
Tx96 h) 
Chick 21/62 (34%) -Exencephaly 
-Reduction deformities 
of the limbs 
-Microphthalmia  
-Buphthalmia  
Scopolamine 
hydrobromide (200µg, 
Tx96 h) 
36/46 (78%) 
Sukra et al., 
1976 
Selenium and mercury Chick Not specified  -Webbed, fused, and 
curled toes 
-Cracked, crooked, and 
shortened beaks 
-Liver malformations 
-Renal malformations 
Fisher and 
Sawyer, 1980 
Triamcinolone 
acetonide 
Chick Not specified -Reduced body weight  
-Encephalocele  
-Micrognathia, 
-Curled toes, and club 
feathers  
-Reduced haematopoiesis 
Padmanabhan 
1998 
Retinoic acid 
(200mg/kg) 
Mouse Not specified -Tail agenesis 
-Caudal vertebral defects  
-Spina bifida 
occulta/aperta 
-Imperforate anus 
-Rectovesicle or 
rectourethral fistula 
-Renal malformations 
-Cryptorchidism  
-Limb malformations 
-Craniofacial 
malformations 
Szabo et al., 
1978 
SK&F 36,914 (4–8 
mg/kg, TxD6–18) 
Rabbit 
 
2/72 (2.8%) -Acephaly 
-Neural tube defects 
-Hydrocephalus, 
-Cleft palate 
-Umbilical hernia 
-Diaphragmatic hernia 
-Amelia-phocomelia 
-Brachy-ectrodactyly 
-Tail anomalies 
-Fused/absent ribs and 
vertebrae 
-Lung anomalies 
-Cardiovascular 
anomalies 
SK&F D-39162 (0.5–3 
mg/kg, TxD6–18) 
1/256 (0.4%) 
SK&F D-39162 (4–8 
mg/kg, TxD6–18) 
2/57 (3.5%) 
SK&F D-39162 (16–32 
mg/kg, TxD6–18) 
1/20 (5%) 
Gold sodium 
thiomalate (1–2.5 
mg/kg, TxD6–18) 
1/89 (1.1%) 
Gold sodium 
thiomalate (20–45 
mg/kg, TxD6–18) 
2/95 (2.1%) 
Gutova et al., 
1971 
6-azauridine (12 
mg/kg, TxD6–12) 
Rat 4/69 (5.8%) -Encephalocele  
-Malformations of the 
extremities 
Beauchemin 
et al., 1984 
Alcohol (0.03ml/g of 
25% alcohol, TxD10) 
Rat 4/51 (7.8%) - Adactyly  
-Wrinkled skin, 
-Umbilical hernias  
-Interatrial-septal defect 
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Study Teratogen Animal Incidence of 
Gastroschisis 
Like Defect 
Concomitant Defects 
Samarawickra
ma and Webb, 
1981 
Candmium Rat Not specified -Renal damage 
-Hydrocephalus 
-Eye defects 
-Umbilical hernia 
Hoffman, 
1979 
Mercury (3µg, Tx72 h) 
 
Duck 2.6% 
 
Low dose:  
-Minor skeletal 
aberrations  
-Incomplete ossification 
 
Higher doses: 
-Micromella 
-Eye defects  
-Brain defects  
Mercury (9µg, Tx72 h) 
 
2.9% 
 
Mercury (27µg, Tx72 
h) 
 
14.0% 
 
Mercury (90µg, Tx72 
h) 
5.1% 
Singh, 2003 Carbon monoxide and 
protein–zinc deficienc 
Mouse Not specified -Growth restriction 
-Skeletal malforma 
 
Yan and 
Hales, 2006 
Hydroxyurea and 
glutathione deficiency 
(400 mg/kg, TxD9) 
Mouse 1/113 (0.9%) 
 
-Curly tail 
-Hind limb 
malformations 
-Hydrocephaly 
-Exencephaly 
-Open eye 
-Spina bifida 
Hydroxyurea and 
glutathione deficiency 
(600 mg/kg, TxD9 
4/61 (6.6%) 
Pampfer and 
Streffer, 1988 
Neutron-irradiation 
(12cGy) 
 
Mouse 4/245 (1.6%) 
 
-Exomphalos  
-Anencephalies 
-Skeletal malformations 
-Growth restriction Neutron-irradiation 
(25cGy) 
 
8/160 (5.0%) 
 
Neutron-irradiation 
(50cGy) 
 
17/220 (7.7%) 
 
Neutron-irradiation 
(75cGy) 
25/119 (21.0%) 
X-irradiation (25cGy) 
 
3/133 (2.3%) 
 
X-irradiation (50cGy) 
 
6/197 (3.0%) 
 
X-irradiation (100cGy) 
 
9/147 (6.1%) 
 
X-irradiation (200cGy) 29/178 (16.3%) 
Quemelo et 
al., 2007 
Retinoic acid 
(70mg/kg, TxD7) 
 
Mouse 2/31 (6.4%) 
 
-Exencephaly  
-Neural tube defects  
-Exomphalos   
-Lower limb alterations  
-Tail agenesis/alteration 
-Imperforated anus 
Retinoic acid 
(70mg/kg, TxD8) 
3/55 (5.4%) 
Table 1-5: Summary of teratogens that result in gastroschisis like defects including dosage, 
incidence and concomitant defects.  
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1.9.4 Animal Models of Gastroschisis 
1.9.4.1 Surgical Animal Models of Gastroschisis 
The creation of an animal surgical model of gastroschisis involves creation of an 
abdominal wall defect in the in-utero fetus and exteriorisation of the fetal bowel. The 
method has been described in chick, rat, rabbit and sheep (Vargun et al., 2007, Auber 
et al., 2013, Hakguder et al., 2011, Oyachi et al., 2004, Krebs et al., 2014, Bergholz 
et al., 2012). Table 1-6 outlines the approximate timing of abdominal defect creation, 
fetal collection and full term for each animal model. In all animals the procedure is 
technically difficult, increases suffering to the pregnant dam and places the 
pregnancy at risk of abortion.  
Animal Model 
Defect Creation 
(days post coitum) 
Fetal Collection 
(days post coitum) 
Full Term 
(days post coitum) 
Chick Between 5 and 15 18 21 
Rat 18.5 21.5 or 22 22 
Rabbit 24 Between 29 and 31 31 
Lamb 77 135 152 
Table 1-6: Timing of in-utero abdominal wall defect creation, fetal collection and duration 
of full term for each type of surgical animal model of gastroschisis. 
1.9.4.2 Genetic Mouse Models of Gastroschisis 
Genetic mouse models of abdominal wall defects are ideal given the short gestation, 
large litter sizes and that the process of abdominal wall closure is very similar to that 
of human development. In the mouse, primary abdominal wall closure starts at 8.5 
days post coitum (dpc) during which the left and right lateral plate mesoderm, which 
are composed of a thin epithelial membrane, elongate laterally and come to meet in 
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the ventral midline. In the midline the umbilical ring is thought to be formed of the 
same four mesodermal folds as previously described for human abdominal wall 
closure namely the cephalic, caudal and 2 lateral mesodermal folds (Brewer and 
Williams, 2004b). Centrally the umbilicus acts as the transition zone between the 
ventral wall ectoderm and the amniotic membrane, which are continuous with each 
other as seen in human development (Bargy and Beaudoin, 2014). At 10.5 dpc the 
relatively wide umbilical ring permits the herniation of the rapidly elongating midgut 
creating a physiological hernia. From 12 dpc, during the period of physiological 
herniation, the process of secondary abdominal wall closure occurs whereby 
myoblasts migrate from the myotome into the primary epithelial abdominal wall 
(Nichol et al., 2012). This process gives rise to the development of the secondary 
abdominal wall structures including keratinised epithelia, muscle and connective 
tissue. At 16.5 dpc the herniated bowel returns to the abdominal cavity and 
secondary closure is completed through closure of the umbilical ring (Kaufman and 
Bard, 1999).  
Other similarities between mouse and humans includes the development of the bowel 
wall neuromusculature and the extra-fetal fluid cavities. Mouse bowel neuromuscular 
development like humans involves anal to oral migration of both the enteric nerves 
(fully populated by 14.5 dpc) (Kapur et al., 1992) and smooth muscle (complete by 
18 dpc) (Torihashi et al., 1997), whilst the myenteric ICC are developed prior to birth 
by 18 dpc with continued development of other ICC populations after birth 
(Torihashi et al., 1997). Mouse extra-fetal fluid cavities like humans comprise an 
amniotic fluid cavity (located between the fetus and the amniotic membrane) and an 
exocoelomic fluid cavity (located between the amniotic membrane and visceral yolk 
sac) (Renfree et al., 1975, Pereira et al., 2011) both of which are similar in 
composition to humans but the amniotic fluid volume shows some differences. The 
mouse amniotic fluid composition is modulated by fetal urine, meconium, secretions 
of oral and airway fluids, swallowing and amniotic membrane absorption and over 
the course of gestation the potassium, chloride and lactate levels increase and the 
sodium, calcium and glucose levels decrease (Cheung and Brace, 2005). Whilst the 
composition of mouse exocoelomic fluid is determined by exchange of substances 
from the overlying visceral yolk sac serving as the principle site for materno-fetal 
protein exchange (Jauniaux and Gulbis, 2000). The volume of the mouse amniotic 
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fluid rises from mid gestation (11 dpc) to peak at 16 dpc (50% of the embryo weight) 
but then, unlike humans, sharply declines after this point and by 18 dpc only weighs 
10% of the embryo weight (Renfree et al., 1975, Cheung and Brace, 2005).  
In the literature four genetic models have been described as exhibiting a gastroschisis 
like defect (Table 1-7) - the Scribble mutant mouse model (Murdoch, 2003), the 
aortic carboxypeptidase-like protein (ACLP) knockout mouse (Layne et al., 2001, 
Danzer et al., 2010), Alx-4 mutant mouse (Qu et al., 1997) and Bmp1 mutant mouse 
(Suzuki et al., 1996). However, the Alx-4 mutant mouse was later described to be 
exomphalos (Matsumaru et al., 2011) and the Bmp1 mutant mouse is reported to 
exhibit failed folding of the amniotic membrane around the umbilical vessels(Suzuki 
et al., 1996)  resulting in the externalised bowel lying in the exocoelomic cavity 
rather than the amniotic fluid cavity and is therefore not a true gastroschisis defect.   
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Table 1-7: Summary of reported genetic mouse models that exhibit a gastroschisis like 
defect.  
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1.9.5 Surgical Versus Genetic Gastroschisis Animal Models 
Surgical models of gastroschisis require the pregnant dam and the fetuses to undergo 
a technically difficult (in the case of small animals) invasive surgical procedure in 
order to create an abdominal wall defect similar to gastroschisis. This procedure 
increases the risks of fetal loss and the level of animal suffering. Given the amniotic 
fluid is replaced with saline during the procedure the potentially deleterious amniotic 
fluid components causing bowel dysmotility are removed. However, the natural 
turnover of amniotic fluid is 24 hours and therefore the effect of replacing the 
amniotic fluid is likely to be short lived. Additionally, the surgical procedure will 
create confounding inflammatory changes, which could impact on the bowel 
development. In small animal gastroschisis surgical models the time between defect 
creation and collection of the fetuses is short reducing the duration of bowel 
exposure to amniotic fluid and the time available to experimentally manipulate the 
amniotic fluid environment. As such, large animal surgical models are the most 
advantageous. However, large animals are costly, have long gestations and small 
litter sizes increasing the number of dams required to complete experiments and are 
therefore not ideal for this type of research.  
In comparison, genetic mouse gastroschisis models exhibit an abdominal wall defect 
that occurs early in pregnancy similar to humans providing a more representative 
model of the effects of amniotic fluid exposure without the development of 
confounding inflammation caused by surgical defect formation. There are no known 
or anticipated negative effects for heterozygote mice or pregnant dams thus reducing 
the level of suffering. Additionally, mice have short gestations, similar sequence of 
abdominal wall closure to humans and large litter sizes reducing the number of dams 
required to complete the experiments. To prevent suffering of affected pups 
pregnancies are prevented from reaching full term.  
1.10 Summary 
Gastroschisis-related intestinal dysfunction is a significant issue affecting most 
infants with gastroschisis. Although the pathophysiology of GRID is not fully 
understood, there are significant data within the literature to suggest that deficiency 
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and immaturity of bowel wall ICC (the pacemaker of the gut) secondary to 
inflammation during fetal life is the cause of GRID. Given the evidence for ICC 
plasticity in response to inflammation, the transient nature of GRID could be 
explained by the gradual postnatal resolution of bowel wall inflammation and 
resultant maturation and increase in bowel wall ICC. Therapeutic options antenatally 
and postnatally have been trialled but no improvements in postnatal intestinal 
function have been achieved to date.  
1.11 Hypotheses 
Gastroschisis-related intestinal dysfunction is secondary to deficient, immature 
bowel wall ICC caused by bowel inflammation and amelioration of inflammation 
antenatally will improve gut function. 
1.12 Thesis Aims 
The underlying aims of the work contributing to this thesis are centred on addressing 
the pathophysiology of GRID with a primary line of investigation focussing on ICC 
development in gastroschisis from which further research could develop an antenatal 
therapy to improve intestinal function before birth for gastroschisis infants. The aims 
of this work are to determine: 
1. The morphology of gastroschisis bowel wall including ICC, enteric neurons 
and bowel wall architecture  
2. The impact of inflammatory modulation on gastroschisis bowel wall ICC and 
bowel contractility 
3. The impact of clinical antenatal interventions on infant outcomes. 
1.13 Outline of Work to be undertaken 
In order to address these aims a number of studies have been designed utilising a 
variety of resources including genetic mouse gastroschisis models, human 
pathological gut tissue and retrospective analysis of clinical data. 
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1.13.1 Gastroschisis Bowel Wall Morphology 
Quantitative morphological analysis of bowel wall ICC, enteric neurons and 
architecture will be performed using immunofluorescence and histological 
techniques utilising a genetic mouse gastroschisis model and human pathological gut 
tissue. Gastroschisis bowel will be compared to bowel from controls.  
1.13.2 Impact of Inflammatory Modulation on Gastroschisis Bowel Wall 
Morphology and Bowel Contractility 
Intra-amniotic injections of the pro-inflammatory mediator IL-8 will be performed in 
the genetic mouse gastroschisis model following which quantitative morphological 
analysis of the bowel wall ICC, enteric neurons and architecture will be undertaken. 
In addition, bowel contractility of untreated and injected fetal mice will be analysed 
within an organ bath.   
1.13.3 Impact of Simple Clinical Antenatal Measures on Clinical Outcomes 
Retrospective clinical data from three paediatric surgical centres will be collected to 
determine whether early delivery of gastroschisis fetuses or the administration of 
maternal antenatal corticosteroids could improve infant morbidity and if antenatally 
detected bowel dilatation could be used to predict infant outcomes.  
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Chapter 2: Materials and Methods 
2.1 Animal Models General Methods 
2.1.1 Ethics Statement 
All animal experimental protocols were approved by the University College London 
(UCL) Biological Services Ethical Review Committee and granted Home Office 
approval under the UK Animals (Scientific Procedures) Act 1986 (PPL 70 7408 - 
Prenatal therapy with stem cells and gene transfer).  
2.1.2 Selected Animal Models 
Genetic rodent models were considered to be the most refined animal model for this 
application whilst reducing the number of animals required and the level of suffering 
induced. The similar mouse abdominal wall closure time sequence and ICC/enteric 
neuron development compared to humans makes genetic mouse models of 
gastroschisis ideal for this research. The Scribble knockout mouse model and the 
ACLP knockout mouse model were used in this thesis. 
2.1.3 Model Source and Creation of Null Fetuses 
2.1.3.1 Scribble Knockout Mouse Model 
A Scrib
fl
 mutant mouse colony was already housed in the UCL Biological Services. 
The Scrib
fl
 allele was originally a kind gift from Dr Patrick Humbert, Peter 
MacCullum Cancer Centre, Melbourne. Null alleles (Scrib
-
) were created by matings 
between Scrib
fl/fl
 homozygotes with mice expressing the ubiquitously expressed 
βactin-Cre. Timed matings between adult heterozygotes (Scribfl/-) generated Scrib 
knockout fetuses (Scrib
-/-
). 
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2.1.3.2 ACLP Knockout Model 
Two male and two female heterozygote (ACLP
+/-
) mice with a mixed C57BL/6J-
129Sv background were a kind gift from Matthew Layne, School of Medicine 
Biochemistry, Boston University. Rederivation was performed at University College 
London using C57BL/6J female mice to avoid prolonged quarantine of imported 
mice. Colony expansion was achieved through mating of rederived heterozygote 
female mice with C57BL/6J wild type males. Timed matings between adult 
heterozygotes (ACLP
+/-
) generated ACLP knockout fetuses (ACLP
-/-
). 
2.1.4 Animal Husbandry 
2.1.4.1 Housing of Mouse Colonies 
The mouse colonies were housed in the UCL Biological Services. The Scribble 
knockout mouse colony was housed in open cages throughout the duration of the 
experiments. However, the ACLP mouse colony was housed from September 2012 
in open cages but moved to individually ventilated cages in June 2014 following a 
laboratory wide change in caging system. The bedding material used was 3R`s 
premium white bedding/Litaspen B8/20 sawdust bedding material. The laboratory 
was kept at a temperature of 19-23 degrees with a 12 hour light dark cycle with 
graded transition between light settings. Harlan 2018 feed and tap water were 
replenished daily.  
2.1.4.2 Pinworm treatment 
The animal facility developed a laboratory wide infestation of pinworm. As a 
consequence, all mice were treated for 9 weeks (September 2014 to December 2014) 
with a Fenbendazole diet and rooms were deep cleaned with Neopresidan 2% and 
fumigated. ACLP knockout mouse model experiments were stopped for the duration 
of the treatment period to prevent results being compromised by unknown fetal drug 
side effects. Experimental data from animals prior to September 2014 have been used 
because pinworm is transmitted by the faecal-oral route and cannot cross the placenta 
therefore mouse fetuses are thought to be unaffected by the infestation.  
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2.1.4.3 Breeding Pairs 
Six adult (mice >8 weeks old) breeding pairs were maintained at all times crossing 
wild type females with heterozygote males. Breeding females were exchanged after 6 
pregnancies or if litter sizes decreased. Breeding males were exchanged when they 
reached >18 months of age or fertility dropped.  Pups from breeding pair litters were 
genotyped. To maintain a sustainable colony a minimum of 6 wild type females and 
3 heterozygote males were kept to enable replacement of breeding pairs when 
required. For time matings, 6 stud heterozygote males and all heterozygote females 
were maintained in the colony. All other pups were euthanized to ensure an 
affordable colony. 
2.1.4.4 Timed Mating 
Timed matings between adult heterozygote females and stud heterozygote males 
generated null (homozygote knockout) fetuses. Timed matings were paired at 6pm 
and vaginal plugs checked by 10am the following morning. The morning on which a 
vaginal plug was detected was designated 0.5 dpc. 
2.1.4.5 Fetal Collection 
Pups born with an abdominal wall defect (AWD) die postnatally and therefore to 
prevent suffering of affected pups fetuses were collected by 18.5 dpc at the latest. 
Pregnant dams were euthanized by cervical dislocation and fetuses collected in-utero 
by maternal hysterectomy. Fetuses were transported in the intact uterus to the 
dissecting room in 1x phosphate buffered saline (PBS).  
2.1.5 Genotyping 
2.1.5.1 Tissue for Genotyping 
Genotyping was performed by polymerase chain reaction (PCR). Ear biopsies were 
taken from pups generated from breeding pairs for the purpose of identification and 
DNA extraction for genotyping. Tail biopsies were taken from fetuses generated 
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from time matings and used for DNA extraction for genotyping. All biopsies were 
stored dry at -20°C prior to DNA extraction.  
2.1.5.2 DNA extraction 
DNA extraction was performed on approximately 3mm segments of tissue. The 
tissue was added to 75µl of 25mM sodium hydroxide containing 0.2mM ethylene 
diamine tetraacetic acid disodium (EDTA Na2) at pH 12 and heated to 95°C for 10 
minutes. The mixture was allowed to cool to room temperature followed by addition 
of 75µl of 40mM Tris hydrochloride at pH 5. At this point the DNA extraction 
mixture could be stored at -80°C for PCR genotyping at a later date or used 
immediately for genotyping by PCR 
2.1.5.3 Genotyping by PCR 
PCR genotyping was performed with HotStarTaq Master Mix® (Qiagen). Two 
separate reactions were set up for identification of wildtype ([WT], Scrib and ACLP) 
and knockout (Scrib
flox-neo 
and ACLP
-
) DNA sequences. The primers used were as 
outlined in Table 2-1. The WT reaction included common forward and WT reverse 
primers. The knockout reaction included common forward and mutant reverse 
primers. The PCR reagents and volumes were as outlined in Table 2-2. A DNA 
extraction sample from a known heterozygote was used as a positive control. RNase-
free water was used instead of DNA to create a negative control. The PCR 
programmes used were as outlined in Table 2-3 following which samples were stored 
at 4°C until gel electrophoresis was performed.  
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Primer Type Primer Sequence 
Scrib common forward 5’ GGACTCAGACCCTCTTTCGT ‘3 
Scrib WT reverse 5’ GCCATGGTGGCAGAGGTTGG 3’ 
Scrib mutant rev 5’ CTTCCATTTGTCACGTCCTGC 3’ 
ACLP Common forward 5’ CAATATGGCACGAGCAGAG ‘3 
ACLP WT reverse 5’ GAGGCAAGCGAGGAGGTA 3’ 
ACLP mutant reverse 5’ TCTTGACGAGTTCTTCTGAG 3’ 
Table 2-1: Primers used for genotyping. 
Reagent Volume (µl) 
HotStarTaq Master Mix® 12.5 
forward primer (0.1µg/µl common) 0.375 
reverse primer (0.1µg/µl WT or mutant) 0.375 
RNase-free water 10.25 
DNA extraction mixture 2 
Table 2-2: PCR reagents and volumes for genotyping. 
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Temperature and duration Number of Cycles 
Scribble Mouse Model 
94°C, 5 minutes 1 
94°C , 1 minute 
56°C, 1 minute 30 seconds 
72 °C, 1 minute 30 seconds 
35 
72°C, 10 minutes 1 
ACLP Mouse Model 
94°C, 5 minutes  
58°C, 30 seconds  
68°C, 45 seconds 
3 
94°C, 30 seconds  
58°C, 30 seconds  
68 °C, 45 seconds 
32 
68°C, 7 minutes 1 
Table 2-3: PCR temperature cycle settings 
2.1.5.4 Gel Electrophoresis 
The electrophoresis gel was made from 1.5% agarose in 100mls of 1x TAE (mixture 
of Tris base, acetic acid and EDTA) buffer, which was heated in a microwave for 2 
minutes until the agarose dissolved. 8µl of ethidium bromide was added to the 
mixture and the gel left to set for 30 minutes. A mix of 2µl of loading dye and 12µl 
of DNA sample were loaded into the wells. Each line of wells contained a positive 
control and TrackIt™ DNA ladder (Thermo Fisher Scientific) for identification of 
positive bands.  
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2.1.5.5 Electrophoresis Bands 
2.1.5.5.1 Scribble Knockout Mouse Model 
The Scrib (WT) allele fragment size was 286 bp and Scrib
flox-neo 
(knockout) allele 
fragment size was 512 bp (Figure 2-1).  
 
Figure 2-1: Scrib and scrib
flox-neo
 allele gel electrophoresis, including DNA ladder and 
control DNA from a known heterozygote fetus. A. Gel electrophoresis for Scrib (WT) allele, 
box highlights positive allele bands. B. Gel electrophoresis for scrib
flox-neo
 (knockout) allele, 
box highlights positive allele bands. 
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2.1.5.5.2 ACLP knockout Mouse Model 
The ACLP (WT) allele fragment size was 381 bp and ACLP
-
 (knockout) allele 
fragment size was 475 bp (Figure 2-2).  
 
Figure 2-2: ACLP and ACLP
-
 allele gel electrophoresis, including DNA ladder and control 
DNA from a known heterozygote fetus. A. Gel electrophoresis for ACLP (WT) allele, box 
highlights positive allele bands. B. Gel electrophoresis for ACLP
-
 (knockout) allele, box 
highlights positive allele bands. 
2.1.6 Abdominal Wall Defect Phenotyping 
2.1.6.1 Fetal Preparation 
Phenotypically normal and AWD fetuses were collected at varying time points. The 
intact uterus was dissected in 1x PBS under a dissecting stereo microscope (Zeiss 
SV6, USA). The uterine muscle was carefully removed leaving the amniotic 
membranes and placenta intact for each fetus. Visualisation and gross identification 
of phenotypically normal and mutant fetuses was performed through the relatively 
translucent intact amniotic membranes. Phenotypically normal and AWD fetuses 
were imaged under the Zeiss SV6 microscope.  
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2.1.6.2 Microdissection and Imaging 
The anatomy of the abdominal wall in relation to the amniotic membranes and 
umbilical cord of both phenotypically normal and AWD fetuses was assessed by 
careful opening and dissection of the amniotic membranes with as little disruption as 
possible to the umbilical/AWD region. The fetuses were then euthanized by cervical 
dislocation and the anatomy of the abdominal wall including the insertion of the 
amniotic membrane and umbilical cord examined under the Zeiss SV6 microscope 
and imaged with a Leica DC500 camera.  
The amniotic membranes in mice are extremely delicate and difficult to dissect 
without causing damage to the important anatomical relations between the fine fetal 
membranes and the AWD and externalised abdominal viscera. Therefore, two 
techniques were developed in order to visualise the fetal anatomy in-amnio without 
disruption to the delicate fetal membranes. These techniques were in-amnio micro-
magnetic resonance imaging (micro-MRI) and in-amnio paraffin embedded cross-
sections as described below.  
2.1.6.3 In-Amnio Fetal Micro-MRI 
Phenotypically normal and AWD fetuses with intact amniotic membranes and 
placenta (intra-amniotic fetuses) were fixed in 4% paraformaldehyde (PFA) for 1 
hour and then embedded in 1% agarose gel in individual 50ml centrifuge tubes to 
prevent amniotic membrane rupture. The embedded fetuses were stored at 4°C and 
imaging performed within 24 hours of fixation.  
During preliminary development of this technique it was found that smaller 15ml 
centrifuge tubes were too narrow resulting in amniotic membrane rupture. 
Additionally, attempts to inject gadolinium-based MRI contrast agent to enhance the 
distinction of the amniotic fluid compartment resulted in rupture of the amniotic 
membrane.  
Embryos were scanned, performed by Thomas A Roberts, UCL Centre for Advanced 
Biomedical Imaging, using a 9.4T VNMRS system (Agilent Technologies, Inc., 
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Santa Clara, CA, USA) with a 33mm volume coil (RAPID Biomedical GmbH, 
Germany). T2-weighted, high-resolution (256
3
 pixels with a 25.6
3
 mm field of view; 
resolution of 100 μm/pixel) micro-MR images were acquired using a 3D fast spin 
echo sequence with repetition time of 1500ms. Images were converted and 
reconstructed using Analyse 7.5 data format using ImageJ (NIH, USA) and images 
generated using Amira 5.4 (Visage Imaging, Inc., Berlin, Germany). Across the 
image being compared the contrast levels were windowed equally. Imaging was 
performed by Roberts, Norris, et al (Roberts et al., 2014). 
2.1.6.4 In-Amnio Paraffin Embedded Cross-Sections 
2.1.6.4.1 Paraffin Embedding 
Phenotypically normal and AWD fetuses were fixed in 10% formalin in amnio at 
room temperature for 48 hours, dehydrated in increasing concentrations of ethanol 
(70% ethanol one wash for 30 seconds, 95% ethanol one wash for 30 seconds and 
100% ethanol 2 washes for 30 seconds), cleared in xylene (2 washes of 5 minutes 
duration) and then paraffin embedded using the automated Sakura Tissue-Tek TEC 
FFPE embedding station. Full penetration of the paraffin through the larger 18.5 dpc 
fetuses was achieved by creating tiny needle punctures in the amniotic membrane 
with a 33G needle. Puncturing the amniotic membrane in the region adjacent to the 
fetal spine enabled full penetration of the paraffin without causing disruption to the 
amniotic membrane associated with the umbilical/AWD region. Serial 3µm sagittal 
sections were cut through the umbilical/AWD region.  
2.1.6.4.2 Dewaxing and Rehydration of Paraffin Embedded Cross-Sections 
Sections were allowed to dry overnight at 37°C and then transferred to a 60°C oven 
for 1 hour. Sections were dewaxed in xylene (2 washes of 5 minutes duration), 
rehydrated in decreasing concentrations of alcohol (100% ethanol 2 washes for 5 
minutes, 95% ethanol one wash for 5 minutes and 70% ethanol one wash for 5 
minutes) and washed in distilled water for 1 minute. Slides were then ready for either 
Haematoxylin and Eosin (H&E) staining or epitope retrieval in preparation for 
immunostaining.  
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2.1.6.4.3 Antigen Retrieval 
Paraffin embedding can result in masking of epitopes due to cross-linking of amino 
acids. Antigen retrieval was therefore performed to reverse epitope masking and 
enable reliable epitope-antibody binding.  
Sections were washed in 1x PBS for 10 minutes, placed in a citrate/EDTA (pH 6) 
buffer and heated in a pressure cooker to a temperature of 125°C. Slides were 
washed in 1x PBS and allowed to cool prior to immunostaining.  
2.1.6.4.4 H&E Staining 
Sections were stained with H&E for histological analysis. Slides were soaked in 
Mayer’s Hematoxylin solution for 5 minutes, washed 3 times in distilled water (1 
minute each wash), placed in 95% ethanol for 1 minute and then soaked in Eosin 
solution for 1 minute 30 seconds.  
2.1.6.4.5 ACLP/AEBP1 and TGFβ Labelling 
To determine the expression and distribution of ACLP protein within AWD fetuses 
cross-sections were labelled for ACLP/AEBP1. Additionally, there is evidence to 
suggest that ACLP interacts with TGFβ signalling and affects collagen expression 
(Tumelty et al., 2014), which can lead to disruption of collagen fibrils located at the 
level of the amniotic membrane (Suzuki et al., 1996). Cross-sections were therefore 
also labelled for TGFβ. 
In-amnio paraffin embedded cross-sections were single labelled for ACLP and TGFβ 
on a Leica Bond-Max autostainer using anti-ACLP/AEBP1 (Santa Cruz 
Biotechnology, polyclonal IgG raised in rabbit, concentration 1:100) or anti-TGFβ 
(abcam, polyclonal IgG, raised in rabbit, concentration 1:200) respectively with a 
3,3’- diaminobenzidine (DAB) detection kit.  
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2.1.6.4.6 Dehydration and Mounting of Stained Paraffin Embedded Cross-Sections 
Stained sections were then dehydrated in increasing concentrations of ethanol (70% 
ethanol one wash for 30 seconds, 95% ethanol one wash for 30 seconds and 100% 
ethanol 2 washes for 30 seconds), cleared in xylene (2 washes of 5 minutes duration) 
and coverslip mounted with Permount™ mounting media (Fisher Scientific). Slides 
were then stored at room temperature. 
2.1.6.4.7 Imaging of In-amnio Paraffin Embedded Cross-Sections  
Slides were imaged with 40x objective using Zeiss AxioScan Z1 slide scanner, which 
digitally captures large sample areas creating a virtual image of entire slides through 
digital stitching of multiple high-resolution tiles. It was therefore possible to create a 
digital high powered microscopy image of an entire in-amnio fetus enabling detailed 
examination of the fetal anatomy. Images were viewed using Zeiss ZEN lite imaging 
software. Differences in ACLP and TGFβ labelling were visually compared.  
2.1.7 Experimental Groups 
2.1.7.1 Scribble Knockout Mouse Model Experiments 
Gut was analysed from two experimental groups; (1) phenotypically normal fetuses 
and (2) AWD fetuses. No fetal intervention groups were included in this study. 
2.1.7.2 ACLP Knockout Mouse Model Experiments 
Gut was analysed from four experimental groups; (1) untreated phenotypically 
normal fetuses, (2) untreated AWD fetuses, (3) phenotypically normal fetuses who 
received intra-amniotic IL-8 injection at 16.5 dpc and (4) AWD fetuses who received 
intra-amniotic IL-8 injection at 16.5 dpc. 
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2.1.8 Intra-Amniotic Injections 
In order to potentiate the inflammatory environment of the fluid surrounding the 
externalised gut, intra-amniotic injections of IL-8, which induces neutrophil 
chemotaxis (Bickel, 1993), diluted in 1x PBS were performed.  
2.1.8.1 Timing of injections 
Injections were performed at 16.5 dpc following resolution of physiological 
herniation and fetuses were collected as previously stated at 18.5 dpc for ileal 
studies.  
2.1.8.2 Procedure 
The procedure was performed using loupes with a 2.8 magnification, by a sterile 
technique including sterile drapes, instruments, IL-8 and PBS. Pregnant dams were 
anaesthetised using inhalational isoflurane and transferred to the operating table. 
Inhalation anaesthesia was maintained via a nose cone. The dam was laid supine on a 
warming mat and the legs taped. Veet sensitive hair removal cream was applied to 
the abdominal wall and left for approximately 5 minutes and removed with a swab. 
Chlorhexidine was used to prepare the abdominal skin. A midline laparotomy was 
performed and each horn of the uterus externalised. To prevent drying of uterine 
tissues, approximately 0.5ml of 1x PBS was applied to the uterine surface. 20µl of 
IL-8 solution was injected using a 33G needle into the fluid compartment 
surrounding the externalised gut of each mutant fetus and the intra-amniotic cavity of 
each phenotypically normal fetus. Following injection, the uterus was returned to the 
abdominal cavity and approximately 0.5ml of 1x PBS instilled into the abdominal 
cavity. Closure was performed with 5/0 VICRYL RAPIDE™ using a continuous 
suture to close the peritoneum and interrupted sutures with a buried knot to close the 
skin. Subcutaneous marcaine local anaesthetic was given for pain relief. Animals 
were housed individually, recovered overnight in a warming cage and returned to 
their normal environment the next day.  
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2.1.8.3 IL-8 Dose-Finding Study 
The presence of uterine inflammation can lead to pre-term labour and early delivery 
of fetuses. Therefore varying concentrations of intra-amniotic injected recombinant 
IL-8/CXCL8 (PeproTech, biological range for neutrophil chemotaxis 0.025µg/ml 
and 0.15µg/ml) were trialled using WT pregnant dams at 16.5 dpc. Concentrations of 
0.025µg/ml, 0.05µg/ml, 0.075µg/ml, 0.1µg/ml, 0.125µg/ml and 0.15µg/ml were 
tested. Preterm delivery occurred following injection of IL-8 at a concentration of 
0.125µg/ml and 0.15µg/ml. IL-8 concentration of 0.075µg/ml was therefore used for 
intra-amniotic injection during the ACLP experiments to induce inflammation 
without inducing preterm labour.  
2.1.9 Gut Tissue Gross Dissection, Handling and Specimen Numbers 
2.1.9.1 Harvest Timing, Number and Coding of Gut Specimens 
The gut from the gastroesophageal junction to the ileocaecal valve was removed 
from 10 fetuses from each experimental group at 18.5 dpc. Ileal lengths of the 
excised gut were used for immunofluorescence (1.5cm ileal length taken 1cm from 
the ileocaecal valve, eviscerated in AWD group) and haematoxylin and eosin (H&E) 
staining (1cm ileal length taken 2.5cm from the ileocaecal valve). All fetuses were 
pseudonymised and all specimens labelled with the relevant code blinding the 
investigator to the origin of the tissue for the remainder of the experiment.  
Additional internal control bowel samples that could have been included in the study 
were; (1) non-eviscerated bowel from AWD fetuses (e.g. duodenum or colon) and 
(2) corresponding section of bowel from phenotypically normal fetuses. These 
groups were not included due to limitations of time and prioritising the inclusion of 
motility studies.  
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2.1.9.2 Gut Length and Weight 
The excised gut was placed in a pre-weighed 1.5ml centrifuge tube containing 1x 
PBS and weighed. The gut weight (g) was calculated (gut weight = total weight – 
known tube weight).  
The gut was then placed in a dissecting dish (10cm petri dish with SYLGARD® 184 
silicone elastomer covering the base) containing 1x PBS. The gut was straightened 
by cutting the mesentery between gut loops, pinned along the mesentery avoiding 
placing pins into the gut tissue and the length measured (cm), trying not to stretch the 
gut. The weight per unit length (g/cm) was subsequently calculated (weight ÷ 
length).  
2.1.10 Gut Motility Studies 
In order to determine whether differences in ICC numbers resulted in a change in gut 
function, motility studies were performed to compare contractility between ACLP 
mouse model groups.  
2.1.10.1 Gut Preparation 
Fetal dissection was performed in oxygenated physiological Ringer’s solution. The 
gut from gastroesophageal junction to ileocaecal valve was removed from five 
fetuses in each ACLP mouse model experimental group. The gut was straightened 
and the mesentery removed. The tissue was then transferred to an organ bath 
containing physiological Ringer’s solution, heated to a temperature of 37°C with 
bubbled oxygen and a pin placed in the stomach, which was positioned to the right of 
the organ bath and the terminal ileum, which was positioned to the left of the organ 
bath. The gut was allowed to equilibrate for 30 minutes to enable restoration of 
normal bowel contractility before imaging of the ileum was commenced.  
2.1.10.2 Motility Imaging 
The bubbled oxygen was turned off 5 minutes prior to imaging and remained off for 
the duration of the recording to prevent rippling of the Ringer’s solution and 
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movement artefact of the bowel. Additionally, oxygenation of the organ bath created 
air bubbles therefore any bubbles adherent or overlying the gut wall were dislodged 
prior to imaging. Still images of the ileum were taken every 0.5 seconds for 60 
seconds. The camera lens zoom and distance of the gut from the lens was the same 
for all recordings. The camera recorded a horizontally inverted, black and white 
image of the gut resulting in the oral end of the gut positioned to the left of the 
image, the anal end to the right of the image with the gut appearring white (Figure 
2-3A). The lighting in the room was kept consistent for all recordings. A reference 
image was taken of graph paper with 1mm increments in order to calculate the 
number of pixels per unit area and detect any distortion from the camera lens (Figure 
2-3B). 
 
Figure 2-3: Gut motility recording. A. One frame taken from a 60 second recording of ileal 
motility. The ileum appears white in this black and white image. Also evident are numerous 
air bubbles generated from oxygentation of the organ bath. B. Reference image of graph 
paper with 1mm increments.  
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2.1.10.3 Gut Edge Detection and Spatiotemporal Mapping 
A MATLAB algorithm, created by Dr Alison Hart (affiliation: independent) was 
used to analyse the ileal recordings. Firstly, the image was vertically inverted and the 
gut edge detected based on changes in light intensity between the white gut and black 
background and the centre point of the bowel calculated (Figure 2-4B). Following 
edge detection, vertical slice analysis at each pixel incremental point (pixel width 
0.22mm) along the length of the bowel was used to calculate diameter changes. This 
enabled changes in the mean gut diameter at each vertical slice to be calculated over 
time (Figure 2-4C) creating spatiotemporal maps. Measurement of ileal diameter 
change provided a surrogate marker for strength of gut contractions. 
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Figure 2-4: Ileal edge detection using MATLAB software. A. Original frame from ileal 
recording. B. Vertically inverted light intensity image created in MATLAB. Ileum appears 
yellow, the pink line indicates the ileal edge and the green line is the centre point of the 
bowel. C. Graph representing change from mean diameter (mm) against vertical slice bowel 
incremental point (mm) with time (seconds). 
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2.1.10.4 Frequency of Gut Contractions 
For each vertical slice the change in bowel diameter was converted into a plot 
showing change from mean diameter against time (Figure 2-5A). This data was used 
to generate a fast Fourier transform (FFT), which breaks each signal into sine waves 
with an amplitude, frequency and phase. The sine wave with the largest amplitude 
was used to determine the dominant frequency of contraction at each bowel 
incremental point (Figure 2-5B). Frequency was then converted into contractions per 
minute (Figure 2-5C).  
2.1.10.5 Statistical Analysis of Gut Motility 
Mean values for each experiment were calculated and graphically plotted for 
contraction strength and dominant frequency of contractions. These graphs and 
spatiotemporal maps were qualitatively assessed and described. Additionally, the 
data points were used to compare absolute numbers and the area under the curve 
using ANOVA. 
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Figure 2-5: analysis of frequency of gut contractions using MATLAB software. A. Change 
in ileal diameter over time for one vertical slice analysis. B. Fast Fourier transform (FFT) 
highlighting the most dominant frequency of contraction. C. FFT converted from frequency 
to contractions per minute.  
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2.2 Archived Human Gut Tissue General Methods 
2.2.1 Ethics Statement 
Studies involving archived human gut tissue were approved by the London – City 
Road and Hampstead NHS Research Ethics Committee (reference number 
11/LO/1030). This allowed for archived human gut tissue stored pre 2006 and those 
stored under the Human Tissue Act to be used for research purposes without the need 
for patient consent.  
2.2.2 Sample Selection Criteria 
Small bowel tissue processed and paraffin embedded in either a longitudinal or 
transverse orientation by the GOSH pathology department and stored pre 2006 or 
under the Human Tissue Act were included. All identified tissue was reviewed by 
Professor Neil Sebire, Professor of Paediatric and Developmental Pathology, Great 
Ormond Street Hospital and only specimens with grossly normal resection margins 
(Figure 2-6A) were selected. Small bowel tissue with grossly abnormal resection 
margins (Figure 2-6B) were excluded due to gross destruction of tissue architecture. 
This enabled comparison of architecturally similar tissue only.  
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Figure 2-6: Sample selection criteria. A. Inclusion of grossly normal resection margins. B. 
Exclusion of grossly abnormal resection margins. 
2.2.3 Specific Inclusion and Exclusion Criteria 
Bowel is not resected from simple gastroschisis or otherwise healthy infants unless 
there is concomitant intestinal pathology. As such, it is not possible to obtain samples 
from otherwise healthy gastroschisis infants or completely normal controls. 
Therefore, specific conditions have been included and excluded from the studies to 
prevent results being impacted by other pathologies. 
  
129 
 
2.2.3.1 Inclusion Criteria for ICC and Enteric Neuron Analysis 
The control group included small bowel specimens resected from otherwise healthy 
infants for intussusception, strangulated hernia, volvulus, Meckel’s diverticulum, 
isolated perforation and stenosis. The gastroschisis study group included small bowel 
specimens that were resected from gastroschisis infants due to ischaemia, necrosis, 
anastomotic stricture, stenosis, perforation and persistently dysmotile bowel. Due to 
poor labelling at the time of surgery the resected tissue was generally labelled as 
‘small bowel’ and therefore it was not possible to distinguish between ileal and 
jejunal tissue.  
2.2.3.2 Exclusion Criteria for ICC and Enteric Neuron Analysis 
Tissue resected from gastroschisis or otherwise healthy infants for a concomitant 
condition that in the literature has been reported to have low ICC, including atresia 
(Tander et al., 2010, Midrio et al., 2010) and meconium ileus (Toyosaka et al., 1994, 
Yoo et al., 2002) were excluded. Tissue resected for conditions known to cause 
bowel wall inflammation where also excluded to prevent results being influenced by 
inflammation from a different pathological sequence. As such, necrotising 
enterocolitis, which causes significant bowel wall inflammation, and stoma reversal 
tissue, which is known to exhibit chronic inflammatory changes, were excluded. 
Finally, post-mortem bowel specimens were also excluded because the 
gastrointestinal tract autodigests rapidly following death.  
2.2.3.3 Inclusion Criteria for Bowel Wall Morphological Analysis 
In addition to the inclusion criteria for ICC and enteric neuron analysis, in order to 
increase numbers within the morphological study, small bowel resected from 
gastroschisis and otherwise healthy infants for atresia and meconium ileus were also 
included as there is no evidence that these conditions cause gross morphological 
changes. 
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2.2.3.4 Exclusion Criteria for Bowel Wall Morphological Analysis 
Inflammation and necrosis causes significant disruption to the normal architecture of 
the bowel wall and therefore post-mortem bowel specimens and bowel resected for 
necrotising enterocolitis and stoma closure were excluded.  
2.2.4 Specimen Identification 
Specimens were identified through interrogation of the GOSH pathology electronic 
database. All H&E sections relating to the identified specimens were reviewed under 
a microscope with a Consultant Histopathologist and any abnormal resections were 
identified and excluded.   
2.2.5 Specimen Pseudonymisation  
All samples were given a unique identifier ensuring confidentiality. The code for the 
pseudonymisation was kept on a password protected NHS computer by the 
histopathology pathology department and the investigator blinded preventing 
potential researcher bias. 
2.2.6 Clinical Data Collection 
Clinical data was collected on the year of birth, GA at delivery, age at bowel 
resection, reason for bowel resection, concomitant gastrointestinal pathology (atresia, 
stenosis, necrosis, perforation, volvulus and necrotizing enterocolitis), ENT and 
LOS.  
2.2.7 Specimen Sectioning 
Twenty two 3µm sections were cut from each specimen block. Table 2-4 delineates 
how these 22 sections were utilised during this study.  
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Number of 
Sections 
Tissue Staining Purpose 
5 
Triple stain: Anti-CD117, anti-
HuC/D and DAPI 
(immunofluorescence) 
 
Quantify ICC and enteric 
neurons 
5 H&E 
Morphological assessment 
of the bowel wall 
3 
Alpha smooth muscle actin 
(immunohistochemistry) 
Quantify smooth muscle 
3 Picrosirius red Quantify collagen 
3 Ki67 (immunohistochemistry) 
Quantify proliferating 
nuclei 
3 TGFβ3 (immunohistochemistry) Quantify inflammation 
Table 2-4: Breakdown of tissue staining performed on the sectioned human small bowel 
tissue.  
2.3 ICC and Enteric Neuron Quantification (Animal and Human 
Tissue) 
2.3.1 Outcome Measures 
The primary outcome measure was ICC density. The secondary outcome measure 
was enteric neuron density. For the archived human gut study, an additional 
secondary outcome measure was ENT defined as the time taken from birth to achieve 
ENT as described in the hospital charts. 
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2.3.2 ICC and Enteric Neuron Quantification Method Selection 
In the literature several quantitative methods for ICC and enteric neuron 
quantification have been described including; flow cytometry to quantify CD117 
positive ICC from fresh bowel tissue (Chen et al., 2014), image software processing 
of high powered fields of view to calculate the area of positive staining (Wang et al., 
2009, Bernardini et al., 2012) and manual counting of cell bodies from high powered 
fields of view (Bernardini et al., 2012). However, all previous gastroschisis animal 
studies (Vargun et al., 2007, Auber et al., 2013, Midrio et al., 2004, Krebs et al., 
2014, Danzer et al., 2010) and the only published human data at the time of starting 
this thesis research  (Midrio et al., 2008)  have utilised semi-quantitative (e.g. cell 
grading system of sparse: 0-2 cells, few: 3-7 cells, moderate: 8-12 cells and many:  
>12 cells (Danzer et al., 2010)), qualitative (e.g. cell grading system of 1 for mature, 
2 for moderately mature and 3 for very mature (Auber et al., 2013)) or descriptive 
(Midrio et al., 2008) methods for quantifying ICC and enteric neuron numbers. All 
off these semi-quantitative methods have limitations and are not suitable for robust 
quantification comparisons between groups.  
For the purposes of this study manual cell counting from high powered fields of view 
was selected for the quantification of ICC and enteric neurons in both animal and 
human tissue in order to provide method uniformity across the study. A cell was 
defined as an area of positive staining containing a nucleus as previously described in 
the literature (Swaminathan and Kapur, 2010). Image software analysis to calculate 
the percentage area of positive staining was not used as background staining may 
impact on the detection of true positive staining resulting in misleading results.    
2.3.3 Animal Gut Tissue Preparation for Immunofluorescence  
Both transverse cross-sectioned and whole mount ileal tissue preparations were 
tested to determine which was the most appropriate for accurate quantification of 
ICC and enteric neurons. For both gut preparation techniques immunofluorescence 
was performed on 1.5cm ileal lengths taken 1cm from the ileocaecal valve.  
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2.3.3.1 Transverse Cross-Sectioned Ileal Tissue 
The luminal contents of the ileum were washed out using 1x PBS. The whole ileal 
tube was then fixed in 4% PFA for 30 mins at room temperature and 60 minutes at 
4°C, followed by 6 washes (20 minutes per wash) in 1x PBS at room temperature 
and placed in 30% glucose solution overnight at 4°C. The ileum was cut into 0.5cm 
sections, stood vertically in OCT wells and stored at -80°C. Five transverse cross-
sections (4µm) were cut using a cryostat. OCT medium was aspirated off the slide, 
the tissue fixed with 4% PFA and washed twice with 0.1% Triton X-100 in 1x PBS 
(PBT). The immunofluorescence protocol was then started on the same day.  
2.3.3.2 Whole Mount Ileal Tissue 
During the Scribble knockout model experiments, whole mount ileal tissue was 
prepared by removing the mucosa from the underlying muscularis propria leaving the 
muscle layers and serosa intact. However, fetal mouse ileum at 18.5 dpc is very 
fragile with a diameter of approximately 1 – 2mm resulting in specimens being 
damaged and therefore discarded. Therefore, a second technique was developed 
during the ACLP knockout experiments in which immunostaining was performed on 
lengths of intact ileum reducing specimen loss and simplifying tissue processing.  
2.3.3.2.1 Whole Mount Tissue: Muscle Layer Only 
In a dissecting dish containing 1x PBS, the ileum was pinned along the mesentery 
avoiding placing pins in the ileal tissue. Micro spring scissors were used to cut the 
ileum longitudinally along the mesenteric border opening the ileal tube. The ileum 
was additionally pinned along the anti-mesenteric border under tension to flatten the 
tissue. Dumont micro forceps were used to delicately strip the mucosa from the 
underlying muscularis propria through application of mesenteric counter traction and 
grasping of the mucosal folds. Specimens were fixed using 4% PFA for 20 minutes 
and washed 6 times (20 minutes per wash) in 1x PBS at room temperature. The 
immunofluorescence protocol was then started on the same day.  
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2.3.3.2.2 Whole Mount Tissue: Intact Gut Tube 
In a dissecting dish containing 1x PBS, the ileum was pinned along the mesentery 
avoiding placing pins in the ileal tissue. Specimens were fixed using 4% PFA for 20 
minutes and washed 6 times (20 minutes per wash) in 1x PBS at room temperature. 
The immunofluorescence protocol was then started on the same day.  
2.3.4 Human Gut Tissue Preparation for Immunofluorescence 
Immunofluorescence was performed on 5 sections per paraffin embedded specimen, 
which were cut a distance of 12µm apart (every fourth slide cut) to reduce the 
possibility of quantifying the same cell more than once. The paraffin sections were 
dewaxed, rehydrated and antigen retrieval performed as previously described in the 
animal models general methods section. The immunofluorescence protocol was then 
started on the same day. 
2.3.5 Immunofluorescence Protocols 
Ileal tissue was triple labelled for ICC, enteric neurons and nuclei. The appropriate 
primary and secondary antibody concentrations were worked up using adult mouse 
gut tissue or human control gut tissue by testing 5 concentrations (e.g. 1:100, 1:250, 
1:500, 1:750 and 1:1000) based around the manufacture’s recommended range. 
During experiments adult gut from the euthanized dam and control human gut tissue 
was used as a positive and negative control. For the negative control the same 
immunofluorescence protocol was followed but the primary antibodies were omitted. 
2.3.5.1 Interstitial Cells of Cajal 
ICC express the protooncogene c-kit (Maeda et al., 1992), which encodes a 
transmembrane receptor tyrosine kinase that when blocked or knocked out results in 
ICC loss, electrical quiescence and loss of bowel motility (Maeda et al., 1992). As 
such, c-kit is an essential pathway for function and maintenance of ICC. Given this, 
anti-CD117/c-kit is the most commonly used ICC marker. However, anti-CD117 
also labels mast cells, which are usually located within the bowel mucosa but have a 
distinctly different architecture compared to ICC (round independent mast cells 
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versus interconnecting, branching ICC). Although ANO1, a calcium-activated 
chloride channel, has been identified as a potentially more specific ICC marker 
(Gomez-Pinilla et al., 2009), anti-CD117 was chosen for these experiments given 
that mast cells are rarely located within the muscularis propria and can be easily 
identified and therefore excluded during manual cell counting. Anti-CD117 reliably 
labelled ICC when applied to cross-sectional and whole mount tissue preparation 
methods.   
2.3.5.2 Enteric Neurons 
There are multiple markers of enteric neurons. For investigations using the Scribble 
knockout mouse model, anti-TUJ1 was used, which is a marker of neuron-specific 
class III beta-tublin and is expressed in neurons of the peripheral and central nervous 
system located in neuronal cell bodies and axons.  
During the ACLP knockout mouse experiments, anti-HuC/D was tested in order to 
improve identification of enteric neuronal cell bodies. HuC/D specifically labels 
antigens that are present only on neuronal cell bodies. However, this antibody did not 
penetrate and label the enteric neurons of whole mount specimens prepared by the 
intact gut tube method even. Multiple alterations to the staining protocol were tried 
with no success including varying concentrations of anti-HuC/D primary antibody 
solution, incubating the tissue in separate anti-HuC/D and anti-CD117 primary 
antibody solutions, modifications to the blocking solution used and longer duration, 
varying temperatures and agitation on a shaker during tissue incubation in the anti-
HuC/D primary antibody solution. Therefore this antibody was not used further for 
this application. Anti-TUJ1 also erratically labelled enteric neurons using the intact 
gut tube whole mount method. Anti-PGP9.5, which labels the cell bodies and axons 
of the peripheral and central nervous system, was used for the ACLP knockout 
mouse model experiments as it reliably labelled enteric neurons of intact gut tube 
whole mounts.  
For human gut tissue anti-HuC/D was used, which reliably labelled the enteric 
neuronal cell bodies of human cross sectioned tissue and has previously been 
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reported as a robust means for counting all enteric neuron cell bodies in human gut 
tissue (Murphy et al., 2007a). 
2.3.5.3 Nuclei 
Nuclei were labelled using DAPI (4',6-diamidino-2-phenylindole), which is a 
fluorescent stain that strongly binds to AT rich regions of DNA. The fluorescent 
stain passes through intact cell membranes providing a robust method of nuclear 
staining.  
2.3.5.4 Immunofluorescence Staining Protocol for Cross-Sectioned Tissue 
Blocking solution (as outlined in Table 2-5) was applied for 2 hours at room 
temperature and then washed off using PBT. A combined primary antibody 
(antibodies listed in Table 2-6) diluted in blocking solution was applied for 2 hours at 
room temperature. This was followed by 6 washes with PBT and application for 1 
hour at room temperature of a combined secondary antibody (antibodies listed in 
Table 2-7) diluted in blocking solution. Slides were washed with PBT, DAPI 
(1:1000, emission colour blue) was applied for 10 minutes at room temperature and 
washed a further 4 times with PBT. Slides were sealed using VECTASHIELD 
HardSet mounting medium and stored at 4°C. 
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Tissue Type Blocking Solution Composition 
Mouse tissue 
0.1% Triton X-100 in 1x PBS (PBT) 
1% bovine serum albumin 
0.15% glycine 
Human tissue 
PBT 
1% bovine serum albumin 
0.15% glycine 
10% sheep serum 
Table 2-5: Blocking solutions for cross-sectioned tissue immunofluorescence. 
Tissue 
Type 
Target Raised in Dilution 
Antibody 
Type 
Supplier 
Mouse CD117 Goat 1:500 Polyclonal 
R&D 
Systems 
Mouse TUJ1 Rabbit 1:500 
Monoclonal 
IgG 
Covance 
Human CD117 Rabbit 1:500 Polyclonal Dako 
Human HuC/D Mouse 1:100 
Monoclonal 
IgG 
Thermo 
Fisher 
Scientific 
Table 2-6: Primary antibodies for cross-sectioned tissue immunofluorescence. 
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Tissue 
Type 
Target Raised in Dilution 
Colour 
Emission 
Supplier 
Mouse Goat Donkey 1:250 
Green 
(488nm) 
Alexa Fluor 
Mouse Rabbit Chicken 1:250 
Red 
(594nm) 
Alexa Fluor 
Human Rabbit Goat 1:500 
Green 
(488nm) 
Alexa Fluor 
Human Mouse Donkey 1:250 
Red 
(594nm) 
Alexa Fluor 
Table 2-7: Secondary antibodies for cross-sectioned tissue immunofluorescence. 
2.3.5.5 Immunofluorescence Staining Protocol for Whole Mount Tissue 
Ileal whole mounts were soaked in blocking solution (PBS + 1% bovine serum 
albumin + 1% Triton X-100) at room temperature for 2 hours. The ileum was then 
soaked overnight at 4°C in a combined primary antibody (antibodies listed in Table 
2-8) mixture diluted in 1x PBS + 1% Triton X-100. Six washes with 1x PBS (20 
minutes per wash) were performed. The ileum was then soaked for 1 hour at room 
temperature in a combined secondary antibody (antibodies listed in Table 2-9) 
mixture diluted in 1x PBS + 1% Triton X-100. This was followed by 10 minutes at 
room temperature in DAPI (1:1000, emission colour blue) and 6 washes of 1x PBS. 
Whole mounts were slide mounted flat, sealed using VECTASHIELD HardSet 
mounting medium and stored at 4°C. 
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Animal 
Model 
Target Raised in Dilution 
Antibody 
Type 
Supplier 
ACLP and 
Scribble 
CD117 Goat 1:500 Polyclonal 
R&D 
Systems 
Scribble TUJ1 Rabbit 1:500 
Monoclonal 
IgG 
Covance 
ACLP PGP9.5 Mouse 1:500 
Monoclonal 
IgG 
abcam 
Table 2-8: Primary antibodies for whole mount immunofluorescence. 
Tissue 
Type 
Target Raised in Dilution 
Colour 
Emission 
Supplier 
ACLP and 
Scribble 
Goat Donkey 1:250 
Green 
(488nm) 
Alexa Fluor 
Scribble Rabbit Chicken 1:250 
Red 
(594nm) 
Alexa Fluor 
ACLP Mouse Donkey 1:250 
Red 
(594nm) 
Alexa Fluor 
Table 2-9: Secondary antibodies for whole mount immunofluorescence. 
2.3.6 Immunofluorescence Imaging 
ICC and enteric neurons at the level of the myenteric plexus were chosen for 
quantification as both cell populations are well developed at 18.5 dpc in mouse 
fetuses and at full term in human fetuses.  
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2.3.6.1 Cross-Sectioned Tissue 
Images of 10 high powered fields of view at 40x objective were taken per specimen 
at the level of the myenteric plexus using a Zeiss Axioplan 310 fluorescence 
microscope. All images were taken with the myenteric plexus running in a transverse 
orientation across the field of view to ensure uniformity of the area quantified 
(Figure 2-7). 
 
Figure 2-7: Random image orientation leads to differing myenteric plexus lengths and 
would give different counts for the same tissue region. A. Horizontal orientation. B. 
Diagonal orientation. C. Vertical orientation. 
2.3.6.2 Whole Mount Tissue 
Images of 10 high powered fields of view at 40x objective were taken per specimen 
at the level of the myenteric plexus using a Zeiss LSM 710 confocal microscope 
(Figure 2-8) creating z stack image sets through the entire three dimensional plexus. 
The confocal settings used were as follows; frame size 784x784, speed 10, averaging 
number 1, pinhole 1 airy unit (AU) at an interval of 0.55µm, imaging in 3 colour 
channels (488nm green, 594nm red and DAPI blue). 
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Figure 2-8: A. Schematic of ileum, rectangle indicating the region imaged at high power 
(40x objective). Maximum intensity project images of confocal z-stacks. B. Anti-CD117 
green, DAPI blue. C. Anti-PGP9.5 red, DAPI blue. 
2.3.7 ICC and Enteric Neuron Quantification 
2.3.7.1 Cross-Sectioned Tissue 
Colour channels were combined as follows; green (ICC)/blue (nuclei, Figure 2-9) 
and red (enteric neurons)/blue (Figure 2-10). Images were reviewed using ImageJ 
(NIH, USA) software. ICC cell bodies (green staining surrounding a blue nucleus, 
Figure 2-9) and neuronal cell bodies (red staining surrounding a blue nucleus, Figure 
2-10) were counted manually using ImageJ cell counter software. Counts were 
performed blinded to the tissue origin.  
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Figure 2-9: ImageJ anti-CD117 (ICC, green) and DAPI (nuclei, blue) combined image and 
ImageJ cell counter software. Magenta markers (indicated with white circles) highlighting 
counted ICC cell bodies. 
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Figure 2-10: ImageJ anti-HuC/D (enteric neuron, red) and DAPI (nuclei, blue) combined 
image and ImageJ cell counter software. Green markers (indicated with white circles) 
highlighting counted ICC cell bodies. 
 
2.3.7.2 Whole Mount Tissue 
The 3 colour channels (ICC green, enteric neurons red, nuclei blue) of the confocal z 
stack image sets were initially separated, followed by combining of green/blue and 
red/blue colour channels to create maximum intensity project images for both ICC 
(Figure 2-11) and enteric neurons (Figure 2-12) using ImageJ software (Figure 2-4). 
ICC cell bodies (green straining surrounding a blue nucleus, Figure 2-11) and 
neuronal cell bodies (red staining surrounding a blue nucleus, Figure 2-12) were 
counted manually using ImageJ cell counter software.  
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Figure 2-11: ImageJ ICC maximum intensity project (anti-CD117, ICC, green and DAPI, 
nuclei, blue) and ImageJ cell counter software. Magenta markers (indicated with white 
circles) highlighting counted ICC cell bodies. 
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Figure 2-12: ImageJ enteric neuron maximum intensity project (Anti-PGP9.5, enteric 
neurons, red and DAPI, nuclei, blue)  and ImageJ cell counter software. Green markers 
(indicated with white circles) highlighting counted enteric neuron cell bodies. 
2.4 Bowel Wall Thickness and Morphology (Animal and Human 
Tissue) 
H&E staining of paraffin embedded transversely sectioned ileum was performed in 
order to analyse the gross architecture of the ileum for each experimental group. 
2.4.1  Animal Gut Tissue Preparation Morphological Studies 
Paraffin embedding was performed on 1cm ileal lengths taken 2.5cm from the 
ileocaecal valve. The ileum was fixed in 4% PFA overnight at 4°C, cut into 0.5cm 
lengths. The tissue was then dehydrated, cleared in xylene and paraffin embedded (as 
previously described in the animal models general methods section) vertically. Five 
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transverse 3µm sections were cut and H&E stained as previously described in the 
animal models general methods section. 
2.4.2 Human Gut Tissue Preparation for Morphological Studies 
Five sections (3µm) were stained with H&E and 3 sections were stained for each 
immunohistochemical marker.  
2.4.3 Histology Staining Protocols 
2.4.3.1 H&E Staining Protocol 
The paraffin sections were dewaxed, rehydrated and H&E stained as previously 
described in the animal models general methods section.  
2.4.3.2 Immunohistochemistry and Picrosirius Red Staining Protocols 
Staining for alpha smooth muscle actin (α-SMA), collagen (picrosirius red [PS]) and 
proliferating nuclei (Ki67) was performed on human gut tissue to determine whether 
increased myopathy, fibrosis or cell proliferation (respectively) was present in 
gastroschisis bowel compared to controls. Additionally, sections were stained for 
TGFβ3 as a marker of inflammatory and morphogenic triggers in gastroschisis bowel 
wall compared to controls. Three sections were stained for each marker.  
Paraffin sections were dewaxed as previously described in the animal models general 
methods section. Antigen retrieval was not required for these markers.  
Alpha-SMA, Ki67 and TGFβ3 staining was performed (one stain per section) using 
the automated Leica BondMax system using the antibodies listed in Table 2-10 with 
a DAB detection kit and Eosin counterstain.  
For PS staining, slides were placed in picrosirius red for one hour.  
Sections were rehydrated and mounted following staining as previously described in 
the animal models general methods section. 
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Target Raised in Dilution Antibody Type Supplier 
α-SMA Mouse 
Ready to use 
preparation 
Monoclonal IgG Leica 
Ki67 Mouse 
Ready to use 
preparation 
Monoclonal IgG Leica 
TGFβ3 Rabbit 1:100 Polyclonal abcam 
Table 2-10: Primary antibodies for immunohistochemistry staining 
2.4.4 Histology Imagaing 
2.4.4.1 Imaging of H&E Cross-Sections 
The H&E ileal transverse cross-sections were imaged using the Zeiss AxioScan Z1 
slide scanner at 40x objective creating a virtual image of the entire cross-section. 
2.4.4.2 Imaging of Immunohistochemistry Cross-sections 
Bright field images of 10 high powered fields of view at 40x objective on a Zeiss 
Axioplan 310 microscope were taken. Bowel wall layers were imaged as outlined in 
Table 2-11. All images were taken with the bowel wall running in a transverse 
orientation across the field of view to ensure uniformity of the area quantified 
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Immunohistochemistry Stain Bowel Wall Layer Imaged 
α-SMA 
Longitudinal muscle 
Circular muscle 
Ki67 
Longitudinal muscle 
Circular muscle 
TGFβ3 
Longitudinal muscle 
Circular muscle 
Submucosa 
Epithelium 
PS 
Serosa 
Longitudinal muscle 
Circular muscle 
Submucosa 
Table 2-11: Bowel wall layers imaged by stain. 
2.4.5 Morphological Bowel Wall Analysis 
2.4.5.1 Bowel Wall Measurements and Muscle Fibre Quantification 
Bowel wall measurements (µm) were taken at the thinnest point in the section to 
remove bias from oblique sectioning using the measurement tool in the Zeiss ZEN 
lite imaging software. Layers measured in mouse bowel include; entire outer wall, 
submucosa and muscle layer thickness, villus length (longest villus in the section) 
and crypt depth (Figure 2-13). Layers measured in the human bowel include; entire 
outer wall, submucosa, circular muscle, longitudinal muscle and serosal thickness, 
villus height (longest villi in the section) and crypt depth (Figure 2-14). The villus to 
crypt ratio (villus height/crypt depth) was calculated for both the animal and human 
measurements. Additionally, the number of circular and longitudinal muscle fibres 
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that bisected the measurement line were counted and the muscle fibre thickness 
calculated (muscle layer thickness [μm]/number of muscle fibres = muscle fibre 
thickness [μm]). For each specimen, a total of 10 of each measurement were made.  
 
Figure 2-13: Mouse bowel wall measurements performed using Zeiss ZEN lite imaging 
software. 
 
Figure 2-14: Human bowel wall measurements performed using Zeiss ZEN lite imaging 
software. 
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2.4.5.2 α-SMA, PS and TGFβ3 quantification 
The total area (mm
2
) of the region of interest ([ROI] i.e. the area filled by the bowel 
layer e.g. serosa, circular muscle, etc, in the imaged 40x field of view) and the 
percentage area of positive α-SMA, TGFβ3 and PS within the ROI were quantified 
using ImageJ software. Due to the large number of images requiring quantification a 
macro was written (with the support from Dr Dale Moulding, ICH Imaging Facility 
Manager) for each stain in order to enable where possible batch analysis of each 
group of 10 images taken per specimen for each bowel wall layer (Figure 2-15). 
 
Figure 2-15: α-SMA quantification macro written for ImageJ software. 
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2.4.5.2.1 α-SMA Quantification Macro 
The macro was opened in ImageJ and run generating a prompt for the investigator to 
select a folder containing 10 images. All images were automatically converted into 
RGB colour. A second prompt enabled the investigator to select the ROI by hand for 
each image. Colour deconvolution using the methyl green DAB vector and automatic 
colour thresholding of the resultant brown colour image was performed to select only 
positive areas of DAB staining and the image converted into a binary image. The 
measurement scale was set automatically based on the known pixels per mm for that 
image. The total ROI area (mm
2
) and the percentage area of positive staining within 
the ROI were measured. An output file with the measurements was then created and 
saved (Figure 2-16).  
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Figure 2-16: Quantification protocol for α-SMA. Step 1: Convert image to RGB and draw 
region of interest (bounded by the yellow line). Step 2: Colour deconvolution using methyl 
green DAB vector. Step 3: Automated colour thresholding of resultant brown colour image. 
Step 4: Convert to a binary image. Step 5: Data output. 
2.4.5.2.2 PS Quantification Macro 
The same macro was used as described for α-SMA. However, in order to accurately 
select for the pink staining of PS a manually created vector of [r1]=19.86824 
[g1]=71.61538 [b1]=58.39616 was used for colour deconvolution instead of the 
methyl green DAB vector.   
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2.4.5.2.3 TGFβ3 Quantification Macro 
The same macro as described for α-SMA was used. However, the TGFβ3 staining 
was associated with a high level of background preventing the automatic colour 
threshold tool from accurately separating positive TGFβ3 staining from background. 
As such, another prompt was added to enable the investigator to perform manual 
colour thresholding for each image (Figure 2-17). 
 
Figure 2-17: Manual colour thresholding following colour deconvolution for TGFβ3 
quantification. 
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2.4.5.3 Ki67 Quantification  
The number of Ki67 positive nuclei and the total number of nuclei (ki67 positive 
nuclei + counter stained nuclei) were quantified using the aid of a macro. 
The macro opened one image at a time and converted the image into RGB colour and 
applied Gaussian blur. A prompt enabled the investigator to select the ROI by hand. 
The measurement scale was set automatically based on the known pixels per mm for 
that image and the total ROI area (mm
2
) was measured. The find maxima tool was 
opened and a second prompt enabled manual adjustment of the maxima settings in 
order to detect as accurately as possible all nuclei within the ROI. Maxima detected 
nuclei were then quantified automatically and an output file generated. Ki67 positive 
cells were counted by hand using the cell counting software (Figure 2-18). 
The proliferation index (proliferation index = ki67 positive nuclei ÷ total number of 
cells x 100) and the number of cells per unit area were then calculated for each 
image. 
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Figure 2-18: Quantification protocol for Ki67. Step 1: Convert image into RGB and apply 
Gaussian blur. Step 2: Draw ROI (bounded by the yellow line). Step 3: Adjust maxima 
settings to detect all nuclei within ROI (imaged zoomed in). Step 4: Manually count Ki67 
positively stained nuclei (magenta marker) with cell counting software (image zoomed in).  
2.4.6 Statistical Analysis ICC, Enteric Neurons and Morphological Data 
A mean value for all measurements was calculated for each specimen.  Data were 
compared using Student T-test (for normally distributed data), Mann-Whitney (for 
non-normally distributed data) or ANOVA (for multiple group analysis) as 
appropriate using GraphPad Prism version 6 software. Additionally, for the human 
  
156 
 
studies, linear regression and Spearman correlation were performed using SPSS 
version 22. A p-value of <0.05 was considered significant.  
2.5 Clinical Retrospective Multicentre Cohort Studies  
The incidence of gastroschisis is 4.4/10,000 live births (Kilby, 2006) and therefore 
falls into the category of a rare disease (defined by the European Union as a 
condition that affects less than 5/10,000 of the general population, 
http://ec.europa.eu/health/rare_diseases/policy/index_en.htm). As such, the number 
of cases seen by one centre per year is low. The previously published gastroschisis 
national cohort study (Bradnock et al., 2011) studied 393 infants from 27 UK centres 
over an 18 month period equating to approximately 10 infants per centre per year. 
Given the low number of cases seen by each individual centre retrospective data 
were collected from multiple centres initially including two London centres. 
However, due to the low number of gastroschisis infants that had received maternal 
antenatal corticosteroids and in order to improve the validity of results with an 
international approach this study was expanded to also include a Canadian centre. 
The collected data were used to analyse the impact of timing of delivery and 
administration of maternal antenatal corticosteroids on infant outcomes.  
2.5.1 Institutional Approval 
Appropriate institutional approvals were obtained to collect antenatal and neonatal 
data by retrospective patient note review without the need for patient consent. Ethical 
approval was obtained from Mount Sinai Hospital, Toronto (Research Ethics Board 
application number 14-0231-C, including agreement for transfer of non-identifiable 
patient data for analysis at the UCL, Institute of Child Health, London, UK) and 
Hospital for Sick Children, Toronto (Research Ethics Board approval number 
1000032644, including agreement for transfer of non-identifiable patient data for 
analysis at the UCL, Institute of Child Health, London, UK). In the UK centres 
(University College London Hospital, Great Ormond Street Hospital for Children 
and King’s College Hospital), the study was approved as audits and waived the need 
for ethical approval. 
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2.5.2 Inclusion Criteria 
All infants with gastroschisis managed between January 1992 and July 2014 at the 
following linked fetal and paediatric surgical centres were included in the 
retrospective cohort study; (1) Fetal Medicine Unit, University College London 
Hospital (UCLH) and the Paediatric Surgery Department at Great Ormond Street 
Hospital for Children (GOSH), London, UK, (2) Fetal Medicine Unit and Paediatric 
Surgery Department at King’s College Hospital (KCH), London, UK and (3) Fetal 
Medicine Unit at Mount Sinai Hospital (MSH) and the Division of General and 
Thoracic Surgery at The Hospital for Sick Children, University of Toronto, Canada. 
Due to the limited numbers of patients and varying study designs of previously 
published studies there was no robust data on which to base a power calculation 
therefore all gastroschisis infants were included in the study.  
The individual retrospective clinical studies included the following specific 
paediatric surgery centres:  
2.5.2.1 Timing of Delivery and Impact on Gastroschisis Infant Outcomes Study 
1. Fetal Medicine Unit, UCLH and the Paediatric Surgery Department at GOSH 
2. Fetal Medicine Unit and Paediatric Surgery Department at KCH. 
3. Fetal Medicine Unit at MSH and the Division of General and Thoracic 
Surgery at The Hospital for Sick Children. 
2.5.2.2 Maternal Antenatal Corticosteroid Administration and Impact on 
Gastroschisis Infant Outcomes Study 
1. Fetal Medicine Unit, UCLH and the Paediatric Surgery Department at GOSH 
2. Fetal Medicine Unit and Paediatric Surgery Department at KCH. 
3. Fetal Medicine Unit at MSH and the Division of General and Thoracic 
Surgery at The Hospital for Sick Children. 
2.5.2.3 Predicting Infant Outcomes with Antenatal Bowel Dilatation Study 
1. Fetal Medicine Unit, UCLH and the Paediatric Surgery Department at GOSH 
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2. Fetal Medicine Unit and Paediatric Surgery Department at KCH. 
2.5.3 Exclusion Criteria 
Any fetus or infant who received the main portion of their antenatal or postnatal 
treatment in a centre outside of the study centres were excluded from the study due to 
variations in management approaches between centres.  
2.5.4 Patient Management 
Patients managed during the retrospective study period were referred to the study 
hospitals from obstetric centres at local hospitals following diagnosis of gastroschisis 
either at the time of the 12 week GA dating ultrasound scan or 20 week GA anomaly 
ultrasound scan. Patients were then assessed in the tertiary centres at four weekly 
intervals up until 30 weeks and then 1-2 weekly thereafter until delivery. Pregnancies 
were monitored for fetal growth, bowel dilatation, oligohydramnios and signs of fetal 
distress.   
All centres had a policy of elective vaginal delivery by induction of labour at 37-38 
weeks GA. Caesarean section delivery was only performed if there were other 
obstetric concerns e.g. breech position, maternal concerns, failure to progress, fetal 
distress, etc. Vaginal delivery by induction of labour was performed prior to 37-38 
weeks GA if fetal assessment showed evidence of significant intra-uterine growth 
restriction, presence of marked intra-abdominal bowel dilatation, non-reassuring fetal 
heart rate or umbilical Doppler, reduced fetal movements or if there were maternal 
health concerns. Delivery prior to 37-38 weeks GA also occurred if labour onset was 
spontaneous.  
Maternal antenatal corticosteroids had been given for fetal lung maturation if preterm 
labour occurred or was threatened to occur at ≤ 34+6 weeks GA or delivery was 
performed by caesarean section at ≤ 38+6 weeks (the latter in UK centres only) 
(Gynaecologists, Oct 2010, Crane et al., 2003). Antenatal corticosteroid treatment 
involved maternal intra-muscular injection of either 12mg betamethasone, two doses, 
24 hours apart or 6mg dexamethasone, four doses, 12 hours apart. An incomplete or 
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modified antenatal corticosteroid treatment regimen was given to women in whom 
labour progression was quick or emergency caesarean section was required resulting 
in delivery before completion of the course.   
Following delivery, gastroschisis neonates were immediately stabilised within the 
NICU located at the birth centre and then transferred when safe to the linked 
paediatric surgical centre for definitive management. Gastroschisis neonatal 
management varied between centres, including surgical closure method (primary 
closure versus silo staged closure) and feeding regime, due to the differing 
departmental policies and individual surgeon preference.  
2.5.5 Identification of Patients 
Patients were identified through interrogation of hospital databases and linked fetal 
and neonatal data were obtained from computerized and handwritten patient notes at 
the respective hospitals. 
2.5.6 Data Collection 
Data was collected retrospectively from review of maternal and infant case notes. 
Antenatal data collection included GA at time of ultrasound, concomitant fetal 
abnormalities, presence or absence of antenatal intra-abdominal bowel dilation or 
extra-abdominal bowel dilatation and size (mm) of the dilatation if it was 
documented, labour onset, mode of delivery, indication for premature delivery (if 
applicable), GA at delivery, year of birth, birth weight and timing, dosage and reason 
for maternal antenatal corticosteroid administration. GA was calculated as a 
continuous variable with incomplete weeks gestation calculated as a decimal (e.g. 
34
+5
 = 34.7). 
Postnatal data collection included appearance of bowel at birth, concomitant 
intestinal pathology (atresia, stenosis, necrosis, perforation, volvulus and necrotizing 
enterocolitis), time to start enteral feeds, ENT, LOS, episodes of sepsis and death.  
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2.5.7 Outcome Measures 
The primary outcome measure was ENT defined as the time taken from birth to 
achieve full enteral feeds as described in the hospital charts. The secondary outcome 
measures included: LOS defined as time from birth to discharge from hospital; and 
development of sepsis defined as isolation of pathogenic organism detected on blood 
culture. 
2.5.8 Confidentiality 
Collected data was entered into an Excel spreadsheet created for each of the 
fetal/paediatric surgical study centres and all patients given a unique identifier. 
Personal identifying data including name and date of birth were omitted from the 
datasheet. The code for the pseudonymisation was kept on a password protected 
hospital computer (data safe haven) in each centre as per Toronto Research Ethics 
Board and London audit guidelines. 
2.5.9 Statistical Analysis 
Statistical analysis was performed using SPSS version 22 and GraphPad Prism 
version 6 software. Data is presented as median [range] and a p-value of <0.05 was 
considered significant. 
2.5.9.1 Timing of Delivery and Impact on Gastroschisis Infant Outcomes Study 
Log-transformed data were used to perform linear regression analysis of ENT and 
LOS across the entire cohort and those born at ≥34 weeks GA. Infants were also 
divided in two groups; (1) those born 34 and 36
+6
 weeks GA and (2) those born at or 
after 37 weeks GA. Fisher’s exact test and Mann-Whitney was used to compare the 
two groups. Outcomes were compared with and without taking into account 
corrected GA. Cox regression analysis was also used, adjusting for complexity and 
GA and censoring for those infants who failed to achieve the ‘event’ including; 
failure to achieve ENT, not being discharged from hospital and death as appropriate.  
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2.5.9.2 Maternal Antenatal Corticosteroid Administration and Impact on 
Gastroschisis Infant Outcomes Study  
Cox regression analysis was primarily used enabling analysis of time to event data 
whilst adjusting for confounders by multi-variable analysis. Potential confounders 
were identified and adjusted for including; complex gastroschisis, birth GA, source 
hospital and antenatal corticosteroid administration. Censoring was performed for 
those infants who failed to achieve ENT, or infants who were discharged on home 
PN, transfer to another hospital on PN, discharge home following transfer to another 
hospital, babies who were not discharged from hospital or death. Additionally, 
Mann-Whitney and Fisher’s exact test were used as appropriate.  
2.5.9.3 Predicting Infant Outcomes with Antenatal Bowel Dilatation Analysis  
Data were analyzed using Mann-Whitney tests or t-tests as appropriate, positive and 
negative predictive values were used for proportion data and log-transformed data 
was used to perform linear regression analysis of ENT and LOS. 
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Chapter 3: Phenotypic and ICC Characterisation in the 
Scribble Knockout Mouse Model of an Abdominal Wall 
defect                   
3.1 Introduction 
Gastroschisis was previously reported to be exhibited by a Scribble mutant mouse 
model (Circletail), which was initially developed to investigate the neural tube defect 
(NTD) craniorachischisis (Murdoch, 2003). This model has a frame shift in the Scrib 
allele resulting in early termination of the Scribble protein. Since then the Scribble 
mutant mouse model has been further developed through creation of a floxed Scrib 
(Scrib
fl
) allele, whereby the Scrib allele is flanked between two lox P sites, allowing 
for gene excision at the lox P sites with the use of Cre recombinase (Nagy, 2000). 
The floxed allele has enabled conditional Scrib gene targeting allowing Scrib 
function to be analysed in various biological systems (Hartleben et al., 2012, Pearson 
et al., 2011). Scribble null fetuses generated by the Scrib
fl allele have been reported 
to express morphological features that mirror the Circletail mutant model 
including gastroschisis and craniorachischisis (Hartleben et al., 2012, Pearson et al., 
2011). For the purposes of this research the Scrib
fl 
allele was used to create a Scribble 
knockout mouse model to induce the gastroschisis AWD.   
The aims of this part of the study were to; (i) accurately delineate the AWD anatomy 
that results from Scribble loss of function and (ii) compare bowel wall ICC 
development of phenotypically normal fetsues with AWD fetuses.  
3.2 Results 
3.2.1 Gross Characterisation of Scribble Knockout Fetuses  
During the experimental period a total of 127 fetuses were collected, 78 at 18.5 dpc 
and 49 at 17.5 dpc, of which 112 (88%) were phenotypically normal (i.e. no NTD or 
AWD) and 15 (12%) expressed an AWD phenotype. Of those that expressed an 
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AWD phenotype; 5 occurred in isolation and 10 with a concomitant extensive NTD. 
None of the fetuses collected exhibited an isolated NTD (Figure 3-1).  
 
Figure 3-1: Gross phenotypic characterisation of the floxed Scrib (Scrib
fl
) mouse model. 
Genotyping was performed on 58 randomly fetuses revealing 12 (21%) wild types 
(Scrib
fl/fl
), 20 (34%) heterozygotes (Scrib
fl/-
)
 
and 26 (45%) homozygote knockouts 
(Scrib
-/-
). These ratios do not appear to fall into the expected Mendelian ratios of 
25% WT, 50% heterozygotes and 25% knockouts. However, the numbers are too 
small to reliably determine whether this is a significant deviation from the expected 
distribution. All wild type fetuses were phenotypically normal. Nineteen 
heterozygotes were phenotypically normal and 1 expressed a large AWD with 
concomitant NTD. Twenty homozygote knockouts were phenotypically normal and 
6 were phenotypically abnormal of these 4 exhibited an isolated AWD (3 with a 
large AWD and 1 with a small AWD) and 2 exhibited a large AWD with 
concomitant NTD (Table 3-1). Hence, the penetrance of an AWD in Scrib null mice 
was 23% and NTD was 8%.  
  
  
164 
 
Genotype 
Total     
in Group 
Phenotypically 
Normal 
Isolated    
AWD 
AWD + NTD 
Wild Type 
(Scrib
fl/fl
) 
12 (21%) 12 0 0 
Heterozygote 
(Scrib
f/-
) 
20 (34%) 19 0 1 
Homozygote 
(Scrib
-/-
) 
26 (45%) 20 4 2 
Table 3-1: Gross, phenotype-genotype characterisation of the floxed Scrib (Scrib
fl
) mouse 
model. 
3.2.2 Abdominal Wall Defect Phenotype 
3.2.2.1 Timing of Abdominal Wall Phenotyping  
Phenotyping of fetuses was performed at 17.5 dpc (after resolution of physiological 
herniation). This time point was chosen due to the larger amniotic fluid volume 
present compared to 18.5 dpc fetuses, which aided microdissection (n=6 control and 
n=6 AWD fetuses) reducing damage to fine membranous structures associated with 
the externalized abdominal viscera and abdominal wall defect. Additionally, the 
larger amniotic fluid volume aided visualization of fine intra-amniotic structures 
following in-amnio micro-MRI (n=2 control and n=3 AWD fetuses).  
3.2.2.2 Visualisation of Intra-Amniotic Fetuses  
Examination of fetuses through intact amniotic membranes revealed three abdominal 
wall phenotypes; phenotypically normal, small AWD and large AWD. 
Phenotypically normal fetuses (Figure 3-2A) exhibited no structural defects and were 
positioned with the four limbs tightly folded in front of the torso. Viewing these 
fetuses from the side revealed complete closure of the abdominal wall and a centrally 
inserted umbilical cord. Fetuses with a small AWD (Figure 3-2B) exhibited a 
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discrete, central abdominal wall defect through which the abdominal viscera 
(including liver and bowel) herniated into a membranous sac, which was continuous 
with the umbilical cord, consistent with an exomphalos. The limbs were splayed 
laterally to accommodate the centrally herniated viscera. Fetuses with a large AWD 
(Figure 3-2C) exhibited complete failure of the abdominal wall to form and the 
externalised abdominal viscera (including liver and bowel) appeared to be free 
floating within the amniotic cavity. However, there also appeared to be a 
membranous structure compartmentalising the intra-amniotic cavity. The limbs were 
also splayed laterally. Additionally, AWD fetuses (small or large) with a concomitant 
NTD (Figure 3-2B) exhibited exposed neural tissue from the cranium to sacrum.  
The amniotic fluid was clear and non-blood stained in all phenotypically normal and 
isolated small and large AWD fetuses. However, the amniotic fluid was blood 
stained in fetuses with a concomitant NTD. The placenta appeared grossly normal in 
all fetuses. 
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Figure 3-2: Intra-amniotic fetuses including intact placenta (P) at 17.5 dpc, 0.8x objective. 
A. Phenotypically normal fetus. B. Fetus with small AWD. The herniated viscera (HV) is 
contained within a membraneous sac. Also evident in this image is failed closure (FC) of the 
cranium and blood stained amniotic fluid. C. Fetus with large AWD. Externalised viscera 
(EV) appear to be free floating. There is evidence of an intra-amniotic membraneous 
structure (MS) compartmentalising the intra-amniotic cavity. This fetus additionally had a 
concomitant NTD (not visible on this image due to orientation) and blood stained amniotic 
fluid.  
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3.2.2.3 Microdissection 
The presence of three anatomically distinct abdominal wall phenotypes was 
confirmed following microdissection. Phenotypically normal fetuses as previously 
described exhibited complete ventral abdominal wall closure. The umbilical cord was 
found to be structurally normal (3 blood vessels contained within a membrane) 
originating from a grossly normal placenta and inserting centrally on the abdominal 
wall (Figure 3-3A).  
The small AWD was characteristic of exomphalos (total n=3; 18.5 dpc n=1, 17.5 dpc 
n=2) with disruption and failed closure of the umbilical ring resulting in a central 
abdominal wall defect. The herniated abdominal viscera (including bowel and liver) 
were contained within a membranous sac that was continuous with the umbilical 
cord. The umbilical cord was otherwise structurally normal as described above 
originating from a grossly normal placenta (Figure 3-3B).  
The large AWD was confirmed to comprise of a complete failure of the ventral 
abdominal wall to develop (total n=12, 18.5 dpc n=8, 17.5 dpc n=4) with no evidence 
of lateral ventral wall folds. The exteriorised abdominal viscera included bowel, 
stomach, liver and spleen. Following microdissection of the amniotic membranes a 
fine, ruptured membranous structure was identified that covered the externalised 
viscera and exhibited vascular connections to the amniotic membrane (Figure 3-3C). 
At 18.5 dpc it was not possible to dissect the amniotic membranes without damaging 
this fine membrane. The membrane may have therefore either ruptured earlier in 
gestation or during dissection. However, dissection at 17.5 dpc of one fetus revealed 
an intact fine membrane covering the herniated abdominal viscera, which was in 
continuity with an otherwise structurally normal umbilical cord originating from a 
normal placenta and therefore in keeping with a giant exomphalos (Figure 3-3D). 
Dissection of the amniotic membranes was easier at 17.5 dpc due to the greater 
volume of amniotic fluid enabling identification and protection of the fine membrane 
covering the externalised abdominal viscera.  
The concomitant NTD was that of craniorachischisis consisting of complete failure 
of the neural tube to close resulting in exposure of the neural tissue from the cranium 
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to sacrum as previously described in the circletail mouse model (Murdoch, 2003). 
All AWD fetuses exhibited a curly tail but no other gross structural anomalies were 
identified. 
 
Figure 3-3: Scribble mutant mouse abdominal wall phenotypes at 17.5 dpc, magnification 
0.8x objective. A. Normal phenotype with intact abdominal wall and structurally normal 
umbilical cord (UC) that inserts centrally on the abdominal wall. The placenta (P) also 
remains intact. B. Small AWD with membrane covered herniated liver and bowel into the 
base of the umbilical cord (UC) consistent with exomphalos (E). C. Large AWD with 
evisceration of liver, gut and spleen. A ruptured thin membrane (TM) is present associated 
with the abdominal viscera and exhibits vascular attachments to the amniotic membrane 
(AM). The placenta (P) and umbilical cord (UC) have been left intact. D. Large ventral wall 
defect with intact thin membrane (TM) covering herniated abdominal viscera (superior pole 
of the membrane was iatrogenically ruptured (IR) during dissection) consistent with 
exomphalos (E). 
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3.2.2.4 In-Amnio Fetal Micro-MRI 
Imaging of phenotypically normal fetuses (n=2) revealed complete closure of the 
abdominal wall and normal insertion of the umbilical cord (Figure 3-4A). One fetus 
with a characteristic exomphalos was imaged confirming the presence of disruption 
and failed abdominal wall closure at the umbilical ring with herniation of abdominal 
viscera. The membrane covering the herniated viscera could be tracked from the 
abdominal wall to the umbilical cord (Figure 3-4B). Two fetuses with complete 
failure of development of the ventral abdominal wall were imaged, which initially 
suggested the abdominal viscera to be free floating within the amniotic cavity 
(Figure 3-4C). However, following post-processing of the images with contrast 
enhancement a fine membranous structure was revealed in association with the 
externalised abdominal viscera, extending from the abdominal wall to the amniotic 
membrane (Figure 3-4D and E). These images confirm the presence of a fine 
membrane covering the abdominal viscera in this phenotype. However, it was not 
possible to determine on these images whether the membrane was intact or ruptured. 
Additionally, the presence of a normal umbilical cord and placenta were visualised 
(Figure 3-4F). Finally, the craniorachischisis defect was clearly visualised with failed 
closure of the neural tube from the cranium to the sacrum (Figure 3-4B and C).  
Identification of intra-amniotic structures was aided by the bright contrast provided 
by the relatively large volume of amniotic fluid at 17.5 dpc. Imaging of the mutant 
fetuses revealed a higher signal intensity (Figure 3-4B and C) of the entire fetal body 
compared to the normal phenotype fetuses ((Figure 3-4A). This higher signal 
intensity likely resulted from the blood stained amniotic fluid associated with the 
craniorachischisis defect providing greater tissue contrast. 
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Figure 3-4: In-amnio micro-MRI of intra-amniotic fetuses at 17.5 dpc. A. Sagittal image of 
a phenotypically normal fetuses. B. Sagittal image of characteristic exomphalos (E) AWD 
phenotype showing herniation of abdominal viscera contained within an intact membrane. 
Also evident is craniorachischisis (CR) with failed neural tube closure from the cranium to 
sacrum. C. Sagittal image of the large AWD phenotype showing externalised abdominal 
viscera (EAV) with no discernable membrane covering. The craniorachischisis defect is also 
evident. D. Contrast enhanced axial image of the large AWD. The externalised liver is 
associated with a membranous structure (blue arrow). E. Contrast enhanced sagittal image of 
the large AWD. The externalised liver is associated with a membranous structure (blue 
arrows). F. Contrast enhanced coronal image of the large AWD showing the presence of a 
normal placental (P) and umbilical cord (UC). 
3.2.3 Gross Bowel Morphology 
To ensure uniformity of results, only tissue harvested from fetuses with the large 
AWD were included in this study. The bowel from AWD fetuses was observed to be 
shorter in length and more tortuous than controls. There was no evidence of 
macroscopic bowel inflammation or fibrous serosal peel in either group. There was a 
significant and marked difference in bowel length between control (7.2 ± 0.12cm, 
n=15) and AWD fetuses (5.1 ± 0.16cm, n=8, p<0.0001). There was also a significant 
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and marked difference in bowel weight between the groups (control 73.9 ± 1.6mg 
versus AWD 58.3 ± 3.3mg; p<0.0001). Finally, there was a small difference in 
weight per unit length (control 10.3 ± 0.9mg/cm versus AWD 11.4 ± 0.5 mg/cm; 
p=0.0453), suggesting thickening of the bowel in AWD fetuses. 
3.2.4 ICC and Enteric Neurons 
3.2.4.1 Immunofluorescence Staining Protocol 
Immunofluorescence was performed on cross-sectioned samples and positive ICC 
and enteric neuron staining was achieved. However, there was also significant 
background staining, which made it difficult to identify ICC cell bodies or discern 
the ICC branching architecture Figure 3-5B). Enteric neuron cell bodies were easier 
to identify but the cell architecture was poorly defined (Figure 3-5C). Therefore it 
was difficult to accurately quantify either cell types using this method, and 
quantification of ICC was only performed using whole mount tissue. 
 
Figure 3-5: A. Low powered (10x objective) composite image of entire gut cross-section 
(anti-CD117 green, anti-TUJ1 red, DAPI blue), rectangle showing region imaged at high 
power. B. High powered (40x objective) image of ICC (indicated by arrow). C. High 
powered (40x objective) image of enteric neurons (indicated by arrow). 
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The preparation of whole mount, muscle only, tissue preparations was difficult. The 
ileum of 18.5 dpc mouse fetuses is extremely thin (approximately 1 – 2mm in 
diameter) and fragile resulting in tissue damage during stripping of the mucosa from 
the muscle layers. This resulted in tissue being discarded and of the 15 sections of 
ileum resected from control fetuses, 9 whole mount sections were discarded and of 
the 8 bowel sections from AWD fetuses, 5 were discarded. To reduce unnecessary 
use of animals the study was terminated before processing 10 whole mount sections 
in each experimental group on the grounds that the AWD expressed by Scribble 
knockout mice was exomphalos rather than gastroschisis and therefore not suitable 
for intra-amniotic injection. Hence, ICC were quantified from 6 control and 3 AWD 
whole mount specimens.  
3.2.4.2 ICC Architecture and Numbers 
At the level of the myenteric plexus, the ICC were well developed in both control 
(Figure 3-6A) and AWD (Figure 3-6C) fetuses exhibiting numerous branching 
cytoplasmic processes that interconnected with their counterparts creating a mature 
plexus. As expected for this gestational stage, ICC at the level of the deep muscular 
plexus were not observed in either group. The number of ICC per high powered field 
(45nm
2
) in the control group was 129 ± 5 (mean ± SEM), range 105-146. In 
comparison, the number in the AWD group was 193 ± 37, range 119 - 232. 
Although, the number of ICC in the AWD group appear to be higher this was not 
statistically significant (p=0.38) on this small number of animals.  
3.2.4.3 Enteric Neuron Architecture and Numbers 
The enteric neurons at the level of the myenteric plexus appeared similar and were 
well developed in both control (Figure 3-6B) and AWD (Figure 3-6D) fetuses 
exhibiting regularly spaced cell chains lying in parallel with regular perpendicular 
crosslinking between chains creating a crosshatched appearance. Enteric neurons 
were not formally quantified during this study due to inconsistency of staining with 
anti-TUJ1.  
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Figure 3-6: Whole mount 18.5 dpc ileal specimens stained for ICC with anti-CD117 (A and 
C) and enteric neurons with anti-TUJ1(B and D) images acquired by confocal microscopy, 
40x objective, maximum intensity project of z-stack images. A and B. Specimen from 
control mouse. C and D. Specimen from large AWD mutant mouse. 
3.3 Discussion 
3.3.1 Abdominal Wall Phenotype  
3.3.1.1 Exomphalos Phenotype 
Null fetuses derived from the Scrib
fl
 allele exhibit an exomphalos phenotype that 
varies in severity with an intact or ruptured membrane covering the herniated viscera. 
The least severe form of the defect phenotypically resembled exomphalos with a 
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well-defined membrane covering the herniated abdominal viscera. The most severe 
form was more ambiguous with complete failure of development of the ventral 
abdominal wall and evidence of a fine membrane covering the herniated abdominal 
viscera including bowel, stomach, liver and spleen, which may rupture intra-
amniotically. The presence of this covering membrane provides evidence that this 
defect is consistent with a giant exomphalos rather than a large, atypical gastroschisis 
defect. Liver herniation is also very rare in gastroschisis and provides further 
evidence that this defect more closely resembles exomphalos. Additionally, the 
presence of a normal placenta and structurally normal umbilical cord is evidence 
against this AWD being a body stalk defect, which comprises an extensive AWD 
with an absent or extremely short umbilical cord that is frequently associated with 
other structural abnormalities such as failed thoracic wall closure and head, face and 
limb anomalies  (Paul et al., 2001, Bugge, 2012) 
Anatomical delineation of the giant exomphalos was possible through careful 
dissection under a stereo microscope enabling identification and preservation of the 
umbilical cord, placenta and fine membrane covering the herniated abdominal 
viscera. Additionally, high-resolution in-amnio micro-MRI provided a non-
destructive method for visualisation and confirmation of the AWD anatomy and 
associated structures.  
3.3.1.2 A Case of Mistaken Identity 
The exomphalos phenotypic description of Scribble null fetuses outlined above 
contradicts the previous literature. The Scribble mutant mouse AWD was originally 
described in the circletail model to be that of gastroschisis (Murdoch, 2003). Since 
then the AWD has continued to be described as gastroschisis in the Scrib
fl 
mutant 
model (Hartleben et al., 2012, Pearson et al., 2011). However, none of these papers 
provide detailed analysis of the abdominal wall anatomy or associated structures as 
these studies were focused towards the investigation of craniorachischisis. A similar 
case of mistaken identity occurred in the phenotypic description of the Alx-4 mutant 
mouse model, which was originally described as gastroschisis (Qu et al., 1997) but 
later reported as exomphalos (Matsumaru et al., 2011). This clearly highlights the 
difficulties of accurate phenotyping of AWD in genetic mouse models.  
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3.3.1.3 Importance of Accurate Phenotyping 
As previously discussed, exomphalos and gastroschisis differ greatly in terms of their 
associated morbidities and concomitant pathologies. The primary purpose of this 
research was to understand the cause of GRID. However, in exomphalos, intestinal 
dysfunction is not usually a feature. Although GRID is hypothesised to develop due 
to bowel exposure to amniotic fluid, and the fine membrane covering the herniated 
abdominal viscera in the Scrib
fl
 mouse model may rupture intra-amniotically, the 
timing of this rupture is unknown and may vary between fetuses. Timing of 
membrane rupture could only have been assessed if it was possible to serially assess 
the continuity of the covering membrane prenatally in vivo. This may have been 
possible using micro-ultrasound fetal mouse imaging (Foster et al., 2002, Foster et 
al., 2011, Liu et al., 2017), which would have enabled serial in-vivo fetal imaging of 
AWD fetuses and possible assessment of membrane architecture but this imaging 
modality was not available during the experimental period so could not be 
investigated at this time. As such, the Scrib
fl
 model does not reliably mimic the 
impact of prolonged amniotic fluid exposure on bowel development and function. 
Therefore it is an inappropriate model for the investigation of GRID and could result 
in misleading research data.  
However, the Scrib
fl 
model would be potentially useful for the investigation of 
exomphalos related pulmonary hypoplasia, which is one of the most significant 
causes of morbidity and mortality in patients with exomphalos. A strong association 
has been shown between exomphalos defect size and severity of pulmonary 
hypoplasia with major/giant exomphalos defects exhibiting the most severe 
hypoplasia (Vachharajani et al., 2009, Argyle, 1989). The Scrib
fl
 mutant mouse 
model may be advantageous for the investigation of exomphalos related pulmonary 
hypoplasia given the model exhibits both moderate and giant defect sizes. As such, it 
would be possible to directly compare lung development between normal controls 
and differing sizes of exomphalos defect. Characterisation of macroscopic and 
microscopic lung development alongside development of an in-utero therapy to 
improve lung function would be possible with the Scrib
fl
 model.  
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3.3.1.4 Concomitant Pathology and Penetrance 
The majority of fetuses with exomphalos exhibited a concomitant craniorachischisis 
defect (67%), which was associated with blood stained amniotic fluid. Therefore, 
even if the membrane covering the herniated viscera ruptured at a uniform time 
during gestation exposing the bowel to amniotic fluid, this model would be of limited 
use for the investigation of GRID due to the confounding factor of blood within the 
amniotic fluid, which is not a feature of gastroschisis. Even if blood staining was not 
a feature, the penetrance of AWD in Scribble null fetuses was very low (23%). As 
such, the Scrib
fl
 model would require a large number of pregnant dams in order to 
fully investigate the pathophysiology of GRID and is therefore not an optimal model.  
3.3.2 The Use of In-Amnio Micro-MRI for Fetal Structural Phenotyping 
Cutting edge imaging technology is increasingly being used for the phenotyping of 
genetically manipulated mouse models of disease (Turnbull and Mori, 2007). MRI is 
becoming a well-established technique enabling detailed non-invasive visualisation 
of structures (Schneider et al., 2003) with high resolution images (Petiet et al., 2008) 
that can be analysed using automated computational methods (Norris et al., 2013a). 
To date, mouse MRI techniques have mainly involved imaging of ex-vivo fetuses 
removed from the amniotic sac (Norris et al., 2013b). Although in-utero MRI is 
possible the image resolution is limited and therefore can only be used for easily 
defined phenotypes (Nieman and Turnbull, 2010). Therefore, the in-amnio micro-
MRI technique was developed specifically for this study to enable removal of the 
uterine wall whilst retaining the integrity of the fine membranes covering the 
herniated abdominal viscera prior to imaging (Roberts et al., 2014). The use of 
software packages such as ImageJ and Amira 5.4 enabled detailed image 
reconstruction and visualisation of the AWD in multiple orientations (sagittal, 
coronal and axial) aiding phenotyping. This technique allowed for visualisation of 
the AWD and associated membranous structures providing confirmation of the 
exomphalos phenotype. However, further MRI optimisation would be required in 
order to determine whether the fine covering membrane was intact or ruptured. This 
technique could also be used for phenotyping of other ambiguous mouse AWDs as 
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well as amniotic membrane, umbilical cord and placental defects where integrity of 
the amniotic membrane is essential for anatomical preservation.  
The disadvantages of micro-MRI include long scan times, high cost and the ex-vivo 
nature of the imaging results in animal loss and inability to map the natural history of 
AWD formation within one fetus throughout gestation. For the purposes of this study 
the entire fetus was scanned resulting in a long scan duration of approximately 10 
hours in order to obtain high resolution images. However, the scan duration could be 
shortened if site specific imaging was performed in cases where visualisation of the 
whole embryo is not required, which in turn would reduce the cost of performing 
micro-MRI.  
In-vivo fetal Micro-ultrasound may also be a valuable tool for the phenotyping of 
AWDs in fetal mice. Developments in micro-ultrasound have enabled the acquisition 
of high resolution in-vivo fetal mouse images with a rapid imaging speed at a low 
cost (Foster et al., 2002, Foster et al., 2011, Liu et al., 2017). The ability to obtain 
high resolution in-vivo images of fetal mice would enable serial imaging of the same 
dam and in turn her multiple fetuses throughout gestation providing documentation 
of the natural history of AWD formation and associated membrane structures whilst 
reducing animal loss.  
3.3.3 Bowel Development 
3.3.3.1 Gross Bowel Development  
A shorter bowel length was observed in the giant exomphalos defects compared to 
controls. Although mice with the giant exomphalos defect displayed no macroscopic 
evidence of bowel inflammation there was a slightly greater weight per unit length of 
bowel, which only just achieved statistical significance. This phenomenon could 
have been investigated further though analysis of bowel wall thickness on H&E 
stained cross-section bowel. The difference in giant exomphalos bowel compared to 
controls may represent a global failure of intra-abdominal structural development as 
part of the AWD formation. However, it could also represent intra-amniotic 
membrane rupture placing the bowel directly in contact with the amniotic fluid 
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resulting in the initiation of bowel wall inflammation as hypothesised to occur in 
gastroschisis.  
3.3.3.2 ICC and Enteric Neuron Development 
The small number of samples analysed in this study suggested that ICC and enteric 
neuron architecture at the level of the myenteric plexus was normal in giant 
exomphalos fetuses compared to controls. Additionally, in this small cohort the 
results suggested the numbers of ICC were normal in the giant exomphalos fetuses 
compared to controls. No further conclusions can be made due to the small number 
of samples analysed secondary to poor AWD penetrance, high tissue loss due to a 
difficult whole mount processing technique and the decision not to continue any 
further experiments with this mouse model on ethical grounds given the AWD 
expressed by the Scribble knockout mice was that of exomphalos and not 
gastroschisis.  
3.3.4 ICC Quantification 
Fetal mouse bowel at 18.5 dpc has a very small diameter and is very fragile. It was 
not possible to accurately discern individual ICC or enteric neurons from high 
powered images of cross-sectioned bowel as these cells were too small within the 
field of view. Additionally, it was not possible to visualise the architecture of the 
ICC and enteric neuron networks for the same reason. Therefore cells could not be 
reliably counted nor the maturity of the cell networks assessed. This method for cell 
quantification was therefore discarded. These findings also bring into question the 
validity of previously reported ICC numbers in small animal gastroschisis models 
(Vargun et al., 2007, Danzer et al., 2010, Midrio et al., 2004, Auber et al., 2013). All 
such reports have relied solely on cross-sectioned tissue and semi-quantitative or 
qualitative quantification methods, which may have generated inaccurate and 
potentially misleading results due to the random presence/absence of ICC in the 
cross section examined. Also, not all these reports mention blinding of the 
investigator to the origin of the analysed tissue, which could have led to bias during 
quantification.   
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Confocal imaging of whole mount bowel preparations enabled imaging of the entire 
myenteric plexus, providing clear images of the interconnecting cell networks of the 
ICC and enteric neurons from which accurate assessment of cell maturity was 
possible. Individual cell bodies of both ICC and enteric neurons were easily 
discernible providing a robust quantification method using ImageJ cell counting 
software. However, whole mount, muscle only tissue preparations were difficult to 
process in 18.5 dpc mouse gut and therefore for later studies whole tube preparations 
were developed in order to improve processing efficiency and reduce tissue loss.  
3.4 Conclusion  
The terms exomphalos and gastroschisis are being used interchangeably within the 
NTD literature to describe AWD in genetic mouse models without detailed 
assessment of the defect anatomy. Accurate characterisation of AWD is challenging 
but can be aided through meticulous microdissection identifying the defect location, 
umbilical cord insertion, umbilical ring closure and presence or absence of a 
membrane covering the externalised abdominal viscera. Novel imaging techniques 
can also greatly aid phenotyping of ambiguous structural defects in circumstances 
where microdissection leads to disruption of important structures making accurate 
phenotyping by this method difficult. This study highlights the importance of 
performing accurate phenotypic analysis of any structural anomaly prior to 
embarking on research specifically linked to the described defect. Finally, this study 
also highlights the importance of appropriate methods for tissue preparation, 
immunostaining, imaging and cell quantification in order to enable accurate 
qualitative quantification and architectural assessment of bowel wall ICC.  
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Chapter 4: Aortic Carboxypeptidase-Like Protein 
(ACLP) Knockout Mouse Model: Phenotypic 
Characterisation and Impact of Inflammation on ICC 
Development and Gut Motility 
4.1 Introduction 
The aortic carboxypeptidase-like protein (ACLP, also known as adipocyte enhancer 
binding protein 1 [AEBP1]) is a signalling protein with a discoidin I domain 
(Baumgartner et al., 1998) and a signal peptide amino terminus similar to 
metallocarboxypeptidases but missing several amino acids required for catalytic 
activity against standard carboxypeptidase substrates (Gomis-Ruth et al., 1999). 
ACLP is secreted during development into the extracellular matrix of connective 
tissues such as the abdominal wall, blood vessels, skeleton and dermis and acts as a 
binding protein, facilitating cell aggregation/adhesion and cell-cell recognition 
(Layne et al., 2001). The ACLP knockout mouse is reported in the literature to 
exhibit a gastroschisis phenotype. (Layne et al., 2001, Danzer et al., 2010). 
Therefore, failed abdominal wall closure in ACLP null fetuses has been hypothesised 
to occur due to loss of ventral wall migratory signals (Layne et al., 2001). The AWD 
expressed by the ACLP knockout fetuses has been described as gastroschisis with a 
persistent herniation of the intestine into the amniotic fluid through an AWD located 
adjacent to the umbilicus (Layne et al., 2001, Danzer et al., 2010). However, this 
description was based on gross visualisation of the defect presumably of fetuses 
removed from the amnion and no detailed anatomical analysis of the AWD has been 
performed. 
In the ACLP knockout mouse model, immunohistochemical analysis of AWD fetal 
cross sectional intestinal tissue shows the decrease of ICC and enteric neurons 
(Danzer et al., 2010) compared to controls. This suggests that abnormal development 
of ICC and enteric neurons in gastroschisis small bowel could be the cause of GRID. 
However, ICC and enteric neuron cell quantification was performed using cross-
sectioned bowel with a semi-quantitative technique and no bowel motility studies 
were performed.  
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The amniotic fluid of human gastroschisis pregnancies has been shown to be pro-
inflammatory with an elevation in IL-8 (pro-inflammatory cytokine) compared to 
healthy controls (Morrison et al., 1998) and it has been  hypothesised that bowel wall 
exposure to IL-8 could be a trigger of GRID (de Beaufort et al., 1998, Api et al., 
2001, Correia-Pinto et al., 2002, Hakguder et al., 2011, Olguner et al., 2006). 
However, the impact of IL-8 on ICC development in gastroschisis has not previously 
been investigated.  
The aims of this study were to: (i) accurately delineate the AWD anatomy that results 
from ACLP absence; (ii) compare bowel wall ICC and enteric neuron development 
between experimental groups (untreated phenotypically normal, untreated AWD, 
intra-amniotic IL-8 injected normal and intra-amniotic IL-8 injected AWD fetuses); 
(iii) compare bowel motility patterns between experimental groups.   
4.2 Results 
4.2.1 Gross Characterisation of ACLP Knockout Fetuses 
During the experimental period, 298 fetuses were collected, 283 at 18.5 dpc and 9 at 
13.5 dpc. 215 (74%) were phenotypically normal and 77 (26%) exhibited an AWD 
phenotype. These ratios are as expected by Mendelian inheritance for fully penetrant 
phenotypes suggesting that AWD fetuses survive to full term. Mutant fetuses 
exhibited an isolated AWD with no other gross structural defects, such as 
craniorachischisis or other neural tube defects. 
Genotyping was performed on 69 fetuses of which there were: 26 (38%) wild types 
(ACLP
+/+
), 21 (30%) heterozygotes (ACLP
+/-
) and 23 (33%) homozygote knockouts 
(ACLP
-/-
). These ratios do not fall into the expected Mendelian ratios. However, over 
a large population it would be expected that the ratios are similar to those anticipated 
by Mendelian inheritance (1:2:1). All wild type and heterozygote fetuses were 
phenotypically normal and therefore heterozygote fetuses were considered as normal 
controls. Twenty-two homozygote knockout fetuses exhibited an AWD and 1 
homozygote fetus was phenotypically normal. Hence, the penetrance of AWD in 
ACLP knockout mice was 96%. 
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4.2.2 Abdominal Wall Defect Phenotype 
4.2.2.1 Timing of Abdominal Wall Defect Phenotyping 
Microdissection of phenotypically normal and AWD fetuses was performed at 18.5 
dpc prior to harvesting of gut for ileal studies. In-amnio paraffin embedded fetal 
cross-sections of phenotypically normal and AWD fetuses was performed at time 
points 13.5 dpc (during physiological herniation) and 18.5 dpc (after resolution of 
physiological herniation). 
4.2.2.2 Visualisation of Intra-Amniotic Fetuses 
Phenotyping by visualisation through intact membranes was not possible at 13.5 dpc 
as it was not possible to distinguish between normal physiological herniation of the 
bowel and evisceration of the bowel through an AWD due to the translucent nature 
of the membrane containing the physiologically herniated bowel. Phenotyping 
through intact amniotic membranes at 18.5 dpc revealed two abdominal wall 
phenotypes; phenotypically normal fetuses and a single type of AWD. 
Phenotypically normal fetuses (Figure 4-1A) exhibited a closed abdominal wall onto 
which the umbilical cord centrally inserted and the limbs were tightly folded in front 
of the torso. Fetuses with the AWD (Figure 4-1B) exhibited externalised free floating 
abdominal viscera including bowel and liver, which lay in front of the abdominal 
wall obscuring the AWD from view. The limbs were splayed laterally to 
accommodate the externalised viscera. The amniotic fluid was clear and non-blood 
stained in both the phenotypically normal and AWD fetuses and the placenta 
appeared grossly normal in both phenotypes.  
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Figure 4-1: Intra-amniotic fetuses at 18.5 dpc, 0.6x objective. A. Phenotypically normal 
fetus. B. Fetus with AWD exhibiting externalised, free floating bowel and liver.  
4.2.2.3 Microdissection  
Microdissection at 18.5 dpc confirmed the presence of two abdominal wall 
phenotypes. Phenotypically normal fetuses (Figure 4-2A) were observed to have a 
closed ventral abdominal wall and a structurally normal umbilical cord consisting of 
3 blood vessels contained within the amniotic membrane. The umbilical cord 
originated from a grossly normal placenta and inserted centrally on the abdominal 
wall. Microdissection of the AWD fetus (Figure 4-2B-D) revealed a centrally located 
AWD approximately 2mm in diameter permitting externalisation of the bowel, 
stomach, liver and spleen. There was no membrane covering the eviscerated organs, 
which were therefore free floating in fluid. Although the umbilical cord was of a 
normal length and consisted of 3 blood vessels, the blood vessels were not covered 
by the amniotic membrane leaving the cord uncovered. The abnormal cord entered 
the abdominal cavity through the left lateral edge of the ventral wall defect. Careful 
dissection revealed that the amniotic membrane, instead of adhering to the umbilical 
vessels, attached directly onto the abdominal wall defect edge maintaining continuity 
between the amnion and body wall ectoderm. The externalised, non-covered viscera 
were therefore free floating within the exocoelomic cavity, separated from the 
amniotic fluid by the amniotic membrane. As such, these findings suggest that ACLP 
knockout mice do not exhibit a true gastroschisis defect as the bowel is exposed to 
exocoelomic fluid rather than amniotic fluid as it would be in human gastroschisis.  
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Figure 4-2: Microdissection images of ACLP phenotypically normal and AWD fetuses at 
18.5 dpc, orientated with tail inferiorly, 0.6x objective. A. Phenotypically normal fetus with 
a strucutrally normal umbilical cord (UC), consiting of 3 blood vessels, covered by the 
amniotic membrane, which inserts centrally on a closed abdominal wall. B-D. AWD fetuses. 
The amniotic membrane (AM) attaches directly to the ventral wall defect edge (DE) and the 
externalised gut (G) and liver (L) are free floating within the exocoelomic cavity seperated 
from the amniotic fluid by the amniotic membrane. B. Direct view of the ventral abdominal 
wall defect with the amniotic membrane (AM) lying flat against the abdominal wall. C. The 
amniotic membrane is displaced superiorly away from the abdominal wall to reveal the 
direct attachment to the inferior defect edge. D. The amniotic membrane is displaced 
inferiorly away from the abdominal wall to reveal the direct attachment to the superior defect 
edge. A, C and D. The placenta (P) was grossly normal in all fetuses. 
4.2.2.4 Fetal In-Amnio Paraffin Embedded Cross-Sections 
In-amnio paraffin embedded H&E stained sagittal cross-sections of phenotypically 
normal fetuses revealed at 13.5 dpc physiological herniation and at 18.5 dpc a closed 
abdominal wall consistent with the normal sequence of abdominal wall formation.  
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Phenotypically normal fetuses at 13.5 dpc (Figure 4-3) exhibited bowel herniation 
through the patent umbilical ring and into the base of the umbilical cord, which 
provided a membrane coverage protecting the herniated bowel from the amniotic 
fluid consistent with physiological herniation. Tracing the entire course of the 
amniotic membrane showed the membrane to encircle the outer surface of the fetus 
and to become adherent to the umbilical blood vessels at the point of emergence 
from the placenta thus forming a normal umbilical cord. The amniotic membrane 
continued adherent to the umbilical blood vessels before separating to encase the 
herniated bowel and finally attaching to the abdominal wall to continue as the body 
wall ectoderm. The amniotic and exocoelomic cavities were fluid filled and easily 
distinguishable. Phenotypically normal fetuses at 13.5 dpc are schematically 
represented in Figure 4-3B. 
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Figure 4-3: 13.5 dpc phenotypically normal in-amnio paraffin embedded fetus, H&E 
stained, sagittal cross-section through the umbilicus, imaged with Zeiss AxioScan Z1 slide 
scanner with 40x objective. This shows normal physiological herniation of the gut. A. 
Original AxioScan image. B. Schematic representation of fetal anatomy overlaid on the 
original image. 
Cross-sections of phenotypically normal fetuses at 18.5 dpc (Figure 4-4) revealed 
fetuses with a closed abdominal wall and intra-abdominal viscera. The fetuses were 
tightly contained within the fetal membranes with little fluid present in either the 
amniotic or exocoelomic cavities, which is in keeping with the rapid decline in extra-
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fetal fluid that is normally seen in fetal mice between 16 dpc and 18 dpc (Renfree et 
al., 1975) making it difficult to distinguish between the two. However, the amniotic 
membrane could be traced to encircle the fetus and adhere to the umbilical blood 
vessels. In contrast to the 13.5 dpc fetus, the amniotic membrane remained adherent 
to the umbilical blood vessels throughout the full length of the cord, which inserted 
centrally on the abdominal wall and the amniotic membrane continued as the body 
wall ectoderm. The anatomy is schematically represented Figure 4-4B. 
 
Figure 4-4: 18.5 dpc phenotypically normal in-amnio paraffin embedded fetus, H&E 
stained, sagittal cross-section through the umbilicus, imaged with Zeiss AxioScan Z1 slide 
scanner with 40x objective. Showing normal abdominal wall closure and a centrally inserted 
umbilical cord. A. Original AxioScan image. B. Schematic representation of fetal anatomy 
overlaid on the original image. 
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AWD fetuses expressed the same abdominal wall anatomy at both 13.5 (Figure 4-5) 
and 18.5 dpc (Figure 4-6). Fetuses exhibited a central defect through which the 
bowel and liver protruded without membrane coverage. The amniotic membrane was 
traced to encircle the fetus but failed to adhere to the umbilical blood vessels. 
Instead, the amniotic membrane directly attached to the abdominal wall defect edge 
becoming continuous with the body wall ectoderm. The gut and liver are visualised 
free floating within the exocoelomic cavity separated from the amniotic fluid by the 
amniotic membrane, confirming that ACLP knockout mice do not express a true 
gastroschisis defect. The amniotic and exocoelomic cavities were fluid filled at both 
time points and therefore easily distinguishable. AWD fetuses are schematically 
represented in Figure 4-5B and Figure 4-6B. 
Phenotyping of AWD fetuses has shown these mutants to have a central abdominal 
wall defect through which bowel and liver are externalised and free floating within 
the exocoelomic cavity rather than the amniotic cavity as would be expected in a 
gastroschisis defect. The exocoelomic fluid composition is determined by the 
exchange of substances from the overlying visceral yolk sac serving as the principle 
site for the exchange of proteins between mother and fetus (Jauniaux and Gulbis, 
2000), whilst the amniotic fluid composition is determined by fetal urine, meconium, 
secretions of oral and airway fluids and the amniotic membrane. As such, the 
composition of the exocoelomic fluid to which the externalised bowel of the AWD 
fetuses is exposed to is very different and potentially less noxious than that of the 
amniotic fluid, which the bowel would be exposed to if a true gastroschisis defect 
was present. However, phenotyping also reveals that the bowel is not contained 
within a membranous sac and therefore it is possible through in-utero injections to 
manipulate the composition of the exocoelomic fluid, which is in direct contact with 
the bowel. 
 
  
189 
 
 
Figure 4-5: 13.5 dpc AWD in-amnio paraffin embedded fetus, H&E stained, sagittal cross-
section through the umbilicus, imaged with Zeiss AxioScan Z1 slide scanner with 40x 
objective. This shows failed abdominal wall closure and failed attachment of the amniotic 
membrane to the umbilical cord resulting in the externalised bowel lying within the 
exocoelomic cavity separated from the amniotic fluid by the amniotic membrane. A. 
Original AxioScan image. B. Schematic representation of fetal anatomy overlaid on the 
original image. 
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Figure 4-6: 18.5 dpc AWD in-amnio paraffin embedded fetus, H&E stained, sagittal cross-
section through the umbilicus, imaged with Zeiss AxioScan Z1 slide scanner with 40x 
objective. This shows failed abdominal wall closure and failed attachment of the amniotic 
membrane to the umbilical cord resulting in the externalised bowel lying within the 
exocoelomic cavity separated from the amniotic fluid by the amniotic membrane. A. 
Original AxioScan image. B. Schematic representation of fetal anatomy overlaid on the 
original image. 
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4.2.2.5 Fetal Expression of ACLP and TGFβ  
ACLP interacts with TGFβ signalling and affects collagen expression (Tumelty et 
al., 2014), which could lead to disrupted amniotic membrane collagen fibrils and be 
the cause of failed adherence of the amniotic membrane to the umbilical cord. 
Therefore, in-amnio paraffin embedded fetuses were labelled for ACLP/AEBP1 and 
TGFβ with a DAB detection kit to identify possible abnormal signalling at the level 
of the abdominal wall and amniotic membrane. However, there was significant 
background staining for both the ACLP/AEBP1 (Figure 4-7) and TGFβ (Figure 4-8) 
labels and in the 18.5 dpc fetuses there was absent ACLP/AEBP1 (Figure 4-7C and 
D) staining for both phenotypically normal and AWD fetuses. Therefore, it was not 
possible to identify areas of positive staining from background straining and in turn 
assess the difference in expression of ACLP or TGFβ between the phenotypically 
normal and AWD fetuses. Further work would be necessary to optimise 
ACLP/AEBP1 and TGFβ staining in these fetuses.  
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Figure 4-7: ACLP/AEBP1 labelling with DAB detection kit of in-amnio paraffin embedded 
fetus, sagittal cross-section through the umbilicus, imaged with Zeiss AxioScan Z1 slide 
scanner with 40x objective. This shows significant background staining of the 13.5 dpc 
phenotypically normal (A) and AWD fetuses (B). There is absent staining in both the 18.5 
dpc phenotypically normal (C) and AWD (D) fetuses. Key: AM – amniotic membrane, PH – 
physiological hernia, AWD – abdominal wall defect. 
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Figure 4-8: TGFβ labelling with DAB detection kit of in-amnio paraffin embedded fetus, 
sagittal cross-section through the umbilicus, imaged with Zeiss AxioScan Z1 slide scanner 
with 40x objective. This shows significant background staining of cross-sections. A. 13.5 
dpc phenotypically normal fetus. B. 13.5 dpc AWD fetus. C. 18.5 dpc phenotypically normal 
fetus. D. 18.5 dpc AWD fetus. Key: AM – amniotic membrane, PH – physiological hernia, 
AWD – abdominal wall defect. 
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4.2.3 In-Utero IL-8 Injections 
In-utero IL-8 injections in AWD fetuses were performed into the exocoelomic fluid 
compartment due to the externalised bowel lying free floating within the 
exocoelomic cavity and not the amniotic fluid cavity. However, in the phenotypically 
normal (control) fetuses the exocoelomic cavity was not identifiable under direct 
vision and therefore in-utero IL-8 injections were performed into the amniotic cavity. 
Injections into the exocoelomic cavity in control fetuses may have been possible 
using micro-ultrasound guidance but this form of imagining was not available during 
the experimental period.   
Comparisons of bowel wall morphology and ICC/enteric neuron numbers were made 
between the following experimental groups; untreated control versus untreated 
AWD, untreated AWD versus IL-8 injected AWD and untreated control versus IL-8 
injected control.  
4.2.4 Gross Bowel Morphology 
4.2.4.1 Pre-injection Comparison of Untreated Phenotypically Normal and 
Untreated AWD Fetuses 
There were no visual differences in the appearance of the bowel between either the 
untreated phenotypically normal (control) or untreated AWD fetuses. Bowel 
harvested from untreated AWD fetuses showed no evidence of inflammation or 
fibrous peel. There was no difference in bowel length (control 5.9 ± 0.1cm [mean ± 
SEM), n=10 versus AWD 5.7 ± 0.2, n=10, p=0.26), bowel weight (control 66.1 ± 
1.6mg versus AWD 66.1 ± 4.3mg, p>0.99) or weight per unit length (control 11.2 ± 
0.3mg/cm versus AWD 11.5 ± 0.6mg/cm, p=0.66, Table 4-2). Although 
measurements of bowel wall thickness on H&E transverse cross sections showed a 
trend toward the untreated AWD bowel being thicker there was no significant 
difference in any measured parameter between the two groups (Table 4-1). 
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Bowel Wall Layer 
Measured 
Untreated 
Control (n=10) 
Untreated 
AWD (n=10) 
p-value 
Entire Wall Thickness (µm) 34 ± 1.4 38 ± 1.7 0.10 
Muscle Thickness (µm) 17 ± 0.7 19 ± 1.4 0.08 
Submucosa (µm) 18 ± 1.0 19 ± 1.0 0.27 
Villus height (µm) 190 ± 15.4 194 ± 14.2 0.87 
Crypt depth (µm) 25 ± 1.4 28 ± 1.9 0.19 
Villus to Crypt ratio (µm) 8 ± 0.5 7 ± 0.6 0.11 
    
Number of Muscle Cells 4.7 ± 0.12 5.0 ± 0.11 0.052 
Muscle Cell Thickness (µm) 3.6 ± 0.16 3.8 ± 0.10 0.44 
Table 4-1: Comparison of bowel wall measurements (mean ± SEM) between untreated 
control and untreated AWD bowel. 
4.2.4.2 Statistical Comparison between Experimental Groups 
Visually the serosal surface of IL-8 injected AWD bowel (n=10) compared to the 
other three groups appeared inflamed with more prominent blood vessels (IL-8 
injected control group included n=10). On performing comparison of bowel length, 
weight and weight per unit length between experimental groups it showed a 
significant difference in bowel length between untreated AWD (5.7 ± 0.2cm) and IL-
8 injected AWD groups (4.9 ± 0.2cm, p=0.0008) but no difference between weight 
(p=0.24) or weight per unit length (p=0.82). There were no significant differences in 
any measurements between the untreated control and IL-8 control groups (Table 
4-2). 
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Bowel Wall Layer 
Measured 
Untreated Control 
(n=10) 
Untreated AWD 
(n=10) 
p-value 
Bowel length (cm) 5.9 ± 0.1 5.7 ± 0.2 0.26 
Bowel weight (mg) 66.1 ± 1.6 66.1 ± 4.3 0.99 
Bowel weight per 
unit length (mg/cm) 
11.2 ± 0.3 11.5 ± 0.6 0.66 
Bowel Wall Layer 
Measured 
Untreated AWD 
(n=10) 
IL-8 AWD      
(n=10) 
p-value 
Bowel length (cm) 5.7 ± 0.2 4.9 ± 0.2 *0.0008 
Bowel weight (mg) 66.1 ± 4.3 56.9 ± 6.2 0.24 
Bowel weight per 
unit length (mg/cm) 
11.5 ± 0.6 11.8 ± 1.3 0.82 
Bowel Wall Layer 
Measured 
Untreated Control 
(n=10) 
IL-8 Control      
(n=10) 
p-value 
Bowel length (cm) 5.9 ± 0.1 5.6 ± 0.4 0.05 
Bowel weight (mg) 66.1 ± 1.6 60.0 ± 3.3 0.11 
Bowel weight per 
unit length (mg/cm) 
11.2 ± 0.3 10.7 ± 0.5 0.40 
Table 4-2: Comparisons of bowel length, weight and weight per unit length (mean ± SEM) 
between experimental groups. Comparisons made between: untreated control versus 
untreated AWD, untreated AWD versus IL-8 injected AWD and untreated control versus IL-
8 injected control. *Indicates p-values that reached significance.  
Comparisons of bowel wall layer measurements between the untreated AWD and IL-
8 injected AWD groups showed no significant differences in bowel wall thickness 
but evidence of crypt hyperplasia and villus blunting in the IL-8 injected AWD 
fetuses (Table 4-3).  
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Bowel Wall Layer 
Measured 
Untreated 
AWD (n=10) 
IL-8 AWD      
(n=10) 
p-value 
Entire Wall Thickness (µm) 38 ± 1.7 34 ± 1.7 0.07 
Muscle Thickness (µm) 19 ± 1.4 19 ± 1.0 0.80 
Submucosa (µm) 19 ± 1.0 17 ± 2.7 0.48 
Villus height (µm) 194 ± 14.2 144 ± 10.8 *0.015 
Crypt depth (µm) 28 ± 1.9 41 ± 2.4 *0.0002 
Villus to Crypt ratio (µm) 7 ± 0.6 4.0 ± 0.4 *0.002 
    
Number of Muscle Cells 5.0 ± 0.11 4.9 ± 0.13 0.45 
Muscle Cell Thickness (µm) 3.8 ± 0.10 3.9 ± 0.2 0.71 
Table 4-3: Comparisons of bowel wall layer measurements (mean ± SEM) between 
untreated AWD and IL-8 injected AWD groups. *Indicates p-values that reached 
significance. 
Comparisons of bowel wall layer measurements between the untreated control and 
IL-8 injected control groups showed the IL-8 injected control fetuses entire bowel 
wall to be significantly thinner (30 ± 1.3µm) than that of the untreated controls (34 ± 
1.4µm, p=0.04). There were no other significant differences in bowel wall thickness 
measurements but there was evidence of crypt hyperplasia in the IL-8 injected AWD 
fetuses (Table 4-4). 
These results therefore suggest that in-utero IL-8 injection did not cause increased 
bowel wall thickness in AWD or control fetuses but may have induced crypt 
hyperplasia and villus blunting.  
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Bowel Wall Layer 
Measured 
Untreated 
Control (n=10) 
IL-8 Control      
(n=10) 
p-value 
Entire Wall Thickness (µm) 34 ± 1.4 30 ± 1.3 *0.04 
Muscle Thickness (µm) 17 ± 0.7 15 ± 0.7 0.15 
Submucosa (µm) 18 ± 1.0 15 ± 1.0 0.15 
Villus height (µm) 190 ± 15.4 166 ± 10.1 0.21 
Crypt depth (µm) 25 ± 1.4 42 ± 2.3 *<0.0001 
Villus to Crypt ratio (µm) 8 ± 0.5 4 ± 0.5 *<0.0001 
    
Number of Muscle Cells 4.7 ± 0.12 4.3 ± 0.1 0.06 
Muscle Cell Thickness (µm) 3.6 ± 0.16 3.5 ± 0.1 0.67 
Table 4-4: Comparisons of bowel wall layer measurements (mean ± SEM) between 
untreated control and IL-8 injected control groups. *Indicates p-values that reached 
significance. 
4.2.5 ICC and Enteric Neurons 
4.2.5.1 Intact Gut Tube Whole Mount Preparation Technique 
The preparation of intact gut tube, whole mount preparations was straightforward 
and required minimal tissue handling resulting in no tissue loss. Immunofluorescence 
staining was achieved reliably with anti-CD117 (ICC), anti-PGP9.5 (enteric neurons) 
and DAPI (nuclei). However, anti-HuC/D, which would have been the preferred 
option for quantification of enteric neurons did not penetrate or label the enteric 
neurons of intact gut tube preparations and therefore could not be used. The number 
of analysed whole mount specimens per experimental group was 10 untreated 
control, 10 untreated AWD, 9 IL-8 injected control and 11 IL-8 injected AWD.  
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4.2.5.2 ICC Architecture and Numbers: Comparison of Untreated Phenotypically 
Normal and AWD Fetuses 
The ICC at the level of the myenteric plexus were well developed in both untreated 
control (Figure 4-9A) and untreated AWD (Figure 4-9B) fetuses. The ICC exhibited 
numerous branching cytoplasmic processes, which interconnected with their 
counterparts creating a mature plexus. As expected for this gestational age, the 
myenteric ICC were the most well developed ICC population and ICC at the level of 
the deep muscular plexus were not observed in either group. The number of ICC per 
high powered field (45nm
2
) was significantly lower in the AWD group (80 ± 2.1) 
compared to the control group (90 ± 2.5, p=0.005) i.e. 11% reduction in ICC number 
(Table 4-5).  
4.2.5.3 ICC Architecture and Numbers: IL-8 Injected Groups 
The ICC at the level of the myenteric plexus in both the IL-8 injected control (Figure 
4-9C) and IL-8 injected AWD (Figure 4-9D) fetuses exhibited normal cell and 
network architecture as described above. The numbers of ICC per high powered field 
(45nm
2
) appeared lower in the IL-8 injected groups (IL-8 injected AWD 72 ± 3.3 and 
IL-8 injected control 69 ± 2.7) than the untreated groups. However on performing 
comparisons of ICC numbers between experimental groups (Table 4-5) it showed no 
significant difference between untreated AWD and IL-8 injected AWD groups 
(p=0.08) but a significant difference between untreated control and IL-8 injected 
control groups (p=<0.0001). These results suggest ICC numbers are affected by 
increased IL-8 concentrations but to a greater extent within the IL-8 injected control 
group than the IL-8 injected AWD group. Additional experimental animals would be 
necessary to examine these potential differences further and reach a definitive 
conclusion. 
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Untreated Control 
(n=10) 
Untreated AWD 
(n=10) 
p-value 
ICC 90 ± 2.5 80 ± 2.1 *0.005 
 
Untreated AWD 
(n=10) 
IL-8 AWD      
(n=11) 
p-value 
ICC 80 ± 2.1 72 ± 3.3 0.08 
 
Untreated Control 
(n=10) 
IL-8 Control     
(n=9) 
p-value 
ICC 90 ± 2.5 69 ± 2.7 *<0.0001 
Table 4-5: Comparisons of the number of ICC (mean ± SEM) per high powered field of 
view (45nm
2
) between experimental groups. Comparisons made between: untreated control 
versus untreated AWD, untreated AWD versus IL-8 injected AWD and untreated control 
versus IL-8 injected control. *Indicates p-values that reached significance.  
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Figure 4-9: Whole mount 18.5 dpc ileal specimens stained for ICC with anti-CD117, images 
acquired using confocal microscopy, 40x objective, maximum intensity project of z-stack 
images. A. Untreated control. B. Untreated AWD. C. IL-8 injected control. D. IL-8 injected 
AWD. 
4.2.5.4 Enteric Neuron Architecture and Numbers: Comparison of Untreated 
Phenotypically Normal and AWD Fetuses 
Enteric neurons at the level of the myenteric plexus were normally developed in both 
the untreated control (Figure 4-10A) and untreated AWD (Figure 4-10B) fetuses. 
There were regularly spaced cell chains running parallel to each other with 
perpendicular crosslinking between chains giving a normal crosshatched appearance 
of the network. Cell quantification revealed no significant difference in the number 
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of enteric neurons per high powered field (45nm
2
) between the untreated control and 
untreated AWD fetuses (control 85 ± 3.5 and AWD 89 ± 3.8, p=0.46).  
4.2.5.5 Enteric Neuron Architecture and Numbers: IL-8 Injected Groups 
The enteric neurons at the level of the myenteric plexus in both the IL-8 injected 
control (Figure 4-10C) and the IL-8 injected AWD (Figure 4-10D) fetuses also 
exhibited a normal well developed architecture as described above. The numbers of 
enteric neurons per high powered field (45nm
2
) appeared slightly higher in the IL-8 
injected groups (IL-8 injected AWD 93 ± 3.9 and IL-8 injected control 90 ± 2.9) than 
the untreated groups. However, on performing comparison of enteric neuron 
numbers between the experimental groups (Table 4-6) it showed no significant 
difference between untreated AWD and IL-8 injected AWD (p=0.47) or untreated 
control and IL-8 injected control (p=0.29) groups. Suggesting increased levels of 
inflammation did not impact on enteric neuron development. 
 
Untreated Control 
(n=10) 
Untreated AWD 
(n=10) 
p-value 
Enteric Neurons 85 ± 3.5 89 ± 3.8 0.46 
 
Untreated AWD 
(n=10) 
IL-8 AWD      
(n=11) 
p-value 
Enteric Neurons 89 ± 3.8 93 ± 3.9 0.47 
 
Untreated Control 
(n=10) 
IL-8 Control     
(n=9) 
p-value 
Enteric Neurons 85 ± 3.5 90 ± 2.9 0.29 
Table 4-6: Comparisons of the number of enteric neurons (mean ± SEM) per high powered 
field of view (45nm
2
) between experimental groups. Comparisons made between: untreated 
control versus untreated AWD, untreated AWD versus IL-8 injected AWD and untreated 
control versus IL-8 injected control.  
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Figure 4-10: Whole mount 18.5 dpc ileal specimens stained for enteric neurons with anti-
PGP9.5, images acquired by confocal microscopy, 40x objective, maximum intensity project 
of z-stack images. A. Untreated control. B. Untreated AWD. C. IL-8 injected control. D. IL-
8 injected AWD. 
4.2.6 Motility Studies 
4.2.6.1 Experimental Groups 
Recording of bowel motility and analysis of spatiotemporal maps were performed to 
determine whether presence of AWD or IL-8 injection affected bowel contractility. 
Motility studies were performed on bowel from 5 untreated control, 5 untreated 
AWD and 5 IL-8 injected AWD but not IL-8 injected control fetuses due interruption 
of the study secondary to colony infection with pinworm and subsequent treatment 
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regimen. However, the motility of one of the untreated control bowel segments failed 
to recover following dissection and transfer to the organ bath even after allowing 30 
minutes for the bowel to equilibrate. Therefore this bowel segment was excluded 
from the analysis and only 4 untreated control bowel segments were included.  
4.2.6.2 Pattern of Contractions 
Visual analysis of the spatiotemporal maps showed contractions to be present in all 
experimental groups. Shallow contractions considered to be ripples were present in 
all groups (Figure 4-11). Propagation of contractions along the bowel (contraction 
complexes) in both anal and oral directions was also evident in the untreated control 
and untreated AWD fetuses (Figure 4-11A, B and C) but not in the IL-8 injected 
AWD fetuses. This suggests that gut inflammation leads to rudimentary gut motility 
patterns. 
4.2.6.3 Contraction Strength 
On visual comparison of the spatiotemporal maps, the untreated control bowel 
appeared to exhibit the strongest contractions followed by the untreated AWD and 
finally the IL-8 injected AWD bowel (Figure 4-11). To graphically visualise this data 
more clearly, the maximum percentage change from the mean diameter for each 
vertical slice was calculated. Each bowel segment was plotted on a graph depicting 
proportion (%) of bowel that achieved a given maximum percentage change (Figure 
4-12A). The values were then averaged and displayed graphically as the mean for 
each experimental group (Figure 4-12B). Visually, Figure 4-12B depicts that the 
untreated control group achieves stronger contractions more frequently than the other 
groups particularly in the range of 20% to 50% maximum percentage change from 
the mean diameter. The IL-8 injected AWD bowel appears to achieve the weakest 
contractions.  
To determine whether these observations reached statistical significance the area 
under the curve for each individual experiment was calculated and groups compared 
by ANOVA, which showed no statistical difference between the groups (p=0.14, 
Figure 4-12C). Additionally, ANOVA comparison of the proportion of bowel 
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achieving contractions that reached 20% (p=0.14), 25% (p=0.13), 30% (p=0.20), 
35% (p=0.21), 40% (p=0.22), 45% (p=0.20) and 50% (p=0.20) maximum percentage 
change from the mean diameter showed no significant difference. Although ANOVA 
analysis showed no statistical differences between the groups this could be due to the 
small number of experiments undertaken per group reducing the power of the 
comparisons. 
 
Figure 4-11: Representative spatiotemporal maps from each experimental group. A and B. 
Untreated control. C and D. Untreated AWD. E and F. IL-8 injected AWD. A, B and D. 
Black diagonal lines represent contraction complexes travelling in the oral to anal direction. 
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Figure 4-12: Contraction strength, represented as proportion of bowel achieving a given 
maxium percentage change from the mean diameter. A. Data from all experiments. B. Mean 
from each experimental group. C. Mean area underneath the curve for each experimental 
group.  
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4.2.6.4 Frequency of Contractions 
The frequency of contractions was measured in two ways: (i) selection of the 3 most 
contractile vertical slices for each piece of bowel and (ii) analysis of the dominant 
number of contractions at all vertical slices for each piece of bowel. Figure 4-13 A, C 
and E shows the 3 vertical slices selected for a piece of bowel from each 
experimental group. The fast Fourier transform (FFT) was plotted for each selected 
vertical slice and the maximum amplitude taken as the dominant number of 
contractions per minute (Figure 4-13B, D and F). ANOVA analysis revealed a 
significant difference (p=0.009) in the dominant contractions per minute between the 
groups. The most frequent contractions were seen in the untreated control group (8.9 
± 0.8 contractions per minute), followed by untreated AWD group (6.9 ± 0.6 
contractions per minute) and lastly the IL-8 injected AWD group (5.7 ± 0.6 
contractions per minute). However, multiple comparisons post test revealed the only 
significant difference was between the untreated control and IL-8 injected group 
(Figure 4-13G). Again, this is probably due to the small numbers of experiments 
performed. 
For each piece of bowel the dominant number of contractions was calculated for all 
0.022mm incremental vertical slices and plotted against the percentage of bowel 
contracting at each dominant frequency (Figure 4-14A – C). Any vertical slice 
contracting at a dominant frequency of less than 2 per minute was considered to be 
non-contractile and excluded from the analysis. The values were then averaged and 
displayed graphically as the mean for each experimental group (Figure 4-14D). 
Visually, Figure 4-14D depicts that the untreated control group was the most active 
with the commonest dominant contraction rate being 7 to 8 contractions per minute. 
A high proportion of the untreated AWD and IL-8 injected AWD bowel was non-
contractile as evidenced by the commonest dominant contraction rate being 2 for 
both groups. ANOVA analysis revealed a statistically significant difference between 
the groups at a dominant frequency of 7 contractions per minute (p=0.029) with 
multiple comparison testing revealing a significant difference between the untreated 
control and untreated AWD groups. However, statistical significance was not 
reached for any other dominant frequency rate.   
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Figure 4-13: Fast Fourier transform (FFT) analysis of the selected 3 most contractile vertical 
slices per bowel segment. Representative vertical slice selections and corresponding FFT 
output for untreated control (A and B), untreated AWD (C and D) and IL-8 injected AWD 
(E and F). Compairson of dominant number of contractions per minunte between groups. 
Brackets show significant comparison (one-way ANOVA). 
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Figure 4-14: Fast Fourier transform (FFT) analysis for all 0.022mm incremental vertical 
slices for all segments of bowel. A. Untreated control. B. Untreated AWD. C. IL-8 injected 
AWD. D. Mean from each experimental group. 
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4.3 Discussion 
4.3.1 Abdominal Wall Phenotype 
4.3.1.1 An Unusual Exomphalos Phenotype? 
ACLP knockout fetuses exhibit failed abdominal wall closure at the umbilical ring 
and failed umbilical cord formation. The abdominal wall defect was centrally located 
and permitted the exteriorisation of abdominal viscera including bowel, stomach, 
liver and spleen. The amniotic membrane failed to adhere to the umbilical vessels 
and attached directly to the abdominal wall defect edge, resulting in the externalised 
viscera lying within the exocoelomic fluid. If normal umbilical cord formation had 
occurred in association with this centrally located AWD, then the externalised 
viscera would have been enclosed within the base of the umbilical cord and exhibited 
an exomphalos phenotype. Physiological herniation displays the same anatomical 
attributes as an exomphalos. Therefore direct comparison of the 13.5 dpc AWD fetal 
anatomy with the 13.5 dpc phenotypically normal fetuses exhibiting physiological 
herniation confirms failed umbilical cord formation in the ACLP mouse but 
illustrates that if the amniotic membrane had adhered to the umbilical vessels the 
AWD would be that of exomphalos (Figure 4-15). Additionally, the presence of 
multi-visceral herniation including the liver (as demonstrated by the ACLP knockout 
fetuses) is usually indicative of an exomphalos phenotype. It is unlikely this AWD is 
a body stalk defect due to the presence of a normal placenta (Bugge, 2012, Paul et 
al., 2001). 
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Figure 4-15: Comparison of schematic representations of a 13.5 dpc phenotypically normal 
fetus exhibiting physiological herniation (A) with a 13.5 dpc AWD fetus (B). If adherence of 
the amniotic membrane to the umbilical blood vessels had occurred forming a normal 
umbilical cord in the AWD fetus (B) then it would have the same anatomical appearance as 
the phenotypically normal fetus, which exhibits physiological herniation (A). 
Anatomical delineation of the AWD phenotype was possible through careful 
dissection under a stereo microscope enabling identification and preservation of the 
amniotic membrane and umbilical cord. These anatomical findings were confirmed 
by imaging of sagittally sectioned in-amnio paraffin embedded fetuses. Paraffin 
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embedding of intra-amniotic fetuses enabled preservation of the visceral yolk sac and 
amniotic membrane. Imaging of serial sections allowed the visceral yolk sac and 
amniotic membranes to be traced throughout their course and the relationship of the 
amniotic membrane to the umbilical blood vessels and abdominal wall to be easily 
defined. It was therefore possible to confirm the anatomical findings described at 
microdissection without causing disruption to amniotic membrane, the anatomy of 
which was essential for accurate phenotyping of this AWD. This method of 
abdominal wall phenotyping provided clearer delineation of the anatomical detail 
than that provided by the in-amnio micro-MRI performed for the phenotyping of the 
Scribble knockout model (Chapter 3). 
4.3.1.2 Another Case of Mistaken Identity 
Similar to the Scribble null fetuses, the above phenotypic description of the ACLP 
knockout fetuses contradicts the literature. The ACLP model has been described in 
two papers as exhibiting gastroschisis (Layne et al., 2001, Danzer et al., 2010) but 
neither paper performed detailed anatomical assessment of the abdominal wall defect 
or amniotic membrane. The abdominal wall defect of gastroschisis in humans is a 
full thickness defect to the right of a normally formed and inserted umbilical cord of 
which the covering amniotic membrane continues as the abdominal wall ectoderm. 
Therefore in gastroschisis, there is an abdominal wall deficiency, which also disrupts 
the continuity of the amniotic membrane enabling the eviscerated bowel to lie within 
the amniotic cavity. In the ACLP knockout mouse, there is a full thickness AWD but 
the amniotic membrane, although abnormal, remains intact throughout its course and 
separates the externalised viscera from the amniotic fluid. Hence, the externalised 
abdominal viscera in ACLP knockout fetuses is free floating in the exocoelomic 
cavity and not the amniotic fluid as would be expected for gastroschisis.  
The composition of amniotic and exocoelomic fluid compartments are very different; 
whilst the amniotic fluid contains fetal urine, meconium and respiratory secretions 
(Gilbert and Brace, 1993) the exocoelomic fluid does not and the fluid composition 
is determined by the exchange of substances from the overlying visceral yolk sac 
serving as the principle site for the exchange of proteins between mother and fetus 
(Jauniaux and Gulbis, 2000). As such, the eviscerated bowel of the ACLP knockout 
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mouse is not in direct contact with the substances that are hypothesised to cause 
intestinal inflammation, damage and ultimately intestinal dysfunction in 
gastroschisis. Therefore, interpretations of experimental data using this model that 
infer gastroschisis pathophysiology findings must be interpreted with care. However, 
it is possible through in-utero injections into the exocoelomic cavity to manipulate 
the environment surrounding the gut and it is therefore a useful model for 
investigating the impact of potential amniotic fluid irritants on bowel development. 
The additional benefit of this model is the high penetrance of the AWD, good litter 
sizes (8 to 9 pups per litter) and the isolated nature of the AWD. 
4.3.1.3 Failed Umbilical Cord Formation and Abdominal Wall Closure 
The anatomical relationship between the amniotic membrane, umbilical cord and 
AWD exhibited by the ACLP knockout mice is the same as that described in 
homozygous Bone Morphogenetic Protein 1 (Bmp1) mutant embryos (Suzuki et al., 
1996). BMP1 is a metalloproteinases extracellular protein with an amino-terminus 
activation region, astacin-like protease domain, EGF-like motifs and protein-protein 
interaction domains. BMP1 is required for the activation of procollagen (Kessler et 
al., 1996, Li et al., 1996), is essential for the formation of cross-links to stabilise 
fibrous collagen and elastin (Panchenko et al., 1996) and enhances the activity of 
TGFβ growth factors  (Hogan, 1996). Electron microscopy has revealed disrupted 
collagen fibrils in the amniotic membranes of BMP1 mutant embryos consisting of 
thinner fibrils with barbed wire appearance surrounded by large amounts of 
amorphous material (Suzuki et al., 1996). Suzuki et al. hypothesised that disruption 
to the collagen fibrils resulted in failed folding of the amniotic membrane around the 
herniated bowel and the umbilical vessels at the time of physiological herniation 
resulting in persistence of bowel herniation and ultimately failed abdominal wall 
closure. The authors could not rule out that the amniotic membrane and mesodermal 
cells of the abdominal wall also had altered cell-cell or cell-matrix adhesion 
preventing adhesion of either tissue to the umbilical vessels.  
It is possible that in the ACLP knockout model, failed folding and adherence of the 
amniotic membrane to the umbilical blood vessels was partly due to disruption of 
amniotic membrane collagen deposition. It has previously been shown that ACLP 
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promotes collagen and myofibroblast formation through the activation of TGFβ 
signalling (Tumelty et al., 2014). ACLP knockout fetuses exhibit reduced TGFβ 
activation (Tumelty et al., 2014), which could lead to disruption of collagen 
production as seen in the BMP1 mutants. Although ACLP and TGFβ staining was 
performed on cross-sections of in-amnio paraffin embedded fetuses it was not 
possible to assess whether differences in expression existed between AWD and 
phenotypically normal fetuses due to the presence of significant background staining. 
Therefore, it is not possible to comment on the involvement of TGFβ in the 
development of the anatomical defects present in the ACLP knockout mouse. 
However, given ACLP is highly secreted in the extracellular matrix and acts as a 
signalling protein, it is likely that abnormal cell-cell migration, signalling and 
adherence is also implicated in the failed adherence of the amniotic membrane and 
mesodermal ventral wall cells to the umbilical blood vessels resulting in the AWD.  
4.3.2 Bowel Wall Development  
4.3.2.1 Comparison of Untreated Control and Untreated AWD Fetuses 
The previously published description of bowel development in the ACLP knockout 
mouse model (Danzer et al., 2010) revealed the AWD fetuses to have normal bowel 
length, weight and wall thickness compared to controls. There was no evidence of 
inflammation or serosal peel, which the authors felt was due to the relatively short 
mouse gestational period although my results would suggest this is due to the bowel 
being exposed to exocoelomic fluid rather than amniotic fluid. However, they 
reported a reduction in ICC and enteric neuron staining of the externalised gut of 
AWD fetuses. The ICC were reportedly reduced by 70% in the AWD fetuses and 
exhibited an altered architecture with failed formation of a continuous network at the 
level of the myenteric plexus. This analysis was performed on cross-sections of 
bowel with immunohistochemistry and using a semi-quantitative scoring system.  
The results presented here also confirm there was no significant difference between 
the bowel wall appearance or morphology of the AWD and control fetuses. 
However, phenotyping and quantification of ICC and enteric neurons was performed 
using whole mount specimens with immunofluorescence staining and in contrast to 
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the Danzer et al. paper both cell types were found to be architecturally normal within 
the AWD fetuses compared to controls. Additionally, although there was a reduction 
in the number of ICC in the AWD fetuses, this was only an 11% reduction as 
opposed to 70% reported by Danzer et al. and no difference in the numbers of enteric 
neurons was found between the groups. These results highlight the benefits of whole 
mount preparations over cross-sections providing the ability to image the entire 
network with confocal microscopy giving a complete and detailed picture of the cell 
architecture and networks and a more robust method for quantification.  
The lack of bowel inflammation and the presence of normal ICC architecture may be 
due to the gut free floating within the exocoelomic fluid rather than the amniotic 
fluid providing protection from fetal urine, meconium, respiratory secretions and 
growth factors, which may negatively impact bowel development. Although ICC 
were reduced in number it is not possible to know whether this was caused by a 
developmental delay secondary to ACLP deficiency or exposure to exocoelomic 
fluid and if this would also be present in true gastroschisis.  
4.3.2.2 Impact of IL-8 In-Utero Injections 
In-utero injections of IL-8, an inflammatory mediator present in meconium (de 
Beaufort et al., 1998), were performed to determine whether increased bowel 
exposure to inflammation would impact on bowel morphology or ICC and enteric 
neuron development. In the control fetuses, IL-8 injection was performed into the 
amniotic fluid cavity and therefore fetal physiological swallowing would have 
resulted in an increased IL-8 exposure at the mucosal surface. However in the AWD 
fetuses, IL-8 injection was performed into the exocoelomic cavity increasing serosal 
exposure to the inflammatory mediator but without increased mucosal exposure.  
Increased serosal IL-8 exposure was associated with evidence of macroscopic serosal 
inflammation with the presence of prominent serosal blood vessels. Additionally, 
there was significant shortening of the bowel when compared to all other groups but 
there was no effect on the weight per unit length suggesting the bowel was not 
thickened. This was confirmed on measurement of bowel wall thickness in which 
increased serosal and mucosal exposure to IL-8 did not result in increased entire 
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bowel wall or muscle layer thickening unlike other animal studies (Api et al., 2001, 
Correia-Pinto et al., 2002). This could have been due to the short duration of 
exposure to increased IL-8 and bowel wall thickening/remodelling may require a 
longer time period for an effect to occur. However, there was evidence in both the 
IL-8 injected groups of increased hyperplasia of villus crypts suggesting mucosal 
development had been affected.  
ICC and enteric neurons within both the IL-8 injected control and IL-8 injected 
AWD fetuses showed normal architecture and exhibited established cell networks. 
Although ICC were reduced in both groups this was more evident within the IL-8 
injected control group, which was significantly reduced compared to both untreated 
control fetuses. However, there was no significant difference between the untreated 
AWD and IL-8 injected AWD fetuses. These data suggest that increased mucosal 
exposure to IL-8 had a greater impact on ICC development than increased serosal 
exposure. This suggests that GRID may result from an additive effect of both serosal 
and mucosal exposure to the pro-inflammatory amniotic fluid environment (Morrison 
et al., 1998).  
4.3.2.3 Bowel Contractility and ICC Numbers 
Mouse gut motility develops prior to birth (Burns et al., 2009, Ross and Nijland, 
1998) initially within the duodenum as non-neuronal mediated ripples from 13.5 dpc, 
neuronally/ICC mediated contraction complexes from 18.5 dpc and finally mature 
migrating motor complexes develop after birth (Roberts et al., 2010). The data 
presented here confirms the presence of contraction complexes that propagate along 
the bowel at 18.5 dpc within the small bowel.  
There was a trend of decreasing ICC numbers with increasing fetal manipulation. 
The highest numbers of ICC were exhibited in the untreated control fetuses, followed 
by untreated AWD fetuses and the lowest number within the IL-8 injected AWD 
fetuses. A similar pattern was evident from the contraction data. Taking into account 
all variables the IL-8 injected bowel appeared to be the most dysfunctional, as 
evidence by: (i) the lack of contraction complexes suggesting a more rudimental 
motility pattern, (ii) a lower percentage change from the mean diameter than controls 
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indicating shallower contractions and (iii) the highest percentage of dominant 
contractions occurring at a rate of 2 per minute suggesting that a large proportion of 
the bowel was inactive. Based on the same parameters, bowel from untreated 
controls showed a mature-for-stage contraction pattern, strong contractions with a 
high dominant frequency of contractions occurring most commonly at a rate of 7 to 8 
per minute, suggesting good contractile function across the entire bowel length.  
This trend is consistent with the published literature, which shows that disruption to 
ICC through generation of  ICC knockout models (Der-Silaphet et al., 1998), 
blockade of ICC kit signalling (Beckett et al., 2007), or ICC disruption secondary to 
inflammation (Der et al., 2000) results in disorganised reduced contractility of the 
bowel. Although the ACLP knockout model does not exhibit gastroschisis, it shows 
that disruption of myenteric ICC numbers through manipulation of the inflammatory 
environment acting on the serosal bowel surface may result in disrupted bowel 
contractility and could be the cause of GRID.  
4.3.3 Limitations of the Study 
4.3.3.1 ACLP Knockout Model 
The ACLP knockout model is not a true representation of human gastroschisis. 
Although bowel is free floating within fluid this was not within the amniotic fluid 
and therefore any reduction in ICC cannot be stated to replicate the pathology seen in 
gastroschisis. However, it was possible to manipulate the exocoelomic fluid 
environment through in-utero injection but it must also be acknowledged that it was 
not possible to visualise the amniotic membrane separating the exocoelomic and 
amniotic cavities during these injections. As such, even though IL-8 injections were 
performed into the space between bowel loops it cannot be guaranteed that some 
injections were not misdirected into the amniotic cavity instead of the exocoelomic 
cavity. If this was the case then some AWD fetuses would not have received an 
increased serosal exposure. Additionally, within the control fetuses it was not 
possible to identify the exocoelomic cavity under direct vision and therefore in-utero 
IL-8 injections were performed into the amniotic cavity therefore not generating a 
true comparative control. Access to a micro-ultrasound was not available during the 
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study period but ultrasound guidance may have enable injection into the exocoelomic 
cavity in control fetuses and also the amniotic cavity in AWD fetuses providing a 
comprehensive set of experimental and control conditions for the analysis of the 
effect on bowel wall development. Also, phenotypically normal fetuses were used as 
controls, which included both wild types and heterozygotes. The study by Layne, et 
al., 2001 shows through complementary DNA and messenger RNA studies in ACLP
-
/-
 and ACLP
+/-
 fetuses that the observed phenotype in knockout fetuses is secondary 
to the result of the complete absence of ACLP. Also Danzer, et al., 2010 reported the 
intra-abdominal bowel of ACLP null fetuses to exhibit the same expression of bowel 
wall ICC and enteric neurons as control intestine suggesting ICC development was 
not effected by absence of ACLP. However, this does not completely rule out that 
bowel wall development in heterozygotes may be effected by partial ACLP loss and 
therefore could have impacted results.  
Further studies that could have been done to further improve the validity of results 
are: (1) the inclusion of intra-abdominal bowel from AWD fetuses (e.g. duodenum or 
colon) and corresponding bowel from control fetuses to act as an internal control to 
determine whether changes in AWD bowel wall development are secondary to the 
AWD or as a result of ACLP deficiency and (2) to quantify inflammation in extra-
fetal fluid and bowel wall.  
4.3.3.2 Experimental Numbers and Treatment for Pinworm 
Statistically significant results may not have been observed for some measured 
parameters due to the small number of fetuses included in the study. Low numbers 
were partly as a result of study interruption due to a laboratory wide pinworm 
infection and subsequent fenbendazole treatment regimen lasting 9 weeks. The 
treatment resulted in reduction of fertility and small litter sizes in all mice that had 
received or were conceived during the pinworm treatment. To improve fertility, fresh 
wild type C57BL/6J female mice that had not received the fenbendazole diet were 
introduced into the colony. Re-establishment of the colony took 6 months from 
completion of the fenbendazole diet. 
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4.3.3.3 Motility Study Analysis Optimisation 
Bowel edge detection using MATLAB relied upon light thresholding. However, the 
light cast during experiments resulted in a small degree of reducing light intensity in 
the oral to anal direction (Figure 4-16A) resulting in an underestimation of the bowel 
diameter at the anal end. Therefore, a software correction within MATLAB was 
applied to remove this artefact. Additionally, bowel diameter naturally tapers in the 
oral to anal direction with the terminal ileum being visually thinner than the 
duodenum resulting in an apparent reduction in the contraction depth (surrogate for 
contraction strength) when measuring absolute bowel diameter changes in 
millimetres. This was apparent on spatiotemporal maps showing diameter change 
(mm) against bowel incremental point (mm) with time (seconds) (Figure 4-16B) due 
to the change in the represented colour across the graph from red to green in the oral 
to anal direction. To improve data analysis, contraction depth was calculated based 
on the percentage change in bowel diameter from the calculated mean diameter on 
vertical slice analysis at each 0.022mm incremental point along the bowel length. 
This data was then plotted on a spatiotemporal map showing percentage change from 
mean diameter against bowel length with time (Figure 4-16C) providing a clearer 
visual plot of contractions. Finally, oxygenation of the Ringer’s solution resulted in 
the formation of bubbles, some of which adhered to the edge of the bowel. 
Dislodgement of these bubbles resulted in paralysis of the bowel requiring a period 
of recovery therefore it was not possible to dislodge all bubbles. Where a bubble is 
adherent to the bowel it led to an artefact in measurement of the diameter change 
(Figure 4-16A – C). However, due to the large number of vertical slice analyses 
performed these bubble artefacts had minimal impact on the results.   
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Figure 4-16: Analysis optimisation using MATLAB software. A. Bowel edge detection 
performed by light thresholding showing reducing light intensity in the oral to anal direction 
and the presence of a bubble artefact. Gut appears in yellow, pink line marks ileal edge, 
green line marks centre point of bowel. B. Spatiotemporal map of change in bowel diameter 
in absolute millimetres showing decreasing bowel diameter from the oral to anal direction 
(normal bowel anatomy) and bubble artefact (black arrow). C. Spatiotemporal map of 
change in bowel diameter as a percentage change from the mean diameter providing uniform 
analysis of contraction depth along the length of the bowel. Black arrow indicates bubble 
artefact. 
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4.3.4 Conclusion 
The ACLP knockout mouse model is another example of inaccurate phenotyping 
resulting from a lack of detailed assessment of the AWD and associated membranes. 
Rather than expressing a gastroschisis defect, the ACLP knockout mouse exhibits an 
unusual exomphalos defect with failed adhesion of the amniotic membrane to the 
umbilical vessels placing the externalised bowel free floating within the exocoelomic 
fluid, which is an ultra-filtrate of the maternal serum. This could explain the lack of 
bowel wall thickening and normal ICC architecture present within the untreated 
AWD fetuses. The whole mount ICC data presented here did not agree with the 
previously published data acquired through analysis of cross-sectioned small bowel 
(Danzer et al., 2010) and therefore calls into question the validity of results obtained 
from analysis of small animal cross-sectioned bowel. Although not an ideal model of 
gastroschisis, the ACLP model enabled the in-utero manipulation of serosal and 
mucosal inflammatory exposure as two independent variables. These results suggest 
there is a link between increased inflammation, reduced ICC and bowel dysmotility. 
As such, these data support the potential for GRID to be caused by an ICC deficiency 
but interpretation of these results and direct application to human gastroschisis must 
be undertaken with care.  
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Chapter 5: Analysis of Gastroschisis ICC and Enteric 
Neurons in Infant Human Pathological Gut Tissue 
5.1 Introduction  
At the start of this study only one paper (Midrio et al., 2008) had been published 
investigating ICC development in gastroschisis bowel. This study involved a single 
case of gastroschisis. The infant was born at 36 weeks GA and required resection of 
necrotic bowel and stoma formation shortly after delivery. One month later when 
partial enteral feeding was tolerated, the stoma was closed. The resected tissue was 
immunostained for CD117 and ICC differentiation at the level of the myenteric 
plexus (the first ICC population to develop in the human bowel, which is also well 
developed at full term (Faussone-Pellegrini et al., 2007)) was described. At the time 
of the first operation the authors described the ICCs as infrequent and 
ultrastructurally immature but at one month of age the cells had matured and formed 
rows or groups, suggesting that ICC differentiation is delayed in gastroschisis and 
may be the cause of GRID. However, the method used was not quantitative and no 
controls were included in the study.  
Gastroschisis infants are hypothesised to exhibit deficient and architecturally 
immature bowel wall ICC, which may be the cause of GRID. As such, the aim for 
this part of the study was to determine with a larger patient series whether 
development of ICC at the level of the myenteric plexus was impaired in 
gastroschisis infants compared to control infants.  
5.2 Results 
5.2.1 Study Population and Demographics 
Following ethical approval a total of 17 control and 20 gastroschisis small bowel 
specimens were included in the study, which had been resected between 1988 and 
2012. Bowel resection had been performed in the control and gastroschisis groups for 
pathologies as outlined in Table 5-1.  
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Control 
n=17 
Gastroschisis 
n=20 
Dysmotile bowel - 9 
Ischaemia/necrosis - 6 
Anastomotic stricture - 1 
Stenosis 1 3 
Perforation 3 1 
Intussusception 7 - 
Meckel’s diverticulum 2 - 
Strangulated hernia 2 - 
Volvulus 2 - 
Table 5-1: Pathology resulting in small bowel resection in the control and gastroschisis 
groups. 
There was no significant difference in the age at time of bowel resection (control 
median 58, range [1-378] days and gastroschisis 72 [1-717] days, p=0.39) or the 
corrected gestational age (CGA) at time of bowel resection (control 40 [26-94] 
weeks and gastroschisis 48 [34-140] weeks, p=0.34) between the control and 
gastroschisis groups. Linked clinical data was not possible to obtain for 4 
gastroschisis small bowel specimens as the samples were transferred from another 
hospital for a second opinion regarding the cause of persistent dysmotility. Hence, 
CGA for these patients was estimated using a delivery at 38 weeks GA as this is the 
time point at which planned delivery for gastroschisis is commonly undertaken. 
Linked time to full enteral feeds (ENT) data was available for 11 gastroschisis small 
bowel specimens (ENT 62 [18-204] days) the reason for missing data included; PN 
dependency (n=5) and specimens that were transferred from another hospital (n=4).  
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5.2.2 ICC and Enteric Neurons  
5.2.2.1 Optimisation of Immunofluorescence ICC Staining Protocols 
The previous human gastroschisis study utilised immunohistochemistry techniques 
for staining of ICC. However, initial protocols with both immunohistochemistry 
(Table 5-1A) and immunofluorescence (Table 5-1B) revealed ICC cell bodies to be 
more easily identified with immunofluorescence. Additional advantages of 
immunofluorescence included; the ability to triple label sections for ICC, enteric 
neurons and nuclei, which reduced the number of sections required and improved 
identification of both ICC and enteric neuron cell bodies. Therefore, it was decided 
to continue the study using immunofluorescence.   
 
Figure 5-1: Images taken with; (1) 5x and (2) 40x objective. Image (3) is an enlarged section 
of 40x objective image. A. Immunohistochemistry. ICC stained with CD117 and DAB 
detection kit (dark brown staining), nuclei stained with Eosin counterstain (purple). B. 
Immunofluorescence. Composite images showing triple staining for ICC with anti-CD117 
(green), enteric neurons with anti-HuC/D (red) and nuclei with DAPI (blue). Key: LM – 
longitudinal muscle, CM – circular muscle, MP – myenteric plexus, ICC – interstitial cells of 
Cajal.  
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5.2.2.2 ICC and Enteric Neuron Architecture 
ICC at the level of the myenteric plexus were well developed in both control (Figure 
5-2A and B) and gastroschisis (Figure 5-2C and D) small bowel. ICC intercellular 
branching connections were evident creating cell networks that were closely 
associated with the myenteric plexus. ICC networks were found to surround and be 
continuous either side of the myenteric ganglion cells. The myenteric neuronal 
plexus was also well developed in both groups. The enteric neurons formed regular 
clumps of cells consistent with myenteric ganglia.  
 
Figure 5-2: Composite images showing triple staining of ICC (green), enteric neurons (red) 
and nuclei (blue), images taken with 40x objective. A and B. Control small bowel images. C 
and D. Gastroschisis small bowel images. Key: LM – longitudinal muscle, CM – circular 
muscle, MP – myenteric plexus, arrows indicating example ICC adjacent to ganglia. 
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5.2.2.3 ICC and Enteric Neuron Numbers  
On group comparison with t-test analysis there were no differences in either the 
number of ICC per high powered field (control 16.2 ± 1.9 [mean ± SEM] and 
gastroschisis 15.2 ± 1.7, p=0.71) or enteric neurons per high powered field (control 
13.2 ± 2.2 and gastroschisis 10.6 ± 1.1, p=0.23) between control and gastroschisis 
small bowel (Figure 5-3).  
 
Figure 5-3: Correlation between ICC numbers (A) and enteric neuron numbers (B) between 
control and gastroschisis small bowel. 
5.2.2.4 ICC and Enteric Neuron Numbers and Age at Bowel Resection 
Given that ICC networks continue to develop after birth (Faussone-Pellegrini et al., 
2007), a linear regression analysis was performed of all bowel resection specimens to 
determine whether there was a relationship between ICC numbers and age at time of 
bowel resection. This showed no significant relationship (R
2
=0.02, p=0.44, Error! 
eference source not found.A). However, this analysis may have been skewed by the 
outlier that underwent bowel resection at 717 days. Removing this outlier from the 
analysis resulted in a significant relationship (R
2
=0.21, p=0.005, Error! Reference 
source not found.B) showing an increase in ICC numbers with age. A similar linear 
regression analysis was performed for neuron numbers, which showed a significant 
trend of decreasing neuron numbers with age when the outlier was included 
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(R
2
=0.11, p=0.049, Error! Reference source not found.C) but no significant trend 
when the outlier was excluded (R
2
=0.07, p=0.11, Error! Reference source not 
found.D). Further analysis was performed using multiple regression analysis taking 
into account both the effect of age at time of bowel resection and diagnosis of 
gastroschisis. Results showed neither factor to be significant when considering ICC 
or neuronal cell number (Table 5-2).  
 
Figure 5-4: Linear regression analysis comparing ICC (A and B) and neuron (C and D) 
numbers with age at time of bowel resection, including all bowel resection specimens. A and 
C. Including the outlier (indicated by the blue circles). B and D. Excluding the outlier.  
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ICC Number 
Regression Coefficient 
(95% CI) 
p-value 
Age at time of bowel 
resection 
0.008 (-0.01, +0.03) 0.36 
Gastroschisis -1.4  (-6.8, +3.9) 0.59 
Neuron Number 
Regression Coefficient 
(95% CI) 
p-value 
Age at time of bowel 
resection 
-0.014 (-0.03, +0.001) 0.07 
Gastroschisis -1.8 (-6.4, +2.776) 0.43 
Table 5-2: Multiple regression analysis of ICC and neuron numbers taking into account age 
at time of bowel resection and diagnosis of gastroschisis, including all bowel resection 
specimens. 
5.2.2.5 ICC and Enteric Neuron Numbers and Time to Full Enteral Feeds 
To determine whether ICC or neuron numbers were associated with ENT in the 
gastroschisis population, a Spearman’s correlation was performed, which showed no 
significant correlation with ICC (rs=0.3, p=0.33,) or neuron (rs=0.2, p=0.66) numbers 
(Figure 5-5).  
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Figure 5-5: Relationship between gastroschisis ICC (A) and neuron (B) numbers with time 
to full enteral feeds (ENT). 
5.2.2.6 ICC in Meconium Ileus 
As a positive control, two bowel resection specimens from patients with meconium 
ileus without cystic fibrosis were immunostained and imaged. Both cases showed 
immature, scanty ICC (ICC number across both specimens 1.4 ± 0.4) that lacked 
intercellular branching connections. The enteric neurons were architecturally normal 
forming regular myenteric ganglia but also appeared to be low in number (5.4 ± 1.1) 
(Figure 5-6). 
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Figure 5-6: Composite images from 2 different meconium ileus small bowel specimens, 
showing triple staining of ICC (green), enteric neurons (red) and nuclei (blue), images taken 
with 40x objective. Key: LM – longitudinal muscle, CM – circular muscle, MP – myenteric 
plexus, arrows indicating example ICC adjacent to ganglia. 
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5.3 Discussion 
5.3.1 Tissue Selection for Inclusion in the Study 
Small bowel is only resected in gastroschisis or otherwise normal infants when there 
is concomitant intestinal pathology. Therefore, it is impossible to compare bowel 
from uncomplicated gastroschisis infants with completely healthy infants. To reduce 
the confounding effect of concomitant pathologies, bowel conditions described in the 
literature to have reduced ICC such as atresia (Tander et al., 2010, Midrio et al., 
2010) and meconium ileus (Toyosaka et al., 1994, Yoo et al., 2002) and those 
associated with significant bowel wall inflammation that may adversely impact ICC 
numbers including necrotising enterocolitis (NEC), stoma closure and post-mortem 
specimens were excluded. Additionally, only grossly normal resection margins were 
included thus selecting as near macroscopically normal small bowel as possible. 
Where available pathologies that involved mechanical compromise of healthy bowel 
were included to ensure selection of as near normal bowel resection margins as 
possible. However, the worst cases of gastroschisis with prolonged intestinal 
dysmotility were included in this cohort. If ICC deficiency is the cause of GRID, a 
significant reduction in ICC numbers between gastroschisis and control small bowel 
resections would be expected. Finally, the gastroschisis and control groups were aged 
matched to reduce the impact of potential continued ICC development in the infant 
period. 
5.3.2 ICC and Enteric Neuron Numbers and Architecture 
This study found no differences in the number or architecture of ICC or enteric 
neurons between the gastroschisis and control groups. Additionally, regression 
analysis revealed no effect of gastroschisis on ICC or enteric neurons. In comparison, 
as a positive control two meconium ileus small bowel specimens were 
immunostained and analysed revealing immature, scanty ICC as expected (Toyosaka 
et al., 1994, Yoo et al., 2002). This indicates validity of the staining and 
quantification method for analysis of ICC and enteric neurons and supports the lack 
of effect of gastroschisis on ICC or enteric neuron cell numbers.  
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Age at resection also did not appear to significantly affect the number of ICC or 
enteric neurons at the level of the myenteric plexus. This is in keeping with a study 
that documented the development of different ICC populations within the bowel wall 
during fetal life, which suggested the ICC of the myenteric plexus appeared early in 
gestation (17 weeks GA) and were well differentiated by full term (Faussone-
Pellegrini et al., 2007). Finally, no correlation was found between ICC and enteric 
neuron numbers and the time to achieve full enteral feeds.  
5.3.3 Quantification of ICC and Enteric Neurons 
Reliable ICC and enteric neuron immunofluorescence staining was possible with 
anti-CD117 and HuC/D (respectively) antibodies following antigen retrieval of 
paraffin embedded human gut sections. Due to the relatively large size of the small 
bowel specimens (unlike rodent small bowel), ICC and enteric neurons were easily 
identified and architecture discerned following imaging of cross-sectioned tissue 
with 40x objective. Therefore it was possible to perform accurate cell counts 
providing a robust and reliable method of cell quantification. Background staining 
was present, which did not affect manual cell counting. However, if an automated 
method was used such as the use of image software processing to calculate the area 
of positive staining (Wang et al., 2009, Bernardini et al., 2012), background staining 
may have led to inaccurate results. The two meconium ileus small bowel specimens, 
which were processed as positive controls confirmed that the quantification method 
used in this study can discriminate between varying degrees of ICC numbers and 
architecture. 
5.3.4 Comparison with Other Studies  
The original human gastroschisis ICC data was derived from a single case report 
(Midrio et al., 2008) as previously described. Recently, another larger study has been 
published investigating the differences in ICC numbers between gastroschisis and 
control small bowel specimens (Zani-Ruttenstock et al., 2015). This larger study has 
several fundamental differences in the methods used for specimen selection, 
immunostaining, cell quantification and data analysis compared to the data presented 
here. Zani-Ruttenstock et al. only included patients who underwent stoma formation 
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(time point 1) and later stoma closure (time point 2). The gastroschisis group (n=24 
in total) consisted of patients who took >42 days to achieve ENT, however, the 
reason for stoma formation was not fully documented for patients within this group. 
The control group (n=22 in total) included patients with NEC, atresia, atresia with 
volvulus and malrotation/volvulus. Resection margins included evidence of 
inflammation as outline in Table 5-3. Quantification was performed on sections 
stained by immunohistochemistry (DAB detection kit) from 25 randomly orientated 
fields of view taken with 20x objective.  
Categorisation of 
Inflammation 
Number of Gastroschisis 
Samples  
Number of Control 
Samples  
Severe 10 8 
Transmural 12 10 
Necrosis 6 9 
Ulceration 13 16 
Peritonitis 10 9 
Table 5-3: Degree, distribution and type of inflammation present in resected bowel sections 
included in Zani-Ruttenstock et al. study. 
The results showed at time point 1 there was no significant difference between the 
control (mean ICC number 6) and gastroschisis (mean ICC number 2.5, p=0.06) 
groups but at time point 2 there were significantly more cells in the control (mean 
ICC number 11) compared to gastroschisis (mean ICC number 3.5, p=0.01) group. 
Overall ICC numbers were higher in the control (mean ICC number 11) compared to 
gastroschisis (mean ICC number 3, p<0.003) group. Morphological analysis showed 
no difference in cell architecture between the groups with branching, interconnecting 
cells seen in both.  
Although, the results of that study appear to be contradictory to this one it is 
important to note that at time point 1 Zani-Ruttenstock, et al. also showed no 
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significant difference in ICC numbers and overall ICC maturity was the same in both 
groups. It is also interesting to note that the mean number of ICC quantified within 
the Zani-Ruttenstock study were significantly lower than that of the study presented 
here even though quantification was performed at a lower magnification. It is 
possible that this lower cell number could have occurred secondary to the use of 
inflamed, grossly abnormal resection tissue (including stoma reversal tissue, which is 
known to exhibit chronic inflammation) or from inclusion of conditions such as 
atresia (Tander et al., 2010, Midrio et al., 2010) both of which could have negatively 
impacted on ICC numbers. Finally, the accuracy of their data is unknown due to 
quantification being performed on randomly orientated fields of view. As such, this 
study may have resulted in bias and the incorrect rejection of a true null hypothesis 
(type 1 error).  
5.3.5 Limitations of the Current Study 
This was a retrospective study and therefore the original handling and paraffin 
embedding of the small bowel tissue was not performed uniformly although it would 
have followed normal histopathology protocols. It was also only possible to analyse 
gut tissues from patients requiring bowel resection therefore patients with simple 
gastroschisis or healthy control infants could not be included in the study. 
Additionally, the most common reason for bowel resection in gastroschisis infants is 
intestinal atresia and therefore the number of small bowel specimens available for 
analysis was limited. Although cell numbers and architecture can be analysed it is 
not possible to assess function of ICC or enteric neurons from paraffin embedded 
tissue. Finally, clinical data was not available for all small bowel specimens due to 
tissue being transferred from outside hospitals for a second opinion.  
5.4 Conclusion 
The data showed no differences in the number or architecture of ICC or enteric 
neurons at the level of the myenteric plexus in gastroschisis small bowel compared to 
control tissues. Additionally, no association was found between numbers of ICC or 
enteric neurons with age at bowel resection or duration of GRID (measured as ENT). 
Therefore, this study does not support the hypothesis that GRID is secondary to 
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reduced or poorly differentiated ICC and contradicts the published literature to date. 
This finding was unexpected particularly as only bowel specimens from infants with 
the worst postnatal outcomes were included and highlights the need for further 
investigation into the bowel wall development of gastroschisis fetuses before a 
therapy to improve gastroschisis gut function can be developed. A further detailed 
morphological analysis of the small bowel specimens was performed to determine 
whether another factor could be identified for the cause of GRID (Chapter 6).  
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Chapter 6: Analysis of Gastroschisis Bowel Wall 
Morphology in Infant Human Pathological Gut Tissue 
6.1 Introduction 
At birth the bowel wall of infants with gastroschisis has frequently been described as 
appearing thickened and inflamed (Tibboel et al., 1986) and investigations using 
surgical animal models (Api et al., 2001, Correia-Pinto et al., 2002, Langer et al., 
1989, Srinathan et al., 1995) have shown increased serosal and muscle layer 
thickening of gastroschisis bowel compared to normal controls. The serosal and 
muscle layer thickening in animal studies has been hypothesised to be induced by 
inflammation secondary to amniotic fluid exposure (Api et al., 2001, Correia-Pinto et 
al., 2002, Olguner et al., 2006, Guo et al., 1995, Bittencourt et al., 2006, Yu et al., 
2004, Langer et al., 1989) or constriction at a tight abdominal wall defect (Shah et 
al., 2012, Langer et al., 1989). In human gut, increased levels of the inflammatory 
cytokine transforming growth factor-beta 3 (TGF-β3) have been found in 
gastroschisis infants compared to control infants (Moore-Olufemi et al., 2015) and 
TGF-β3 has been hypothesised to be a mediator of bowel wall thickening in 
gastroschisis. However, to date there are no published morphological studies of 
histological human gastroschisis gut therefore the nature of the observed bowel wall 
thickening at birth in gastroschisis infants remains unknown.   
Gastroschisis infants are hypothesised to exhibit thickened bowel wall, which may be 
the cause of GRID.  The aims of this part of the study were to; (i) determine whether 
bowel wall thickening was present in human gastroschisis infants compared to 
controls and (ii) determine the architectural basis of any differences.  
6.2 Results 
6.2.1 Study Population and Demographics 
This study included the same small bowel specimens that were used for the ICC and 
enteric neuron analysis in Chapter 5 with the addition of specimens resected from 
  
237 
 
infants with atresia and meconium ileus. However, due to the young age at bowel 
resection of the control atresia infants, one gastroschisis small bowel specimen from 
the original cohort, who underwent bowel resection at 717 days of life for 
persistently dysmotile bowel, was excluded from this study in order to maintain age 
matching between the groups. Additionally, one control small bowel specimen from 
the original cohort, who underwent bowel resection for a strangulated hernia, was 
excluded from this study due to significant abnormal thickening of the bowel wall 
(entire bowel wall measured 5437µm). In total, 26 control and 21 gastroschisis small 
bowel specimens were included, which were resected for pathologies as outlined in 
Table 6-1.  
  
  
238 
 
 
Control 
n=26 
Gastroschisis 
n=21 
Dysmotile bowel - 8 
Ischaemia/necrosis - 6 
Anastomotic stricture - 1 
Stenosis 1 3 
Perforation 3 1 
*Atresia 8 1 
*Meconium Ileus 2 - 
Intussusception 7 - 
Meckel’s diverticulum 2 - 
Strangulated hernia 1 - 
Volvulus 2 - 
Table 6-1: Pathology resulting in small bowel resection in the control and gastroschisis 
groups. *Indicates the pathologies that are different to those infants included in the analysis 
of ICC and enteric neurons in human gut tissue.  
There was no significant difference in age at time of bowel resection (control median 
6, range [1-378] days and gastroschisis 44 [1-322] days, p=0.06) or the corrected 
gestational age (CGA) at time of bowel resection (control 40 [26-94] weeks and 
gastroschisis 43.2 [34-92] weeks, p=0.1) between the control and gastroschisis 
groups. Linked ENT data was available for 11 of the 21 gastroschisis small bowel 
specimens (ENT 62 [18-204] days). The reasons for missing data included; PN 
dependency (n=5), death before attaining full enteral feeds (n=1) and specimens that 
were transferred from another hospital (n=4). 
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6.2.2 Bowel Wall Thickness 
The bowel wall of gastroschisis infants was found to be significantly thicker (median 
1284, range [755-2258] µm) compared to controls (703 [340-1601] µm, p=0.0001, 
Mann-Whitney analysis, Table 6-2 and Figure 6-1). This increased small bowel wall 
thickness in gastroschisis infants was comprised of proportional thickening of the 
serosa (266 [80-1031] µm versus 76 [35-231] µm, p<0.0001), longitudinal muscle 
(317 [131-675] µm versus 138 [63-395] µm, p<0.0001), circular muscle (308 [137-
834] µm versus 245 [104-684] µm, p=0.04) and entire muscle layer (644 [755-2258] 
µm versus 429 [199-1044] µm, p=0.0003). However, there was no difference in the 
villus height or crypt depth between the groups, but the villus to crypt ratio was 
greater in controls (2.7 [1.4-5.0]) compared to the gastroschisis group (2.1 [0.4-3.3], 
p=0.01). In children, a ratio of >2:1 is considered normal (Dickson et al., 2006) 
suggesting normal villus and crypt development was present within both groups and 
the decreased villus crypt ratio in gastroschisis may reflect the lack of stimulation 
from enteral feeds. The longitudinal muscle comprised significantly more muscle 
cells (quantified as the number of muscle fibres that bisected the measurement line) 
in the gastroschisis group (33 [12-66]) than controls (19 [9-50], p<0.0001, Table 6-3, 
Figure 6-2A). However, the muscle cell thickness (muscle layer thickness/number of 
muscle fibres) was similar between the groups. Although the number of circular 
muscle cells was greater in the gastroschisis group, this did not reach significance 
and the circular muscle cell thickness was not different between the two groups 
(Table 6-3, Figure 6-2).  
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Bowel Wall Layer 
Measured 
Control 
Median [range] 
μm 
Gastroschisis 
Median [range] 
μm 
p-value 
Serosa 76 [35-231] 266 [80-1031] *<0.0001 
Longitudinal 
muscle 
138 [63-395] 317 [131-675] *<0.0001 
Circular muscle 245 [104-684] 308 [137-834] *0.04 
Submucosa 193 [49-971] 223 [67-843] 0.35 
Villus height 445 [233-771] 346 [67-783] 0.054 
Crypt depth 161 [112-222] 172 [127-320] 0.09 
Villus to Crypt 
ratio 
2.7 [1.4-5.0] 2.1 [0.4-3.3] *0.01 
    
Entire wall layer 
thickness 
703 [340-1601] 1284 [755-2258] * 0.0001 
Entire muscle layer 
thickness 
429 [199-1044] 644 [377-1344] *0.0003 
Table 6-2: Comparison of bowel wall measurements between control and gastroschisis small 
bowel. Entire wall layer thickness measurement includes all bowel wall layers from the 
serosa to submucosa. Entire muscle layer thickness measurement includes the circular and 
longitudinal muscle layers. *Indicates p-values that reached significance.  
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Figure 6-1: Comparison of A. entire wall thickness, B. entire muscle thickness, C. 
longitudinal muscle thickness D. circular muscle thickness, E. serosal thickness and F. villus 
to crypt ratio between the control and gastroschisis groups. All comparisons reached 
statistical significance.  
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Muscle layer 
Control 
Median [range]  
Gastroschisis 
Median [range]  
p-value 
Longitudinal 
number of cells 
19 [9-50] 33 [12-66] *<0.0001 
Longitudinal 
thickness of cells 
8.0 [5.1-11.0] μm 8.7 [6.3-7.6] μm 0.12 
Circular  
number of cells 
29 [14-69] 40 [16-68] 0.08 
Circular  
thickness of cells 
7.8 [4.8-11.3] μm 8.2 [5.7-12.4] μm 0.20 
Table 6-3: Number and thickness of muscle cells within the longitudinal and circular muscle 
layers of control and gastroschisis small bowel specimens. *Indicates p-values that reached 
significance. 
 
Figure 6-2: Comparison of A. longitudinal muscle number of cells, B. longitudinal muscle 
thickness of cells, C. circular muscle number of cells and D. circular muscle thickness of 
cells. *Comparison that reached statistical significance. 
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6.2.2.1 Bowel Wall H&E Qualitative Description 
Significant serosal and muscle layer thickening was observed in three of the 
gastroschisis cases. The H&E slides for these three outlier gastroschisis cases were 
blindly reviewed alongside two randomly selected gastroschisis cases and two 
randomly selected control cases by Professor Neil Sebire, Professor of Paediatric and 
Developmental Pathology, Great Ormond Street Hospital. The three outlier 
gastroschisis cases showed fibrosis and loose connective tissue with mild chronic 
inflammatory infiltrate, foreign body giant cells and foreign body granulomata. 
There was no evidence of acute inflammation and findings were in keeping with 
organising granulation tissue. In these cases there was no evidence of inflammatory 
infiltrate within the muscle layers. The two randomly selected gastroschisis cases 
showed dense serosal fibrosis, inflammation and granulation tissue with no evidence 
of inflammatory infiltrate within the muscle layers. The two control cases were 
almost normal in appearance with very mild chronic inflammatory infiltrate of the 
serosa and normal muscle layers. There was no evidence of cutting artefacts in any of 
the slides. Figure 6-3 shows representative H&E images of control and gastroschisis 
bowel.   
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Figure 6-3: Representative H&E images of A. control and B. gastroschisis bowel. Bowel 
sections imaged using Zeiss AxioScan Z1 slide scanner using 40x objective and analysed 
with Zeiss ZEN lite imaging software. Key: S – serosa, LM – longitudinal muscle, CM – 
circular muscle, Sub – submucosa, V – villi. Images showing scale bar indicating 500µm. 
Control bowel (A) shows very mild serosal inflammatory infiltrate. Gastroschisis bowel (B) 
shows serosal fibrosis, loose connective tissue and chronic inflammatory infiltrate.  
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6.2.2.2 Bowel Wall Thickness and Age at Bowel Resection 
Linear regression analysis was performed to determine whether there was a 
relationship between bowel wall thickness and age at time of bowel resection. 
Analysis of control small bowel specimens revealed no significant relationship 
between entire bowel wall thickness (p=0.06, R
2
=0.27, Figure 6-4A) or entire muscle 
layer (p=0.7, R
2
=0.007, Figure 6-4C) thickness with age at time of bowel resection. 
However, analysis of gastroschisis small bowel specimens showed a significant 
relationship between increasing entire bowel wall (p=0.003, R
2
=0.4, Figure 6-4B) 
and entire muscle layer (p=0.006, R
2
=0.35, Figure 6-4D) thickness with older age at 
time of bowel resection. 
 
Figure 6-4: Linear regression analysis comparing entire bowel wall and age at time of bowel 
resection. A.  Control group (p=0.06, R
2
=0.27). B. Gastroschisis group p=0.003, R
2
=0.4. 
Linear regression analysis comparing entire muscle thickness and age at time of bowel 
resection. C. Control group p=0.7, R
2
=0.007.  D. Gastroschisis group (p=0.006, R
2
=0.35).  
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6.2.2.3 Bowel Wall Thickness and Time to Full Enteral Feeds 
Additionally, a linear regression analysis was performed to determine whether the 
degree of entire bowel wall thickening impacted ENT in the gastroschisis population, 
which showed that increasing bowel wall thickness was significantly correlated with 
increased time to ENT (p=0.01, R
2
=0.5, Figure 6-5A). However, increasing entire 
muscle layer thickness (p=0.08, R
2
=0.3, Figure 6-5 B) and increasing serosal 
thickness (p=0.6, R
2
=0.34, Figure 6-5C) were not significantly correlated with 
increased time to ENT. However, these analyses are limited by the number of data 
points and may be influenced by the outliers with a very long ENT. 
 
Figure 6-5: Linear regression comparing gastroschisis (A) entire bowel wall thickness 
(p=0.01, R
2
=0.5), (B) entire muscle layer thickness (p=0.08, R
2
=0.3) and (C) serosal 
thickness (p=0.6, R
2
=0.34) with time to full enteral feeds (ENT).  Bowel Wall Architecture. 
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6.2.2.4 α-Smooth Muscle Actin  
To determine whether a myopathy was present in the thickened bowel wall of 
gastroschisis infants, specimens were stained for α-smooth muscle actin (α-SMA). 
The total area of longitudinal or circular muscle within the high power (40x 
objective) field of view and the percentage of positive α-SMA staining within these 
muscle layers were quantified using ImageJ software. For the thicker small bowel 
specimens the muscle was too large for the entire muscle thickness to be fully 
imaged in a single high power field of view so the image is a representative view of 
the muscle architecture and area (Figure 6-7B). However, as expected the total area 
of longitudinal and circular muscle was significantly greater in the gastroschisis 
group compared to the control group (Table 6-4, Figure 6-6). The percentage of 
positive α-SMA staining in the longitudinal muscle layer was significantly lower in 
the gastroschisis group compared to the control group with areas of absent staining 
appearing as loculations within the smooth muscle (Table 6-4, Figure 6-6, Figure 
6-7A and B). However, there was no difference in the percentage of positive α-SMA 
staining in the circular muscle layer between the groups (Table 6-4, Figure 6-6, 
Figure 6-7C and D).  
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Control 
Mean±SEM 
Gastroschisis 
Mean±SEM 
p-value 
Longitudinal 
muscle area (mm
2
) 
0.052±0.004 0.079±0.004 *0.0001 
Circular muscle 
area (mm
2
) 
0.075±0.004 0.086±0.002 *0.03 
α-SMA 
longitudinal 
muscle % positive 
staining 
81±2.02 69.4±3.1 *0.0027 
α-SMA circular 
muscle % positive  
staining 
69.5±2.8 72.8±2.5 0.40 
Table 6-4: Muscle area and percentage (%) of positive α-smooth muscle actin (α-SMA) 
staining within the longitudinal and circular muscle layers of control and gastroschisis small 
bowel specimens. *Indicates p-values that reached significance. 
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Figure 6-6: Comparison of A. longitudinal muscle area, B. circular muscle area, C. α-SMA 
longitudinal muscle % positive staining and D. α-SMA circular muscle % positive staining. 
*Comparison that reached statistical significance. 
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Figure 6-7: Images showing α-smooth muscle actin (α-SMA) staining, taken with 40x 
objective. A and C: control small bowel centred on A. longitudinal muscle, C. circular 
muscle. B and D: Gastroschisis small bowel centred on B. longitudinal muscle, D. circular 
muscle. Key: LM – longitudinal muscle, CM – circular muscle, MP – myenteric plexus.  
6.2.2.5 Collagen 
To determine whether there was an increase in collagen deposition in the thickened 
gastroschisis bowel wall, specimens were stained with picrosirius red (PS). The total 
area of the serosa and submucosa within the high power field of view and the 
percentage of positive PS staining in all bowel wall layers was quantified using 
ImageJ software. Again, for the thicker small bowel specimens the serosa and 
submucosa was too large for the entire thickness to be fully imaged in a single high 
power field of view therefore the image is a representative view of the architecture 
and area of these layers (Figure 6-8B, D, F, G and H). However, in keeping with the 
bowel wall thickness measurements, the serosal layer area was significantly larger in 
the gastroschisis group compared to the control group (Table 6-5) and there was no 
difference in the submucosal area between the groups. There was no significant 
difference in the percentage of positive PS staining in the longitudinal muscle, 
circular muscle or submucosa between the two groups (Figure 6-8C-H). However, 
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the percentage of positive PS serosal staining was significantly lower in gastroschisis 
small bowel compared to controls with areas of separation seen between the collagen 
fibres (Figure 6-8A and B). These findings are likely due to the presence of loose 
connective tissue and ongoing low grade serosal fibroinflammatory reaction within 
the gastroschisis bowel as described in 6.2.2.1 Bowel Wall H&E Qualitative 
Description. 
 
Control 
Mean±SEM 
Gastroschisis 
Mean±SEM 
p-value 
Serosal area (mm
2
) 0.038±0.005 0.079±0.004 *<0.0001 
Submucosal area 
(mm
2
) 
0.030±0.002 0.035±0.003 0.14 
PS serosal % 
positive staining 
44.1±3.3 34.4±3.3 *0.046 
PS  longitudinal 
muscle % positive 
staining 
26.3±3.2 29.6±2.5 0.45 
PS  circular muscle 
% positive staining 
20.0±2.6 25.7±2.5 0.13 
PS submucosal % 
positive staining 
47.6±2.8 46.3±3.1 0.76 
Table 6-5: Serosal and submucosal layer area and percentage (%) of positive picrosirius red 
(PS) staining in all bowel wall layers of control and gastroschisis small bowel specimens. 
*Indicates p-values that reached significance. 
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Figure 6-8: Images showing picrosirius red (PS) staining, taken with 40x objective. A, C, E 
and G: control small bowel centred on A. serosa, C. longitudinal muscle, E. circular muscle 
and G. submucosa. B, D, F and H: Gastroschisis small bowel centred on B. serosa, D. 
longitudinal muscle, F. circular muscle and H. submucosa. Key: LM – longitudinal muscle, 
CM – circular muscle. 
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6.2.2.6 Ki67 Staining 
To determine whether muscle layer thickening in gastroschisis is linked to 
hypertrophied cells or increased cell proliferation, specimens were stained for ki67, 
which stains dividing nuclei. The total number of nuclei per muscle area 
(longitudinal and circular) and the percentage of proliferating nuclei in these muscle 
layers were calculated. There was no significant difference in the number of 
nuclei/mm
2
 within the longitudinal or circular muscle layers between the groups 
(Table 6-6) suggesting the gastroschisis muscle cells are not hypertrophic. Equally, 
there was no difference in the percentage of proliferating nuclei in the longitudinal or 
circular muscle layers between the two groups. As cell proliferation in gastroschisis 
small bowel may reduce after birth following cessation of exposure to amniotic fluid, 
the analysis of percentage of proliferating cells was repeated including only those 
specimens resected at <40 days. There was no significant difference in the age at 
time of bowel resection (control median 4, range [1-26] days, n=18 and gastroschisis 
3 [1-37] days, n=9, p=0.08) between the groups. However, again there was no 
significant difference in percentage of proliferating nuclei within the longitudinal or 
circular muscle layers between the groups.  
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Control 
Mean±SEM 
Gastroschisis 
Mean±SEM 
p-value 
Longitudinal 
muscle nuclei/mm
2
 
5770±494 5313±735 0.60 
Circular muscle 
nuclei/mm
2
 
5474±600 5945±624 0.59 
Longitudinal 
muscle % 
proliferating nuclei 
2.0±0.5 2.7±0.7 0.40 
Circular muscle % 
proliferating nuclei 
2.1±0.5 1.8±0.5 0.68 
Longitudinal 
muscle % 
proliferating nuclei 
(<40 days) 
2.6±0.6 4.2±1.2 0.21 
Circular muscle % 
proliferating nuclei 
(<40 days) 
2.7±0.6 3.3±0.7 0.56 
Table 6-6: Total number of nuclei per area and the percentage (%) of proliferating nuclei 
within the longitudinal and circular muscle layers of control and gastroschisis small bowel 
specimens.  
6.2.2.7 Transforming Growth Factor-Beta 3 Staining 
A previous study (Moore-Olufemi et al., 2015) linked gastroschisis with increased 
levels of transforming growth factor-beta 3 (TGF-β3), which was hypothesised to be 
the mediator of bowel wall thickening in gastroschisis. Therefore, TGF-β3 staining 
was performed to determine whether there were increased levels within this 
gastroschisis cohort. There was no significant difference in the percentage of positive 
TGF-β3 staining for any bowel wall layer between gastroschisis and control groups 
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(Table 6-7). However, there was high level background staining, which prevented 
analysis using automated colour thresholding. Although manual thresholding was 
performed the results may still have been affected by the considerable background 
staining present across all bowel specimens (Figure 6-9).  
 
Control 
Mean±SEM 
Gastroschisis 
Mean±SEM 
p-value 
Longitudinal 
muscle % positive 
staining 
26.7±3.2 26.4±4.4 0.96 
Circular muscle % 
positive staining 
31.0±3.6 23.8±3.5 0.17 
Submucosa % 
positive staining 
10.0±0.9 8.6±1.0 0.29 
Villi epithelium % 
positive staining 
38.1±3.9 38.7±4.2 0.91 
Table 6-7: Percentage (%) of positive transforming growth factor-beta 3 (TGF-β3) staining 
within all bowel wall layers of control and gastroschisis small bowel specimens. 
 
Figure 6-9: Images showing transforming growth factor-beta 3 (TGF-β3) staining, centred 
on longitudinal muscle, taken with 40x objective. A. Control small bowel. B. Gastroschisis 
small bowel. Both images showing significant background staining. 
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6.3 Discussion 
6.3.1 Bowel Wall Thickness and Mucosal Morphology 
The bowel wall of gastroschisis infants is significantly thicker compared with 
controls, comprising thickened serosa, longitudinal muscle and circular muscle. 
However, there was no difference in submucosal thickness. These findings were 
consistent both on direct linear measurement of H&E sections and calculation of the 
area per high powered field of view following α-SMA and PS staining. Additionally, 
the mucosa of both gastroschisis and control small bowel exhibited normal 
development without evidence of villus blunting or crypt hyperplasia. Although the 
villus to crypt ratio of gastroschisis small bowel was lower than the control group, 
the ratio was >2:1, which is within the normal limits for children (Dickson et al., 
2006). These results suggest that the inner layers of gastroschisis small bowel 
develop normally but there is altered development of the outer layers, which is 
consistent with a signal originating at the serosal surface.  
Included in this cohort were bowel wall specimens resected from birth up to 
approximately 1 year of age. In the control group there was no significant change in 
wall thickness during this time period suggesting the process of normal infant bowel 
growth results in a fairly constant bowel wall thickness during the first year of life. 
However, the gastroschisis bowel showed a significant increase in bowel wall 
thickness with increasing age implying that within this complex/dysmotile 
gastroschisis cohort abnormal bowel growth continued to be present during the 
postnatal period. Additionally, increased thickness of the entire bowel wall was 
significantly associated with prolonged ENT feeds in this complex gastroschisis 
cohort suggesting that these morphological changes may cause GRID or be a result 
of GRID.  
6.3.2 Bowel Wall Architecture and Composition 
The circular muscle, although thicker in the gastroschisis small bowel, showed no 
other significant structural differences between the groups. However, the 
gastroschisis longitudinal muscle and serosa showed significant morphological 
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differences compared to the control small bowel. This may suggest that the trigger 
for gastroschisis bowel morphological changes is extrinsic to the bowel and may 
originate from the amniotic fluid. This could result in the outer longitudinal muscle 
providing an element of protection and partial ‘sparing’ of circular muscle 
development. 
The gastroschisis longitudinal muscle exhibited an increased number of muscle 
fibres without an increased number of nuclei/mm
2 
suggesting the presence of muscle 
hyperplasia without cell hypertrophy. Although there was no difference in the 
percentage of proliferating nuclei between the groups to support the presence of 
hyperplasia, this could be due to the high powered field of view not including the 
entire muscle thickness for all samples or that following gastroschisis delivery the 
triggers for cell proliferation are removed reducing the rate of cell proliferation to 
normal levels. However, it is also worth noting that although the percentage of 
proliferating cells is the same between the groups this would equate in absolute terms 
to a larger total number of proliferating cells in the thicker gastroschisis muscle 
layer. Additionally, the gastroschisis longitudinal muscle exhibited a lower 
percentage of positive α-SMA staining with areas of loculation in the muscle layers 
without increased PS staining or evidence of cutting artefact suggesting the 
development of these hyperplastic muscle fibres is abnormal. Coordinated and 
effective bowel peristalsis requires normal neuromuscular function involving the 
interaction between enteric neurons, ICC and smooth muscle cells. The results from 
the previous chapter have shown that the numbers of both enteric neurons and ICC 
are normal in human gastroschisis small bowel. This suggests the cause of GRID 
may be a myopathic disturbance of the muscularis smooth muscle rather than a 
neuropathy. 
As expected and in keeping with observations of serosal peel/thickening at birth, the 
serosa within the gastroschisis cohort was significantly thicker mainly due to an 
ongoing low grade chronic fibroinflammatory reaction that was associated with loose 
connective tissue and lower percentage of positive PS staining.  
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6.3.3 Hypothesised Cause of Bowel Wall Thickening 
Throughout life, smooth muscle has the ability to adapt morphologically in response 
to internal and external stimuli for which inflammation is an identified trigger and 
has been shown to cause remodelling of respiratory (Bousquet et al., 2000), vascular 
(Kranzhofer et al., 1999) and intestinal  (Shea-Donohue et al., 2012, Nair et al., 
2014) smooth muscle cells. Inflammation at the intestinal mucosal surface secondary 
to gastrointestinal infection results in smooth muscle hyperplasia and hypertrophy 
causing smooth muscle thickening (Bettini et al., 2003, Blennerhassett et al., 1992) 
providing evidence that extrinsic environmental influences can alter intestinal 
smooth muscle morphology.  
Animal studies investigating gastroschisis bowel wall thickening have shown that 
increased serosal and smooth muscle thickening occurs secondary to amniotic fluid 
exposure (Langer et al., 1989, Guo et al., 1995, Yu et al., 2004, Bittencourt et al., 
2006, Shah et al., 2012, Albert et al., 2001) suggesting that amniotic fluid contains 
extrinsic triggers for intestinal remodelling. Manipulation of the amniotic fluid 
inflammatory environment has previously shown increased amniotic fluid IL-8 
concentrations to be associated with increased bowel wall thickening (Api et al., 
2001, Correia-Pinto et al., 2002), and with decreased IL-8 concentrations associated 
with decerased bowel wall thickening (Hakguder et al., 2011, Olguner et al., 2006). 
Additionaly, surgical gastroschisis animal models treated with either intra-amniotic 
(Guo et al., 1995, Yu et al., 2004) or maternal intraperitoneal (Bittencourt et al., 
2006) injections of dexamethasone have also shown reduced bowel wall thickness.  
Other researchers have investigated the potential of bowel constriction at a tight 
abdominal wall defect as the cause for bowel wall morphological changes. Bowel 
constriction creates lymphatic and vascular stasis resulting in intrinsic bowel wall 
inflammation (Langer et al., 1989). One study using a surgical lamb gastroschisis 
model placed a surgical tie around the bowel to create a point of constriction 
mimicking a tight abdominal wall defect. This resulted in smooth-muscle thickening 
and mucosal blunting without serosal thickening (Langer et al., 1989). However, a 
study using a rabbit model showed the degree of gastroschisis bowel wall thickening 
was independent of the abdominal wall defect size and that bowel wall thickening 
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was unchanged by increased bowel compression. This study therefore concluded that 
abnormal serosal exposure to amniotic fluid was the trigger of the gastroschisis 
bowel wall morphological changes (Albert et al., 2001).  
The results presented in this chapter reveal the morphological changes within human 
gastroschisis small bowel are located within the outer bowel wall layers (serosa and 
smooth muscle) with mucosal and submucosal sparing. Given an intrinsic 
inflammatory trigger secondary to bowel compression at a tight abdominal wall 
defect would more likely cause transmural remodelling it is possibly more likely that 
the trigger for bowel wall thickening has an extrinsic origin associated with direct 
contact of the serosa with the amniotic fluid. It has been previously documented that 
overt signs of bowel wall thickening and serosal peel do not develop until the third 
trimester (Tibboel et al., 1986) when significant changes in the amniotic fluid 
composition take place. Abnormal exposure of the serosal surface to increasing 
levels of meconium, enteric enzymes, urine and airway secretions within the 
amniotic fluid (Underwood et al., 2005) could be the trigger for the pro-
inflammatory amniotic fluid environment, which has previously been reported within 
the third trimester of gastroschisis pregnancies (Morrison et al., 1998, 
Guibourdenche et al., 2006). Given inflammation located at the mucosal surface 
secondary to infection can stimulate smooth muscle remodelling it is therefore 
possible that inflammation located at the serosal surface could also induce smooth 
muscle remodelling and be the cause of the morphological changes present in the 
gastroschisis small bowel.    
Another source of external stimulus could come from abnormal mechanical forces 
being applied to the externalised bowel particularly during birth and postnatal 
manipulation of the externalised bowel prior to abdominal wall closure. Transient 
post-operative ileus (intestinal dysmotility) is a common source of morbidity 
following abdominal and pelvic surgery whereby manipulation of the bowel induces 
inflammation and two phases of intestinal inhibition (Boeckxstaens and de Jonge, 
2009). The first phase occurs during surgery and is mediated by neurotransmitters 
and the second develops 3 to 4 hours after surgery secondary to a leukocytic infiltrate 
within the muscularis externa (Kalff et al., 1998, Kalff et al., 1999a, Kalff et al., 
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1999b). Therefore, postnatal manipulation of the externalised bowel of gastroschisis 
neonates may further compound smooth muscle remodelling and dysfunction.  
The composition of amniotic fluid is complex and its constituents originate both 
from the fetus and the amniotic membranes. In addition to containing products from 
urine, respiratory secretions and meconium, the amniotic fluid also contains growth 
factors produced by the amniotic membranes, which have a trophic effect on the 
bowel and include; epidermal growth factor, transforming growth factor alpha and 
beta, erythropoietin, insulin-like growth factor-1 and granulocyte colony-stimulating 
factor (Underwood et al., 2005). A previous study showed that ligation of the fetal 
rabbit oesophagus preventing swallowing of amniotic fluid resulted in poorly 
developed gut whilst normal gut development was achieved by infusions of amniotic 
fluid distal to the oesophageal ligation (Mulvihill et al., 1986). Fetal swallowing 
results in mucosal exposure to the amniotic fluid growth factors and regulates normal 
fetal bowel development. However, in gastroschisis the serosal surface is abnormally 
exposed to these growth factors, which could cause abnormal hyperplasia and 
development of dysfunctional smooth muscle cells. TGF-β3 has previously been 
shown to be increased in human gastroschisis small bowel specimens compared to 
controls (Moore-Olufemi et al., 2015) and has been hypothesised to be the mediator 
of bowel wall thickening and disordered contractility in gastroschisis. However, this 
finding of increased levels of TGF-β3 could not be replicated in the study presented 
in this chapter but this may have been due to the high levels of associated 
background staining and therefore cannot be used to confirm or deny the findings of 
Moore-Olufemi et al.  
Finally, close regulation of organ size during fetal development is essential requiring 
contact inhibition of proliferation, which is regulated by the Hippo pathway. 
Dysregulation of this pathway leads to tissue overgrowth (Zhao et al., 2011). The 
precise events that integrate mechanical and biochemical signals are not fully 
understood. However, it is thought that yes-associated protein (YAP) and 
transcriptional coactivator with PDZ-binding motif (TAZ) are the nuclear relays of 
mechanical cues such as confined adhesiveness and extracellular matrix stiffness 
(Dupont et al., 2011, Low et al., 2014). In normal fetal organogenesis the bowel 
develops within the confines of the abdominal cavity, which exerts mechanical 
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pressure on the bowel wall. However, the bowel of gastroschisis fetuses herniates 
through the abdominal wall defect without being contained within a peritoneal 
membrane and lies free floating within the amniotic cavity. As such, the mechanical 
pressure exerted and contact stimuli on the bowel is greatly reduced compared to that 
of a structurally normal fetus or even a fetus with an exomphalos. Therefore, it is 
feasible that the loss of regulatory mechanical cues could result in dysregulation of 
the Hippo pathway and over proliferation of bowel smooth muscle. Liver 
regeneration is a good example of this possible mechanism. The liver is able to 
regenerate following hepatic resection until the original liver-to-body weight ratio is 
restored (Michalopoulos, 2007). One study in rats revealed that partial hepatic 
resection resulted in increased nuclear YAP until the original liver-to-body weight 
ratio was achieved following which nuclear YAP levels returned to baseline levels 
(Grijalva et al., 2014). As such, within fetal gastroschisis bowel it is possible that 
nuclear YAP is over expressed due to loss of normal bowel to abdominal cavity 
sizing cues. However, going against this theory, the findings from the ACLP mouse 
model presented in chapter 4 did not show any evidence of bowel wall thickening 
within the AWD group compared to controls. Given the bowel of AWD fetuses was 
contained within the relatively large exocoelomic cavity compared to the smaller 
abdominal cavity if the YAP-TAZ theory was correct the AWD bowel would be 
hypothesised to be thicker. As such, this suggests the YAP-TAZ pathway may not be 
a factor in human gastroschisis bowel wall changes. Additionally, this theory would 
be very difficult to test in human gastroschisis as the molecular events of the YAP-
TAZ pathway may have ceased long before delivery of gastroschisis fetuses and 
therefore may not be easily accessible for investigation. 
The results from this study show that the control small bowel wall thickness did not 
significantly change over the first year of life. This finding is supported by a study 
that investigated bowel wall architecture including fetuses of 10 weeks GA through 
to adults of 70 years old (Bruhin-Feichter et al., 2012). As expected over the entire 
age range the bowel wall increased in thickness but the detailed breakdown of results 
showed similar bowel wall thickness throughout the first year of life. However, 
within the gastroschisis group increasing bowel wall thickness was significantly 
associated with increasing age at time of bowel resection and prolonged ENT. This 
may be due to the presence of ongoing chronic serosal inflammation that was 
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identified within the gastroschisis cases post-partum. This ongoing serosal 
fibroinflammatory reaction may be exerting a persistent smooth muscle remodelling 
effect on the bowel muscle layers prolonging the duration of GRID in these infants.     
6.3.4 Smooth Muscle α-SMA Deficiency and Chronic Idiopathic Intestinal 
Pseudo-Obstruction 
Smooth muscle contains thick myosin and thin actin filaments both of which are 
essential for normal muscular contractions. The actin filaments regulate changes in 
cell size, cell contraction, mechanical support and cellular adhesion. As such, α-SMA 
is a major constituent of the intestinal muscularis smooth muscle apparatus and is 
essential for normal intestinal motility (Hartshome, 1987). Chronic idiopathic 
intestinal pseudo-obstruction (CIPO) is a condition that presents with chronic 
obstructive symptoms including intractable constipation, nausea, vomiting, 
abdominal pain and distension often with episodic exacerbations. The cause of CIPO 
is not fully understood. However, absence of intestinal α-SMA staining has been 
found in some patients most frequently reported to be isolated to the circular muscle 
(Knowles et al., 2004, Donnell et al., 2008, Moore et al., 2002, Smith et al., 1992) 
but occasionally within both the circular and longitudinal muscle layers (Koh et al., 
2008). The findings in CIPO suggest absence of α-SMA staining within only one 
layer of the intestinal muscularis may be sufficient to cause bowel dysmotility and 
obstruction. However, in contrast to CIPO, the small bowel function of gastroschisis 
infants over time generally improves enabling normal bowel transit and full enteral 
tolerance suggesting the α-SMA changes seen in gastroschisis small bowel are not 
persistent and recovers to normal levels with time.  
6.3.5 Limitations of the Study 
As discussed within the previous chapter this was a retrospective study with the 
limitations associated with the use of archival specimens and the ability to only 
include the most severely affected gastroschisis infants. The use of automated 
software analysis was effective for α-SMA and PS staining but due to significant 
background staining associated with the TGF-β3 automated colour thresholding 
could not be used and even following manual colour thresholding results may have 
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been affected by the background staining. Additionally there was no significant 
increase in the proportion of proliferating nuclei measured by ki67, which suggests 
that the molecular triggers that lead to increase in number of smooth muscle cells 
were no longer persistent at the time of bowel resection. Finally, on review of H&E 
sections by a Consultant Pathologist there was evidence of a serosal inflammatory 
infiltrate in gastroschisis bowel, which did not extend to the smooth muscle. 
Although TGF-β3 staining was performed, inflammation was not quantitatively 
evaluated by another method and further work with specific inflammatory 
immunohistochemical stains should be performed to verify the presence or absence 
of inflammation within the bowel wall layers.  
6.4 Conclusion 
This study shows increased bowel wall thickening in gastroschisis infants compared 
to controls. Comprising of serosal and smooth muscle thickening with normal inner 
submucosal and mucosal layers. The most significant morphological changes were 
present in the outer bowel wall layers with smooth muscle hyperplasia and 
deficiency of α-SMA within the longitudinal muscle layer. These findings suggest 
bowel wall thickness could be a biomarker for infant outcome and that GRID maybe 
secondary to a myopathic disturbance of the muscularis smooth muscle rather than a 
neuropathy secondary to ICC deficiency. The trigger for these morphological 
changes could be linked to bowel inflammation or abnormal exposure of the bowel 
serosal surface to growth factors contained within the amniotic fluid. 
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Chapter 7: Gestational Age at Delivery and Maternal 
Corticosteroid Administration: Association with Outcomes 
in Gastroschisis 
7.1 Introduction 
7.1.1 Timing of Delivery 
The optimisation of gastroschisis antenatal management, including timing of 
delivery, may improve neonatal outcomes. Currently many centres worldwide 
electively deliver gastroschisis pregnancies at 37 to 38 weeks GA following the 
report of in-utero fetal deaths in late term pregnancies (Burge and Ade-Ajayi, 1997). 
Additionally, more recent publications have also suggested that early term birth at 
around 37 weeks GA is associated with decreased neonatal morbidity and mortality 
compared with late term birth (Baud et al., 2013, Meyer et al., 2014, Harper et al., 
2014). Furthermore, it has been hypothesized that amniotic fluid negatively impacts 
on bowel development and longer exposure of bowel to amniotic fluid worsens 
postnatal GRID (Morrison et al., 1998, Api et al., 2001). Some surgeons therefore 
propose that elective delivery of otherwise healthy gastroschisis pregnancies in the 
late pre-term period between 34 and 36
+6
 weeks GA would reduce bowel exposure to 
amniotic fluid and result in improved postnatal gut function.  
The literature presents conflicting evidence both for (Gelas et al., 2008, Serra et al., 
2008, Moore et al., 1999, Moir et al., 2004) and against (Maramreddy et al., 2009, 
Youssef et al., 2015, Cain et al., 2014, Logghe et al., 2005, Charlesworth et al., 2007) 
elective delivery in  the late pre-term period as a means to protect bowel from 
ongoing damage. The majority of these studies include small numbers of patients and 
a randomised control study with enough power to determine the optimal timing for 
delivery is elusive due to the relatively small numbers of gastroschisis neonates seen 
per centre per year. 
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7.1.2 Maternal Antenatal Corticosteroids 
Experiments using surgical gastroschisis animal models (rabbit, rat and chick) treated 
either with intra-amniotic (Guo et al., 1995, Yu et al., 2004) or maternal 
intraperitoneal (Bittencourt et al., 2006) injections of dexamethasone have shown  
reduced bowel wall thickness, increased bowel glucose uptake and increased levels 
of bowel protein, DNA and enzymes, suggesting a beneficial effect of 
dexamethasone on intestinal function (Table 7-1).  In humans, a small prospective 
study (only published in abstract form) investigating the impact of maternal antenatal 
corticosteroid administration in gastroschisis pregnancies suggested that gastroschisis 
infants who received maternal antenatal corticosteroids had a reduced duration of 
PN, ENT and LOS (Polnik et al., 2012). Additionally, a study of duodenal 
contractility in normal premature neonates showed that antenatal corticosteroids was 
associated with improved duodenal contractility particularly in those neonates born 
between 29 to 32 weeks gestation suggesting corticosteroids may have a maturational 
effect on the bowel (Morriss et al., 1986) similar to that on the lungs. 
Effect of Antenatal 
Corticosteroids 
Chick Rat Rabbit 
Protein 
↑ Protein and DNA 
content 
↑ Protein and DNA 
content 
↑ Protein content 
Wall thickening ↓ Wall thickening ↓ Wall thickening No reported 
Other parameters ↓ Inflammation 
↑ proliferation and 
↓ apoptosis 
↑ glucose uptake, 
lactase and maltase 
content 
Table 7-1: Impact of antenatal corticosteroids on bowel and intestinal function in animal 
surgical models of gastroschisis. 
Within placental syncytiotrophoblasts, the corticosteroid enzyme 11-β-
hydroxysteroid dehydrogenase isozyme 2 (11β-HSD2) protects the fetus from the 
potentially harmful effects of endogenous maternal glucocorticoids (Benediktsson et 
al., 1997). However, synthetic steroid derivatives such as dexamethasone and 
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betamethasone are minimally metabolised by 11β-HSD2 and therefore cross into the 
fetal circulation (Murphy et al., 2007b). Experiments in fetal animals showed that 
corticosteroid stimulation accelerates type 1 and 2 pneumocyte development leading 
to increases in surfactant production and improved lung biomechanics (Liggins, 
1969, DeLemos et al., 1970, Kotas and Avery, 1971). In a landmark randomised 
controlled trial (RCT), a single course of maternal antenatal corticosteroids in 
women at risk from preterm delivery was shown to reduce neonatal morbidity and 
mortality from respiratory distress syndrome (Liggins and Howie, 1972). Since then 
antenatal corticosteroids are part of routine clinical care for threatened preterm 
labour and have revolutionised the neonatal management of premature neonates, 
reducing respiratory distress syndrome, neonatal death, intraventricular haemorrhage, 
necrotising enterocolitis and sepsis within the first 48 hours of birth without 
increased risks to otherwise healthy mothers (Roberts and Dalziel, 2006). As such, 
maternal antenatal corticosteroid administration for the improvement of GRID is a 
very attractive option and would be a relatively easy intervention to implement. 
7.1.3 Hypothesis, Aims and Study Design 
It is hypothesised that early delivery and maternal antenatal corticosteroids improve 
infant outcomes. The primary outcome measure is time to full enteral feeds (ENT) 
and to be considered a surrogate for bowel function. The secondary outcome measure 
is length of hospital stay (LOS). As such, the aims for this retrospective study were: 
(i) to assess the association of timing of birth in gastroschisis fetuses with ENT and 
LOS; (ii)  to determine whether maternal antenatal corticosteroids were associated 
with improvement of postnatal intestinal function (measured as ENT) in gastroschisis 
infants. 
This was an international multicentre retrospective cohort study, data were obtained 
from three centres: (i) Fetal Medicine Unit, University College London Hospital 
(UCLH) and the Paediatric Surgery Department at Great Ormond Street Hospital for 
Children (GOSH), London, UK; (ii) Fetal Medicine Unit and Paediatric Surgery 
Department at King’s College Hospital (KCH), London, UK; (iii) Fetal Medicine 
Unit at Mount Sinai Hospital (MSH) and the Division of General and Thoracic 
Surgery at The Hospital for Sick Children, University of Toronto, Canada. Data were 
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analysed by Mann-Whitney test, Fisher’s exact test, linear regression and Cox 
regression. 
7.2 Results 
7.2.1 Timing of Delivery and Impact on Time to Full Enteral Feeds and 
Length of Hospital Stay  
7.2.1.1 Study Population and Demographics 
A total of 510 gastroschisis infants were included in the analysis (n=153 from 
UCLH/Great Ormond Street, 125 from King’s College London, and 232 from 
Toronto, Figure 7-1). In the combined cohort there were 76 infants with complex 
gastroschisis comprising; 42 atresias, 28 necrosis, 8 stenosis and 14 perforations 
(there was more than one pathology in 9 complex patients). Twenty-three infants 
died, causes of death were: sepsis in 1 atresia patient; 1 volvulus at birth; 1 volvulus 
following primary closure at day 10 of life; 1 respiratory failure, 2 unexpected infant 
deaths following discharge; 1 patient due to necrotic bowel and multi-organ failure, 1 
due to necrotising enterocolitis, 2 due to parenteral nutrition associated liver failure 
and 1 due to overwhelming sepsis. In the other infants cause of death was unclear. 
284 infants were delivered at <37 weeks GA. The reasons for semi-elective early 
induction of labour/emergency delivery and documented triggers for spontaneous 
delivery are delineated in Table 7-2. Onset of labour in infants delivered at ≥37 
weeks GA was; spontaneous (n=51), elective induction of labour/caesarean section 
(n=155), emergency caesarean section (n=6) and unknown (n=14). 
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Figure 7-1: Study population and demographics 
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Reason for Early 
Delivery/Documented 
Trigger for Spontaneous 
Delivery 
<37 weeks GA 
Spontaneous 
Labour 
(n=115) 
<37 weeks GA 
Early 
Induction of 
Labour (n=83) 
<37 weeks GA 
Emergency 
Delivery 
(n=86) 
No antenatal concerns 93 17 0 
Maternal Factors 
Prolonged rupture of 
membranes 
4 7 1 
Maternal alcohol/smoking/ 
drug use 
8 0 0 
Maternal health reasons 0 2 1 
Maternal infection 1 0 0 
Fetal Factors 
Bowel dilatation 5 27 25 
Intrauterine growth restriction 1 9 5 
Reduced fetal movements 2 3 10 
Non-reassuring fetal heart rate 0 5 16 
Fetal distress / Non-reassuring 
biophysiological profile 
1 3 8 
Oligohydramnios 0 0 2 
Unknown 0 10 18 
Table 7-2: Reasons for early delivery and documented triggers of spontaneous delivery in 
infants born at <37 weeks GA. 
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7.2.1.2 Linear Regression Analysis  
Linear regression analysis of log transformed data (due to non-normally distributed 
data, Table 7-3) revealed that ENT (p<0.0001, Figure 7-2A) and LOS (p<0.0001, 
Figure 7-2B) were significantly longer at lower birth GA. This resulted in an increase 
of 9 days for ENT and 13 days for LOS if delivery occurred at 34 weeks instead of 
37 weeks. The analysis was repeated including only infants delivered at ≥34 weeks 
(n=468) in order to remove the effect of extreme prematurity and the relationship 
remained significant for both ENT (p<0.0005) and LOS (p<0.0005). Lower birth 
weight showed an association with longer LOS (p=0.002) and with longer ENT 
(p=0.007) on linear regression analysis. 
Linear Regression 
Category 
Impact on ENT p-value Impact on LOS p-value 
Gestational age at birth 
(including all infants) 
↑ with ↓GA <0.0001 ↑ with ↓GA <0.0001 
Gestational age at birth 
(including infants born 
at ≥34 weeks GA) 
↑ with ↓GA <0.0005 ↑ with ↓GA <0.0005 
Birth weight (including 
all infants) 
↑ with ↓birth 
weight 
0.002 
↑ with ↓birth 
weight 
0.007 
Table 7-3: Effect of gestational age at birth and birth weight on ENT and LOS (linear 
regression of log transformed ENT or LOS data). 
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Figure 7-2: Effect of gestational age at birth on; A. ENT and B. LOS. Linear regression of 
log transformed ENT or LOS data with 95% confidence interval (dotted lines) of best fit 
line. Vertical lines highlight 34 and 37 weeks GA. 
7.2.1.3 Group Univariate Analysis 
To remove the effect of extreme prematurity group analysis was performed 
comparing infants born at 34 to 36
+6
 weeks GA with those born at ≥37 weeks GA. 
Mann-Whitney comparison of ENT and LOS (results outlined in Table 7-4, 
excluding those patients not achieving full feeds or discharge from hospital, as 
appropriate) revealed no difference in ENT between groups. However, LOS was 
significantly longer in infants born at 34 to 36
+6
 weeks GA compared with those born 
at ≥37 weeks GA. Analysis of corrected GA at ENT and LOS was performed in 
order to remove the effect of earlier birth. Infants born at 34 to 36
+6
 weeks GA had a 
slightly lower corrected GA at ENT compared to those born at ≥37 weeks GA. 
However, corrected GA at hospital discharged was not significantly different 
between the two groups. There was a significantly higher risk (Fisher’s exact test) of 
an episode of sepsis in those infants born at 34 to 36
+6
 weeks GA compared to 
infants born at ≥37 weeks GA.  
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Neonatal Outcomes on 
Univariant Analysis 
34 to 36
+6
 weeks 
GA (n=242) 
≥37 weeks GA 
(n=226) 
p-value 
Time to full enteral feeds 
(days) 
27 [6-283] 26 [4-163] 0.16 
Length of hospital stay 
(days) 
38 [7-346] 32 [11-349] 0.001 
Corrected GA at time to 
full enteral feed (weeks) 
40 [36-77] 42[38-61] <0.0005 
Corrected GA at time of 
hospital discharge 
(weeks) 
42 [37-84] 42 [39-87] 0.017 
*Patients with sepsis 
episode 
83/242 (34%) 50/226 (22%) 0.004 
Table 7-4: Univariate analysis of postnatal outcomes using Mann-Whitney (median [range]) 
and *Fisher’s exact test. 
7.2.1.4 Cox Regression Analysis 
Cox regression analysis was performed for infants delivered at ≥34 weeks in order to 
determine the effect of GA on ENT and LOS (Table 7-5). The model was adjusted 
for complexity and GA. Censoring was performed for death, not achieving full feeds 
and not being discharged from hospital as appropriate. Complex gastroschisis 
compared with simple gastroschisis significantly prolonged ENT (hazard ratio for 
reaching full feeds 0.28 [95% CI: 0.21-0.38], p<0.0005) and LOS (hazard ratio for 
hospital discharge 0.1 [95% CI: 0.23-0.42], p<0.0005). Lower birth GA was also 
associated with a longer ENT (hazard ratio for reaching full feeds 0.87 per week 
earlier birth [95% CI: 0.82-0.93], p<0.0005) and LOS (hazard ratio for hospital 
discharge 0.84 per week earlier birth [95% CI: 0.79-0.90], p<0.0005). In order to 
graphically illustrate these findings the patients were divided into categories of birth 
GA (≥34 to <35 weeks, ≥35 to <36 weeks, ≥36 weeks to <37 weeks, ≥37 to <38 
  
273 
 
weeks and ≥38 weeks) and a cox regression curve is shown for each category for 
ENT (Figure 7-3A) and LOS (Figure 7-3B). 
Cox Regression 
Category 
Impact on 
ENT 
HR        
[95% CI]   
p-value 
Impact on 
LOS 
HR        
[95% CI]   
p-value 
Complexity of 
gastroschisis 
↑ with 
complex 
gastroschisis 
0.28       
[0.21-0.38] 
<0.0005 
↑ with 
complex 
gastroschisis 
0.1         
[0.23-0.42] 
<0.0005 
Gestational age 
(GA) at birth  
↑ with ↓GA 
0.87      
[0.82-0.93] 
<0.0005 
↑ with ↓GA 
0.84      
[0.79-0.90] 
<0.0005 
Table 7-5: The effect of gestational age at birth and complexity of gastroschisis on ENT and 
LOS. Cox regression adjusted for complexity and gestational age and censored for death, not 
achieving full feeds and not being discharged from hospital. Data for gestational age at birth 
is per week earlier birth. HR = hazard ratio, CI = confidence interval. 
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Figure 7-3: Cox regression of effect of gestational age category on: A. ENT and B. LOS. 
As infants delivered at <37 weeks GA were delivered for obstetric concerns rather 
than elective early induction of labour, a post-hoc analysis was performed to 
determine whether the mode of labour onset for those infants born at 34 to 36
+6
 
weeks affected ENT or LOS. Spontaneous labour (14/92 complex patients, mean 
birth GA 35.8±0.1 weeks) was compared with (i) semi-elective early induction of 
labour/caesarean section (7/59 complex patients, mean GA at birth 36.2±0.1 weeks) 
and (ii) emergency (15/68 complex patients, mean GA at birth 35.5±0.1 weeks). The 
association of lower birth GA and longer ENT (hazard ratio for reaching full feeds 
0.69 per week earlier birth [95% CI: 0.55-0.86], p=0.001) and LOS (hazard ratio for 
hospital discharge 0.70 per week earlier birth [95% CI: 0.55-0.89], p=0.003) 
remained significant for those infants born between 34 to 36
+6
 weeks. However, the 
mode of labour onset had no significant effect on ENT (hazard ratio 1.0 [0.7-1.5] 
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p=0.86 for non-urgent compared with spontaneous, hazard ratio 0.9 [0.7-1.6] p=0.78 
for emergency), or on LOS (hazard ratio 0.9 [0.6-1.3] p=0.61 for non-urgent 
compared with spontaneous, hazard ratio 1.0 [0.7-1.6] p=0.91 for emergency).   
Analysis was also performed for mode of Labour onset in infants born at ≥37 weeks 
GA comparing spontaneous labour (4/48 complex patients, mean GA at birth 
37.6±0.09 weeks) with planned induction of labour/caesarean section (15/148 
complex patients, mean GA at birth 37.6±0.04 weeks), and emergency delivery (2/6 
complex patients, mean GA at birth 37.8±0.19 weeks). There was no effect of lower 
GA on ENT (hazard ratio per week 1.0 [95% CI:0.8-1.3], p=0.96) ) or LOS (hazard 
ratio per week 1.0 [95% CI:0.7-1.4], p=0.78) in the ≥37 weeks GA group. 
Additionally, mode of delivery had no impact on ENT (hazard ratio 0.64 [0.25-1.7] 
p=0.36 for non-urgent induction/Caesarean section compared with spontaneous, 
hazard ratio 0.52 [0.21-1.29] p=0.16 for emergency), or on LOS (hazard ratio 0.6 
[0.24-1.58] p=0.31 for non-urgent induction/Caesarean section compared with 
spontaneous, hazard ratio 0.5 [0.22-1.4] p=0.2 for emergency).  
7.2.1.5 Timing of Delivery and Impact on Macroscopic Bowel Wall Inflammation 
Bowel exposure to amniotic fluid has been hypothesised to cause bowel 
inflammation (Morrison et al., 1998) and therefore later birth GA may be associated 
with increased macroscopic bowel inflammation due to prolonged exposure to 
amniotic fluid. The visual appearance of bowel at birth was documented in 425 
(83%) infants of whom 137 (32%) were reported to demonstrate bowel 
inflammation/serosal peel. There was no significant difference in birth GA between 
infants with inflammation/peel (GA median 36.6, range [30.0-41.3] weeks) and those 
without inflammation/peel (GA 36.9 [25.0-39.0] weeks, P=0.24). There was a small, 
but significantly longer time to full feeds 31 [6-1103] days vs. 27 [4-386] days, 
P=0.008) in those infants with inflammation/peel, but no significant difference in 
LOS (42.5 [8-349] days vs. 35 [5-386] days, P=0.06, Table 7-6).  
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Neonatal Outcome 
With Bowel 
Inflammation / 
Serosal Peel 
Without Bowel 
Inflammation / 
Serosal Peel 
p-value 
Gestational Age at 
birth (weeks) 
36.6 [25.0-39.0] 36.9 [25.0-39.0] 0.24 
Time to full enteral 
feeds (days) 
31 [6-1103] 27 [4-386] 0.008 
Length of Hospital 
Stay (days) 
42.5 [8-349] 35 [5-386] 0.06 
Table 7-6: Comparison of postnatal outcomes between those infants with and without bowel 
inflammation/serosal peel using Mann-Whitney (median [range]). 
7.2.2 Maternal Antenatal Corticosteroid Administration and Impact on Infant 
Outcomes 
7.2.2.1 Demographics 
From the complete 3 centre dataset of 510 infants with linked fetal and neonatal data, 
10 infants were excluded as it was not possible to ascertain whether maternal 
antenatal corticosteroids had been administered or not. Of the 500 infants included in 
the corticosteroid analysis, 431 (GA at birth median 37, range [31-41] weeks) did not 
receive maternal antenatal corticosteroids whereas 69 (GA at birth 34 [25-38] weeks) 
did receive maternal antenatal corticosteroids. Of those infants who received 
maternal antenatal corticosteroids, 56 received a full single course and 13 received a 
partial single course. The numbers of infants who received and did not receive 
antenatal corticosteroids were evenly distributed across the study centres (Table 7-7). 
The timing of antenatal corticosteroid administration varied across the group, 2 
infants received corticosteroids <24 hours before birth, 42 infants between >24 hours 
and <7 days before birth, 23 infants at >7 days before birth and for 2 infants the 
timing of administration was not known. Antenatal corticosteroids were administered 
for the following reasons: premature labour (n=15); threatened premature labour 
(n=18); elective caesarean section delivery at 36 weeks GA (n=3); planned delivery 
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at <37 weeks GA for bowel dilatation (n=20); premature delivery for obstetric 
reasons (n=10) or unknown (n=3). As expected, infants who received antenatal 
corticosteroids were born at a significantly earlier GA and lower birth weight than 
those infants who did not receive antenatal corticosteroids (Table 7-7).  
 
Maternal Antenatal Corticosteroids 
No Steroids Steroids 
Study Population: 
Total patients 
included (n=500) 
431 (86%) 69 (14%) 
Centre 1 (n=150) 128 (85%) 22 (15%) 
Centre 2 (n=122) 103 (84%) 19 (16%) 
Centre 3 (n=228) 200 (88%) 28 (12%) 
Birth Demographics: p-value 
Birth gestational age 
(weeks) 
37.0 [30.6-41.3] 34.0 [25.1-38.3] <0.0001 
Birth weight (g) 2500 [220-3884] 1960 [540-3380] <0.0001 
Male 217 36 
0.99 
Female 214 33 
Table 7-7: Gastroschisis antenatal maternal corticosteroid study population and 
demographics. 
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7.2.3 Postnatal Outcomes 
7.2.3.1 Univariate analysis 
A significantly higher proportion of complex gastroschisis infants (22%) received 
maternal antenatal corticosteroids compared with simple gastroschisis infants (12%, 
p=0.03). Table 7-8 indicates the number of complex and simple gastroschisis infants 
who received maternal antenatal corticosteroids, the reason for classification as 
complex and neonatal outcomes. Univariate analysis showed infants who received 
maternal antenatal corticosteroids had a significantly longer time to ENT and LOS 
than those who did not receive maternal antenatal corticosteroids. This is likely due 
to the higher proportion of complex patients and lower gestational age and 
birthweight in the group who received corticosteroids.  
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 No Steroids Steroids p-value 
*Simple and complex gastroschisis patients: 
Simple (n=424, 85%) 372 (88%) 52 (12%) 
0.03 
Complex (n=76, 15%) 59 (78%) 17 (22%) 
Atresia (n=42) 30 12 
Necrosis (n=28) 22 6 
Perforation (n=14) 13 1 
Stenosis (n=8) 7 1 
Neonatal outcomes in univariate analyses:  
**Time to first enteral feed (days) 12 [2-101] 13.5 [2-186] 0.58 
**Time to full enteral feeds (days) 26 [4-283] 30 [2-590] 0.01 
**Length of hospital stay (days) 35 [7-349] 46 [20-346] 0.003 
Deaths (n=23, 5%) 18 (4%) 5 (7%) 0.23 
Table 7-8: Gastroschisis complexity, corticosteroid administration and postnatal outcomes. 
*>1 pathology in 9 complex patients. Univariate analysis was **Mann-Whitney (median 
[range]) and Fisher’s exact tests. 
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7.2.3.1.1 Multivariate Analysis 
Cox regression analysis was performed in order to account for likely confounders 
within the univariate analysis (Table 7-9). The Cox model was adjusted for complex 
gastroschisis, birth GA, source hospital and antenatal corticosteroid administration. 
Censoring was performed for death, not achieving full feeds and not being 
discharged from hospital. Analysis revealed that maternal antenatal corticosteroid 
administration was not associated with faster time to ENT (hazard ratio reaching full 
feeds 1.0 [95% CI: 0.8-1.4], p=0.8) or LOS (hazard ratio for hospital discharge 1.1 
[95% CI: 0.7-1.5], p=0.8) (Figure 7-4A and B). Complex gastroschisis significantly 
increased ENT (hazard ratio 0.3 [95% CI: 0.2-0.4], p<0.001) and LOS (hazard ratio 
0.3 [95% CI: 0.2-0.4], p<0.001) (Figure 7-4C and D) compared to simple 
gastroschisis infants. Conversely, later birth GA significantly decreased ENT (hazard 
ratio for reaching full feeds 1.1 per week of later birth [95% CI: 1.1-1.2], p<0.001) 
and LOS (hazard ratio for hospital discharge 1.2 per week of later birth [95% CI: 1.1-
1.3], p<0.001). Source hospital had no effect on ENT (comparing against centre 3: 
centre 1 hazard ratio 1.2 [95% CI: 0.9-1.5], p=0.2 and centre 2 hazard ratio 1.2 [95% 
CI: 1.0-1.5], p=0.1) but had a significant effect on LOS (comparing against centre 3: 
centre 1 hazard ratio 1.3 [95% CI: 1.0-1.6], p=0.07 and centre 2 hazard ratio 1.5 
[95% CI: 1.2-1.9], p=0.001) possibly due to a differing feeding and/or discharge 
policy in Centre 3. 
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Cox Regression 
Category 
Impact on 
ENT 
HR        
[95% CI]   
p-value 
Impact on 
LOS 
HR        
[95% CI]   
p-value 
Maternal 
antenatal 
corticosteroids 
No effect 
1.0          
[0.8-1.4]    
0.8 
No effect 
1.1           
[0.7-1.5]    
0.8 
Complexity of 
gastroschisis 
↑ with 
Complex 
gastroschisis 
0.3          
[0.2-0.4] 
<0.001 
↑ with 
Complex 
gastroschisis 
0.3          
[0.2-0.4] 
<0.001 
Gestational age 
(GA) at birth  
↓ with ↑ GA  
1.1           
[1.1-1.2] 
<0.001 
↓ with ↑ GA 
1.2          
[1.1-1.3] 
<0.001 
Table 7-9: The effect of antenatal maternal corticosteroids, complexity of gastroschisis and 
gestational age at birth on ENT and LOS. Cox regression adjusted for complex gastroschisis, 
birth GA, source hospital and antenatal corticosteroid administration and censored for death, 
not achieving full feeds and not being discharged from hospital as appropriate. Data for 
gestational age at birth is per week later birth. HR = hazard ratio, CI = confidence interval. 
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Figure 7-4: Cox regression analysis of effect of maternal antenatal corticosteroids on A. 
ENT and B. LOS and effect of gastroschisis complexity on C. ENT and D. LOS. 
7.2.3.2 Post-hoc Exploratory Analyses 
To determine whether maternal antenatal corticosteroids administration was 
associated with any effect on postnatal gastroschisis outcomes in any patient subset, 
further exploratory analyses were performed.  
As the therapeutic effect of maternal antenatal corticosteroids may have been 
impacted by an incomplete course, the analysis was repeated only including infants 
who received a complete course (n=56), which again showed no difference in ENT 
(hazard ratio 0.9 [95% CI: 0.4-1.2], p=0.4) or LOS (hazard ratio 0.9 [95% CI: 0.6-
1.2], p=0.4).  
Extreme prematurity or later birth GA (as very few patients with late birth GA 
received maternal antenatal corticosteroids) may influence results therefore to 
remove this potential confounder only patients born between 31
+0
 to 36
+6
 weeks 
gestation were included in the analysis (n=207 did not receive corticosteroids, n=65 
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received corticosteroids), which showed no effect on ENT (hazard ratio 0.9 [95% CI: 
0.6-1.2], p=0.4) or LOS (hazard ratio 1.2 [95% CI: 0.8-1.7], p=0.4). This was also 
repeated including only those infants born at 34 weeks GA or above (n=44 received 
steroids, n=420 did not). There was no association between administration of 
antenatal corticosteroids and ENT (hazard ratio 1.2 [95% CI: 0.7-1.5], p=0.9) or LOS 
(hazard ratio 1.0 [95% CI: 0.7-1.5], p=1.0). Those born at <34 weeks were also 
analysed separately (n=25 with steroids, n=11 no steroids), again with no association 
either for ENT (hazard ratio 1.0 [95% CI: 0.4-2.2], p=0.9) or LOS (hazard ratio 0.7 
[95% CI: 0.3-1.6], p=0.4) 
Maternal antenatal corticosteroid administration may affect the time to start feeding, 
however, analysis of whether antenatal corticosteroids reduced time to first enteral 
feed, again showed no difference (hazard ratio 1.0 [95% CI: 0.7-1.5], p=0.8).  
As the intestinal function of infants with complex gastroschisis may be adversely 
affected by concomitant intestinal pathologies (atresia, stenosis, necrosis and 
perforation) an analysis including only simple gastroschisis patients (n=372 did not 
receive corticosteroids n=52 received corticosteroids) was performed. Similarly this 
analysis showed no difference in ENT (hazard ratio 1.0 [95% CI: 0.7-1.4], p=0.8) or 
LOS (hazard ratio 1.0 [95% CI: 0.7-1.5], p=1.0).  
To determine whether the timing of antenatal corticosteroid administration prior to 
birth was an important factor, only infants who received corticosteroids between >24 
hours and ≤7 days (n=42) before birth were included also showing no effect on time 
to ENT (hazard ratio 1.0 [95% CI: 0.7-1.5], p=0.9) or LOS (hazard ratio 1.0 [95% 
CI: 0.7-1.6], p=0.8). Additionally, only infants who received corticosteroids at >7 
days (n=23) before birth were analysed, which also showed no effect on ENT 
(hazard ratio 1.1 [95% CI: 0.7-1.7], p=0.7) or LOS (hazard ratio 1.0 [95% CI: 0.5-
1.7], p=0.9).  
Finally, to investigate whether changes in neonatal practices over the 22 year study 
period influenced gastroschisis outcomes, the year of birth was added into the Cox 
regression model. This again showed no difference in ENT (hazard ratio 1.0 per year 
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later birth [95% CI: 1.0-1.0], p=0.5) or LOS (hazard ratio 1.0 per year later birth 
[95% CI: 1.0-1.0], p=0.6). 
7.3 Discussion 
7.3.1 Timing of Delivery and Impact on Postnatal Outcomes 
The data from this international multicentre retrospective cohort study refuted the 
original study hypothesis and shows a significant association between earlier birth 
GA and prolonged ENT and LOS. These findings were independent of gastroschisis 
complexity. As these data only include infants with gastroschisis it is not possible to 
determine whether these associations are due to a general effect of prematurity or 
specific to gastroschisis. Univariate analysis of corrected GA at time of ENT 
suggests that delivery at 34 to 36
+6
 weeks GA confers a small improvement in 
neonatal gut function. However, this is not translated into a faster time to achieve 
ENT. Furthermore, delivery at 34 to 36
+6
 weeks GA did not reduce the corrected GA 
at hospital discharge and regression analysis showed these infants spend longer in 
hospital. The prolonged time taken to ENT and LOS places infants delivered at <37 
weeks GA at increased risk of sepsis as indicated by the nearly doubled (32 vs. 17%) 
risk of blood-culture positive sepsis in the 34 to 36
+6
 week GA group. Additionally, 
visual evidence of bowel inflammation/serosal peel was not associated with later GA 
at birth or duration of LOS but there was a small, but significantly longer time to 
ENT   
7.3.2 Relationship between Maternal Antenatal Corticosteroid Administration 
and Gastroschisis Outcomes 
Again the of linked fetal and neonatal data from this international multicentre 
retrospective cohort study contested the original study hypothesis and showed that 
maternal antenatal corticosteroid administration was not associated with any effect, 
positive or negative, on ENT or LOS. Post-hoc exploratory analysis was performed 
in order to determine if there were any patient subsets in which corticosteroids were 
beneficial. These analyses included effect on time to first enteral feed, timing of 
maternal corticosteroid administration prior to birth, and exclusion of factors that 
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might skew the data such as extreme prematurity, complex gastroschisis and those 
who did not receive a full course of corticosteroids. However, none of these analyses 
were associated with any differences in gastroschisis infant outcomes. These data 
suggest, contrary to the published literature from animal studies and a single abstract 
in humans, that a single course of maternal antenatal corticosteroids with the aim of 
decreasing intestinal inflammation and improving intestinal maturation does not 
prevent or reverse the bowel changes that cause GRID.  
7.3.3 Impact of Other Factors on Gastroschisis Outcomes 
In keeping with previous published studies complex gastroschisis (Bradnock et al., 
2011, Bergholz et al., 2014) was shown to be associated with a significant increase in 
ENT and LOS. This is unsurprising given that atresia, perforation, stenosis and 
necrosis all requires surgical intervention and have a significant concomitant impact 
on bowel function. Source hospital had no impact on ENT but LOS was prolonged in 
one centre likely due to differing management and discharge practices. Interestingly, 
these data showed that changes in neonatal practices over the 22 year study period 
had no impact on postnatal gastroschisis outcomes. 
7.3.4 Timing of Delivery Review of the Literature  
Optimal timing for elective delivery of gastroschisis fetuses remains controversial. 
As previously stated there is conflicting evidence both for (Gelas et al., 2008, Serra 
et al., 2008, Moore et al., 1999, Moir et al., 2004) and against (Maramreddy et al., 
2009, Youssef et al., 2015, Cain et al., 2014, Logghe et al., 2005, Charlesworth et al., 
2007) elective delivery at <37 weeks GA (Table 7-10). The majority of studies are 
small and retrospective in nature. However, there are two prospective studies (Serra 
et al., 2008, Moir et al., 2004) and one randomized control trial (Logghe et al., 2005) 
in the literature. The prospective studies compared outcomes from patients delivered 
prospectively at 34-35 weeks GA with retrospective controls. The numbers were 
small including; 13 prospective and 10 retrospective infants in the Serra, et al study 
and 13 prospective and 14 retrospective infants in the Moir, et al study, but both 
studies showed a significant reduction in ENT and LOS. However, due to the small 
cohort size, partial retrospective nature of the studies and lack of randomisation it is 
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not possible to assess true validity of these results. The only randomised control trial 
(Logghe et al., 2005) included one treatment centre and recruited 42 gastroschisis 
pregnancies that were randomly allocated to either elective delivery at <36 weeks 
GA or continuation of pregnancy to full term with spontaneous delivery. The study 
showed no benefit from early delivery. However, due to early spontaneous labour in 
the control group there was little difference in birth GA between the early delivery 
group (35.8 weeks) and controls (36.7 weeks) hence significantly larger numbers are 
required to determine the true impact of birth GA on postnatal outcomes.  
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Table 7-10: Summary of literature investigating effect of timing of delivery on gastroschisis 
infant outcomes. *Indicates studies supporting elective preterm delivery. GA=gestational 
age. 
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7.3.5 Hypothesised Reason for Prolonged Postnatal Outcomes at Lower Birth 
Gestational Age 
These data suggest that earlier delivery marginally improves corrected GA at time of 
ENT but has no impact on absolute duration of ENT and prolongs absolute LOS. 
Additionally, visual evidence of bowel inflammation/peel at birth was not related to 
later GA at birth.  Therefore, GRID in gastroschisis is likely to be more 
multifactorial than simple duration of bowel exposure to amniotic fluid. As such, 
these data suggest that a longer time in utero is more protective from prolonged use 
of PN or hospital stay and risk of developing sepsis. Furthermore, the positive effects 
of fetal bowel maturation in the later stages of pregnancy appear to have a greater 
influence on postnatal outcomes than the detrimental effects of prolonged amniotic 
fluid exposure.  
7.3.6 Hypothesised Reason for Lack of Effect from Maternal Antenatal 
Corticosteroid Administration 
The composition of amniotic fluid changes significantly after 25 weeks gestation 
with increases in creatinine, urea, enteric enzymes and bile acids, and reduction in 
sodium, chloride and osmolality (Underwood et al., 2005). These changes in 
amniotic fluid composition coincide with increases in bowel wall inflammation in 
fetuses with gastroschisis in the third trimester (Tibboel et al., 1986). As such, the 
lack of effect on ENT and LOS within this cohort may be due to the adminstration of 
maternal antenatal corticosteroids occurring too late in gestation. Potentially, earlier 
administration of corticosteroids at the start of the third trimester may act to prevent 
the onset of bowel inflammation and in turn the gastrointestinal damage leading to 
intestinal dysfunction. 
In addition, corticosteroids are quickly removed from the systemic circulation and 
therefore the therapeutic effectiveness of antenatal corticosteroids may have been 
impeded by the short lived effect. Although corticosteroids given to the mother are 
readily available to the fetus (Della Torre et al., 2010), animal experiments have 
shown that the peak maternal concentration following administration occurs after 15 
minutes and declines rapidly over 3 hours whilst the peak fetal concentration occurs 
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after 1 hour and becomes undetectable at 8 hours (Schwab et al., 2006). Interestingly, 
delivery of corticosteroids via the maternal route provides a longer half-life in the 
fetus than direct fetal administration (Moss et al., 2003). 
Considering both the uncertainty of the optimal timing for administration and the 
short half-life of corticosteroids, it may be that multiple courses throughout the third 
trimester are required in order to exert a prolonged therapeutic anti-inflammatory or 
maturational effect.  Multiple courses of antenatal corticosteroids are controversial 
and have been considered for otherwise normal pregnancies at risk of preterm birth 
that remain pregnant for a further 7 to 14 days after initial antenatal corticosteroid 
administration. Current research is lacking conclusive evidence for the benefit and 
safety of multiple antenatal corticosteroid courses (Murphy et al., 2008, Asztalos, 
2012, Asztalos et al., 2013), which may be associated with adverse events such as 
low birth weight, neurological developmental impairment (Kanagawa et al., 2006, 
Church et al., 2012) and increased risk of developing type 2 diabetes mellitus and 
cardiovascular disease later in life (Asztalos, 2012, Norberg et al., 2013). Due to this 
uncertainty and lack of proven benefit it would be difficult to develop a trial 
involving administration of multiple courses of maternal antenatal corticosteroids in 
gastroschisis pregnancies unless more data was available from relevant animal 
models.  
Finally, the cause of GRID may be more complicated than simply inflammation. 
Intestinal dysfunction may result from bowel morphological changes that occurred 
from abnormal serosal exposure to amniotic fluid growth factors or lack of 
mechanical constraint from the abdominal cavity. Alternatively, inflammation may 
have been caused by mechanical compression at the exit point from the small 
abdominal wall defect resulting in ischaemic intestinal changes. As such, further 
research is required to determine if antenatal corticosteroid administration could be 
beneficial in improving GRID and in turn infant outcomes.  
7.3.7 Limitations of the Study 
These data were collected retrospectively without control over the method/timing of 
delivery or the administration (dosage and timing) of antenatal corticosteroids and 
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the general antenatal and postnatal management were not standardised. Hence, the 
cohort included infants delivered on a semi-urgent or emergency basis due to 
maternal or fetal concerns at <37 weeks GA, infants delivered by spontaneous labour 
at <37 weeks GA and infants delivered as per standard elective induction of labour at 
≥37 weeks GA. Therefore comparisons between infants could be affected by the 
overall health of the neonates who were delivered early for maternal or fetal concerns 
and who could conceivably have poorer outcomes as a result. In addition, 
administration of maternal antenatal corticosteroids occurred in patients with 
threatened preterm delivery or those who had maternal or fetal concerns resulting in 
early delivery in order to improve lung maturation and not for the purpose of bowel 
maturation or anti-inflammatory action. As such, the antenatal corticosteroid group 
were born at an earlier GA, which may have resulted in potentially worse infant 
outcomes. To account for these factors the birth GA was adjusted for in the analysis. 
Additionally, a posthoc analysis removing extreme outliers was performed through 
inclusion of patients born between 31
+0
 and 36
+6
 weeks gestation. Also, the definition 
of ENT was not protocolised and LOS may be affected by socio-economic factors 
surrounding young maternal age. Finally, there may be other sources of bias and 
confounders that were not considered or could not be accounted for in this study. 
7.3.8 Strength of the Study 
These data consistently show lower birth GA to be associated with prolonged ENT 
and LOS and no associated effect of antenatally corticosteroids on postnatal 
outcomes even following detailed post-hoc analysis. These data were collected from 
two UK and one Canadian tertiary referral centres therefore the data includes 
variation in antenatal and neonatal management improving the generalisability of the 
study to other centres.  Finally, this retrospective cohort study contains over 500 
patients forming one of the largest published data sets to date. 
7.4 Conclusion 
Similarly to other tested but failed therapeutic strategies for improving postnatal 
intestinal function in gastroschisis including antenatal amniotic fluid exchange 
(Midrio et al., 2007, Burc et al., 2004, Demir et al., 2013) and postnatal prokinetics 
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(Curry et al., 2004), these data showed; (i) early delivery does not appear to reduce 
bowel damage or improve bowel function and is associated with prolonged ENT and 
LOS and (ii) no association between maternal antenatal corticosteroids and improved 
ENT or LOS in gastroschisis infants. As such, these data do not support elective 
delivery at <37 weeks GA or the routine administration of maternal antenatal 
corticosteroids as strategies to improve postnatal outcomes and enteral feeding. This 
study was not designed to identify antenatal findings that would predict worse 
postnatal outcomes therefore timing of delivery for gastroschisis fetuses with 
evidence of maternal or fetal compromise should continue to be directed by clinical 
indication rather than a specific target gestational age. Further investigation is 
required into the cause of gastroschisis bowel morphological changes as described in 
Chapter 6 in order to develop a therapy that could prevent such changes from 
occurring.  
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Chapter 8: Does Antenatally Detected Bowel Dilation 
Predict Gastroschisis Infant Outcomes? 
8.1 Introduction 
The ability to predict gastroschisis postnatal outcomes based on antenatal ultrasound 
markers would greatly aid prenatal counselling and inform clinical management both 
antenatally and postnatally. It would be of particular benefit if fetuses with 
impending bowel necrosis secondary to closing gastroschisis or a tight abdominal 
wall defect could be detected before extensive ischaemic damage develops enabling 
bowel salvage by urgent antenatal intervention (early delivery or fetoscopic widening 
of the tight defect ring). Intra-abdominal bowel dilatation (IABD) has been found in 
several studies to be associated with complex gastroschisis (Huh et al., 2010, Houben 
et al., 2009, Ghionzoli et al., 2012, Nick et al., 2006, D'Antonio et al., 2015, 
Goetzinger et al., 2014, Contro et al., 2010) and bowel dilatation has been 
hypothesised to represent poorly functioning bowel in cases of simple gastroschisis 
resulting in prolonged ENT and LOS (Langer et al., 1993). However, some studies 
have also found IABD not to be associated with complex gastroschisis (Mears et al., 
2010, Badillo et al., 2008). Conversely, Extra-abdominal bowel dilatation (EABD) 
has been considered by some to be a normal occurrence in gastroschisis (Huh et al., 
2010, Contro et al., 2010) and not to be predictive of either complex gastroschisis or 
outcomes in simple gastroschisis (Badillo et al., 2008, Mears et al., 2010). As such, 
some clinicians instigate early delivery based on the antenatal findings of IABD with 
the aim to prevent development of bowel necrosis from closing gastroschisis. 
However, the data relating to IABD and EABD is limited due to the small number of 
patients included in most studies and little is known regarding the predictive value of 
combined IABD and EABD with complex gastroschisis and infant outcomes. 
Antenatal intra-abdominal bowel dilatation is hypothesised to be predictive of 
complex gastroschisis and poor infant outcomes. The aim of this study is to 
determine the association of IABD and EABD with (i) complex gastroschisis and (ii) 
infants outcomes using ENT and LOS as surrogate markers of outcome.   
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8.2 Results 
Of the 246 gastroschisis infants included from the London centres, 110 had IABD 
detected antenatally (including gastric dilatation), which resolved in 18 fetuses (16 
simple gastroschisis, 2 complex gastroschisis) during the antenatal period after a 
median 1, range [1-3] ultrasound scans. The remaining 92 fetuses had persistent 
IABD that remained detectable at the last antenatal scan before birth, of whom 68 
(74%) were simple gastroschisis and 24 (26%) complex gastroschisis giving a 
positive predictive value (PPV) for detecting complex gastroschisis of 26% (Table 
8-1). IABD was detected prior to 30 weeks GA in 34 fetuses of whom 21 were 
simple gastroschisis and 13 complex gastroschisis giving a PPV for detecting 
complex gastroschisis of 38% (Table 8-1). Of the 136 fetuses who never had 
antenatal IABD detected, 130 were simple gastroschisis and 6 were complex 
gastroschisis (1 perforation, 3 atresia, 2 necrosis) giving a negative predictive value 
(NPV) for detecting complex gastroschisis of 96% (Table 8-1). 
EABD was detected in 65 fetuses, which resolved in 7 fetuses after 1 [1-3] scans and 
was persistent to the last antenatal scan before delivery in 58, fetuses of whom 46 
were simple gastroschisis and 12 complex (9 atresia, 2 necrosis and 1 stenosis, PPV 
21%, Table 8-1). The detection of EABD prior to 30 weeks GA gave a higher PPV 
of 64%. EABD was never detected in 19 (59%) complex gastroschisis giving an 
NPV for detecting complex gastroschisis of 90% (Table 8-1). 
Combined IABD and EABD (combined dilatation) was present in 22 fetuses of 
whom 14 were simple gastroschisis and 8 complex (7 atresia, 1 necrosis). When 
combined dilatation was present prior to 30 weeks GA the PPV for detecting 
complex gastroschisis was relatively high at 75% (Table 8-1). Additionally, IABD 
with collapsed extra-abdominal bowel loops was detected in 3 patients all of whom 
were complex gastroschisis (1 atresia, and 2 necrosis) and in all of whom these 
findings were detectable prior to 30 weeks GA. 
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All Intra-Abdominal Bowel Dilatation (IABD) 
Group 
(n=total in 
group) 
IABD at 
Last Scan  
Number (% 
of group) 
IABD at 
≥30 to ≤34 
Weeks GA 
Number (% 
of group) 
IABD at 
<30 Weeks 
GA   
Number (% 
of group) 
Resolved 
IABD 
Number (% 
of group) 
Never had 
IABD 
Number (% 
of group) 
Simple  
n=214 
68 (32%) 47 (22%) 21 (10%) 16 (7%) 130 (61%) 
Complex  
n=32 
24 (75%) 21 (66%) 13 (41%) 2 (6%) 6 (19%) 
PPV or NPV 26% PPV 31% PPV 38% PPV 89% NPV 96% NPV 
All Extra-Abdominal Bowel Dilatation (EABD) 
Group 
(n=total in 
group) 
EABD at 
Last Scan 
Number (% 
of group) 
EABD at 
≥30 to ≤34 
Weeks GA 
Number (% 
of group) 
EABD at 
<30 Weeks 
GA   
Number (% 
of group) 
Resolved 
EABD 
Number (% 
of group) 
Never had  
EABD 
Number (% 
of group) 
Simple  
n=214 
46 (21%) 28 (13%) 4 (2%) 6 (3%) 162 (76%) 
Complex  
n=32 
12 (38%) 11 (0.34%) 7 (22%) 1 (3%) 19 (59%) 
PPV or NPV 21% PPV 28% PPV 64% PPV 86% NPV 90% NPV 
Combined Intra and Extra-Abdominal Bowel Dilatation (Combined) 
Group 
(n=total in 
group) 
Combined 
at Last 
Scan 
Number (% 
of group) 
Combined 
at ≥30 to 
≤34 Weeks 
GA   
Number (% 
of group) 
Combined 
at <30 
Weeks GA 
Number (% 
of group) 
Resolved 
Combined 
Number (% 
of group) 
Never had  
Combined 
Number (% 
of group) 
Simple  
n=214 
14 (26%) 13 (6%) 1 (0.5%) 1 (0.5%) 200 (93%) 
Complex  
n=32 
8 (25%) 8 (25%) 3 (9%) 1 (3%) 24 (75%) 
PPV or NPV 36% PPV 38% PPV 75% PPV 50% NPV 89% NPV 
Table 8-1: Presence of intra-abdominal bowel dilatation (IABD), extra-abdominal bowel 
dilatation (EABD) and both IABD/EABD (combined) throughout pregnancy by gastroschisis 
complexity group. Positive predictive value and negative predictive value are for complex 
gastroschisis. 
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The diameter of the IABD was measured and documented for 55 fetuses (42 simple 
gastroschisis, 13 complex gastroschisis) revealing no significant difference in 
diameter of IABD between simple (19 [7.2-36.0] mm) and complex gastroschisis (20 
[13-36] mm, p=0.064, Figure 8-1). Additionally, when considering fetuses with 
measured large IABD (diameter ≥18mm), this was present in 64% of simple and 
69% of complex gastroschisis giving a PPV for detected complex patients of only 
25% (Table 8-2). When considering all infants with measured IABD there was no 
correlation between the degree of dilatation and ENT (p=0.33) but larger bowel 
dilatation was weakly associated with prolonged LOS (p=0.049). However, this 
association was not present when LOS for simple (p=0.26) and complex (p=0.42) 
gastroschisis were analyzed separately. Within the simple gastroschisis group, there 
was no significant difference between those patients with IABD and without IABD 
in ENT (24.5 [11-112] days vs. 26.0 [4-365] days, p=0.65) or LOS (32.0 [15-94] 
days vs. 29.0 [7-167] days p=0.13). 
 
Figure 8-1: Relationship of measured intra-abdominal bowel dilatation (IABD) and extra-
abdominal bowel dilatation (EABD) with simple and complex gastroschisis. Hosrizontal line 
at median. 
The diameter of the EABD was measured and documented for 51 fetuses (40 simple 
gastroschisis, 11 complex gastroschisis) revealing no significant difference in 
diameter of EABD between simple (21 [13-50] mm) and complex gastroschisis (22 
[15-31] mm, p=0.91, Figure 8-1). When considering fetuses with measured large 
EABD (diameter of ≥18mm) this was present in 82% of complex and 72% of simple 
gastroschisis giving a PPV for detected complex patients of only 24% (Table 8-2). 
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Additionally, there was no correlation between size of EABD and ENT (p=0.50) or 
LOS (p=0.47). However, patients with combined IABD/EABD had longer ENT (30 
[15-365] days vs. 26.5 [4-365] days, p=0.14) and LOS (37 [16-273] vs. 32 [7-300] 
days, p=0.17) but neither reached significance. 
Degree of Intra-Abdominal Bowel Dilatation (IABD) 
IABD Diameter 
(mm) 
Simple 
Gastroschisis 
n=42            
Number (% in group) 
Complex 
Gastroschisis 
n=13            
Number (% in group) 
Positive 
Predictive Value 
<10 2 (5%) 0 0% 
10 to <18 13 (31%) 4 (31%) 24% 
≥18 27 (64%) 9 (69%) 25% 
Degree of Extra-Abdominal Bowel Dilatation ( EABD) 
EABD Diameter 
(mm) 
Simple 
Gastroschisis 
n=40            
Number (% in group) 
Complex 
Gastroschisis 
n=11            
Number (% in group) 
Positive 
Predictive Value 
<10 0 0 0% 
10 to <18 11 (28%) 2 (18%) 15% 
≥18 29 (72%) 9 (82%) 24% 
Table 8-2: Size of measured intra-abdominal bowel dilatation (IABD) and extra-abdominal 
bowel dilatation (EABD) for both simple and complex gastroschisis 
At birth, 23 neonates with simple gastroschisis were considered at risk of impending 
closing gastroschisis either due to the presence of ischaemic bowel or the need for 
widening of a tight defect prior to definitive surgical management. Of these 23 
neonates, 5 (22%) had persistent IABD (combined with EABD from >30 weeks GA 
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in 2 cases), 5 (22%) had resolved IABD, 4 had persistent EABD but 8 (36%) never 
had IABD or EABD detected. 
Finally, clinical concerns were raised antenatally of impending closing gastroschisis 
resulting in early delivery based on IABD in 20 patients. These concerns were due 
to: persistent/static dimension of IABD (5 simple, 3 atresia, 1 necrosis), sudden onset 
of large IABD in the 3
rd
 trimester (6 simple, 1 atresia), increasing IABD throughout 
pregnancy (3 atresia). There was no difference in the number of infants with necrosis 
in the early delivery and non-early delivery groups (Table 8-3). Of those infants with 
simple gastroschisis who were delivered early, only one was reported to have dusky 
bowel and therefore born with possible signs of impending closing gastroschisis. 
Overall, 59 patients had persistent/static IABD (45 simple, 11 atresia, 3 necrosis), 27 
sudden (21 simple, 5 atresia, 1 necrosis) and 6 increasing (2 simple, 4 atresia).  
 
Planned Early 
Delivery for IABD 
(n=20) 
IABD at Any 
Time but no Early 
Delivery (n=90) 
p-value 
IABD Diameter 
(mm) 
20 [12-36] 19.0 [7.2-36] 0.17 
Patients with 
Bowel Necrosis 
Number (% in group) 
1 (5%) 3 (3%) 0.56 
Patients with 
Atresia  
Number (% in group) 
8 (40%) 13 (14%) 0.023 
Table 8-3: Comparison of complex patients and the diameter of bowel dilatation between 
the planned early delivery for intra-abdominal bowel dilatation (IABD) versus no early 
delivery for IABD.  
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8.3 Discussion 
8.3.1 Predictive Value of Antenatal Bowel Dilatation 
Evaluating the presence of IABD and EABD in isolation gave mixed results. IABD 
was present in a relatively large number of simple and complex gastroschisis fetuses 
resulting in a low PPV for predicting complex gastroschisis. Although the absence of 
IABD yielded a high NPV of 96% it is also important to note that 6 (19%) complex 
gastroschisis fetuses did not exhibit IABD at any time antenatally. EABD at <30 
weeks GA yielded the highest PPV (64%) but the absence of EABD gave a lower 
NPV (90%). There were no apparent pattern of evolving IABD or EABD over the 
course of gestation that was indicative of complex gastroschisis and several infants at 
birth with signs of impending closing gastroschisis had not exhibited any bowel 
dilatation antenatally. However, combined dilatation present at <30 weeks GA 
yielded a relatively high PPV of 75% for detecting complex gastroschisis. 
Additionally, IABD combined with collapsed extra-abdominal bowel was only 
present in complex gastroschisis fetuses and was detected from <30 weeks GA in all 
cases.   
The diameter of IABD and EABD was similar in both simple and complex 
gastroschisis even when considering only large bowel dilatation of >18mm. As such, 
the degree of measured bowel dilatation was poorly predictive of gastroschisis 
complexity. Finally, increasing bowel diameter size was not associated with poorer 
infant outcomes (measured as ENT and LOS) for simple or complex gastroschisis 
infants in this cohort 
8.3.2 Implications of Findings 
Overall, the absence of IABD or EABD (when considered in isolation) is suggestive 
of simple gastroschisis. As such, expectant parents could be cautiously counselled 
accordingly with the caveat that absence of dilatation does not completely rule out 
the possibility of complex gastroschisis. Although the presence of bowel dilatation 
increases the chance of complex gastroschisis, it is also frequently associated with 
simple gastroschisis and the presence of bowel dilatation in simple gastroschisis did 
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not negatively impact postnatal outcomes. Therefore, IABD or EABD considered in 
isolation are not reliable markers for predicting postnatal outcome. On the other 
hand, the presence of combined dilatation or IABD and collapsed extra-abdominal 
bowel particularly when present at <30 weeks GA was highly predictive of complex 
gastroschisis in this cohort. These antenatal findings may suggest that bowel damage 
has already occurred rather than these signs being a prelude to the development of 
bowel complications. As such, it may be too late to achieve bowel salvage by the 
time these findings are detected. Even so, it may still be prudent to consider early 
delivery or fetoscopic intervention with the aim to lessen the degree of bowel 
damage or achieve bowel salvage where possible. 
8.3.3 Literature Review 
It has previously been hypothesised that the presence of IABD in particular is 
prognostically useful in detecting fetuses with poorer postnatal outcomes or 
impending bowel damage (e.g. necrosis or atresia, literature summarised in Table 
8-4) enabling selection of patients who would benefit from fetal intervention such as 
early delivery before further deterioration (Houben et al., 2009). A meta-analysis 
(D'Antonio et al., 2015) assessing prenatal risk factors showed that IABD was 
associated with an increased risk of bowel atresia but the study was unable to 
identify a marker that could accurately predict complex gastroschisis. Additionally, it 
showed that fetuses with EABD were not at increased risk of bowel atresia. 
Interestingly, the results presented in this chapter revealed the highest PPV for 
detecting complex gastroschisis based solely on IABD or EABD was fetuses with the 
presence of EABD at <30weeks GA. A previous study from UCLH and GOSH 
found that the absence of bowel dilatation excluded atresia (Ghionzoli et al., 2012). 
However, the results presented in this chapter did not fully agree with this finding 
and showed that the absence of IABD could not fully exclude atresia. Another study 
concluded that second trimester IABD predicts bowel atresia (Nick et al., 2006) and 
may indicate the need for prenatal intervention or early delivery to prevent ongoing 
damage. Again the data presented in this chapter disagrees with this finding given the 
PPV of IABD at <30 weeks GA was only 38%, as such, instigating prenatal 
intervention or early delivery on the basis of IABD would lead to a large number of 
simple gastroschisis infants being born early for no clinical benefit and could in fact 
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result in poorer infant outcomes in terms of ENT and LOS as discussed in Error! 
eference source not found.pter 7. Additionally, there are conflicting data in terms of 
the association of bowel dilatation and prolonged ENT and LOS. Some studies found 
IABD (Goetzinger et al., 2014, Huh et al., 2010) to be associated with worse infant 
outcomes whilst others found unspecified bowel dilatation (Tower et al., 2009), 
IABD (Badillo et al., 2008, Mears et al., 2010) and EABD (Japaraj et al., 2003, 
Goetzinger et al., 2014, Badillo et al., 2008, Mears et al., 2010) not to be associated 
with poorer outcomes. The data presented in this chapter provides extra support to 
the studies that found no association between bowel dilatation or bowel diameter and 
infant outcomes. Finally, a previous case report has reported IABD combined with 
vanishing externalised bowel detected antenatally (i.e. antenatal ultrasound diagnosis 
of gastroschisis with evidence of externalised bowel followed by disappearance of 
the externalised bowel on subsequent ultrasound scans) to be associated with closed 
gastroschisis at birth including the following features; bowel atresia, short bowel 
syndrome, closed abdominal wall and an intestinal tissue remnant to the right of the 
umbilicus (Winter et al., 2005). Vanishing gastroschisis is a rare occurrence and was 
not present in the cohort presented here but is in keeping with the finding that IABD 
and collapsed extra-abdominal bowel was associated with complex gastroschisis 
particularly bowel necrosis.  
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Table 8-4: Summary of studies investigating the association of antenatally detected intra-
abdominal bowel dilation (IABD) and extra-abdominal bowel dilatation (EABD) with 
complex gastroschisis and surrogate infant outcomes (ENT and LOS). 
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8.3.4 Limitations of the Study 
This was a retrospective study with non-protocolised methods for the measurement 
of bowel diameter. Many of the ultrasound images were not stored and therefore it 
was not possible to design a retrospective study whereby stored images were 
assessed for the presence of bowel dilatation by a single blinded investigator. Bowel 
dilatation was therefore classified based on documentation within the fetal notes and 
hence subject to inter-observer variability. Due to the way IABD was documented, it 
was not possible to distinguish between intestinal or gastric dilatation. It was not 
possible to apply a threshold diameter to define the severity of bowel dilatation as 
only 55 of the 110 patients with IABD and 51 of 65 patients with EABD had bowel 
diameter measurements documented in their notes. This was a retrospective study 
and relies on accurate documentation of clinical findings within the fetal notes as 
such the presence of bowel dilatation may not have been documented accurately for 
all fetuses. Additional, data collection such as volume of amniotic fluid would have 
provided an additional factor that may have aided the reliability of predicting 
postnatal outcomes based on the presence antenatal bowel dilatation. 
8.3.5 Strength of the Study 
This study included two large London centres both of whom routinely assess bowel 
diameter during antenatal monitoring of fetuses with gastroschisis. As such, the 
number of patients included in this study is relatively high improving the validity of 
the results. It was possible to track the presence of documented bowel dilatation 
throughout the course of gestation enabling the identification of bowel diameter 
patterns overtime if any were present. Finally, to date previous studies have focused 
on the presence of IABD or EABD in isolation whilst this study has identified that 
the presence of combined dilatation or IABD with extra-abdominal bowel collapse 
more reliably detects fetuses with bowel necrosis or atresia. However, there were 
only a small number of patients with combined findings and therefore continued 
investigation is required before the reliability of these markers can be fully known.  
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8.3.6 Conclusion 
Prediction of gastroschisis infant outcomes is unreliable when considering IABD or 
EABD as independent antenatal markers. As such, fetal intervention based solely on 
IABD or EABD is not warranted due the lack of difference in size of bowel 
dilatation diameter between simple and complex gastroschisis, lack of association 
between bowel dilatation and infant outcomes (ENT and LOS) and the failure to 
reliably detect fetuses with impending closing gastroschisis, necrosis or atresia. In 
this cohort, more accurate predictors of poor outcomes were the presence of 
combined dilatation or IABD and collapsed extra-abdominal bowel before 30 weeks 
GA. Although antenatal markers may potentially enable identification of 
gastroschisis fetuses with poorer infant outcomes, these ultrasound signs possibly 
occur after the bowel damage has already developed. However, it might still be 
prudent to consider fetal intervention for such fetuses with the aim to salvage bowel 
or reduce the extent of bowel damage. Further research is required to identify more 
reliable antenatal markers that predict infant outcomes, detect fetuses that would 
benefit from antenatal intervention or detect bowel damage before it happens.    
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Chapter 9: Summary, Discussion and Concluding 
Remarks 
9.1 Discussion  
9.1.1 Gastroschisis Bowel Wall Morphology 
The current literature suggests that the most likely cause of GRID is deficiency and 
immaturity of bowel wall ICC secondary to bowel wall inflammation based on 
previous animal (Krebs et al., 2014, Vargun et al., 2007, Danzer et al., 2010, Auber 
et al., 2013, Midrio et al., 2004) and human studies (Midrio et al., 2008, Zani-
Ruttenstock et al., 2015, Morrison et al., 1998). This hypothesis formed the primary 
line of investigation for the work leading up to this thesis.  
Analysis of gastroschisis bowel wall ICC using human pathological gut tissue 
showed no differences in the number or cell architecture of ICC at the level of the 
myenteric plexus between gastroschisis and control bowel. Furthermore, this study 
found no association between the number of ICC and duration of GRID measured as 
ENT. Additionally, there was no difference in the number or architecture of enteric 
neurons between gastroschisis and control bowel. Thus, the data in this thesis 
contradict the current literature and suggests that deficiency and immaturity of ICC 
may not be the primary cause of GRID.  It is important to note that this study only 
included bowel specimens from gastroschisis infants with the worst postnatal 
outcomes and therefore if deficient, immature ICC were the cause of GRID it should 
have been evident from this study.  
The ACLP knockout mouse model study using whole mount gut tissue revealed 
untreated AWD fetuses to have an 11% reduction in ICC numbers compared to 
untreated controls. However, this was in stark contrast to the original published study 
using cross-sectioned gut tissue, which reported AWD fetuses to exhibit a 70% 
reduction in bowel ICC compared to controls (Danzer et al., 2010). Furthermore 
Danzer et al. reported the AWD bowel ICC to be architecturally immature and 
enteric neurons to be absent. However, the results presented in this thesis revealed 
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the untreated AWD bowel ICC to be architecturally normal with no difference in 
enteric neuron number or architecture between untreated AWD and untreated control 
bowel. It is not possible to know if the reduced number of ICC in the AWD fetuses 
was due to ACLP deficiency or exposure to the exocoelomic fluid.  
The ICC data presented in this thesis highlights methodological issues of previously 
published studies including; inaccurate phenotyping of abdominal wall defects in 
genetic mouse models, the unreliability of quantification and architectural 
assessment of ICC from cross-sectioned small animal gut tissue and the imprecise 
nature of semi-quantitative methods for the comparison of gastroschisis and control 
bowel in both human and animal studies. 
The results presented in this thesis suggest that deficiency and immaturity of bowel 
wall ICC is not the primary cause of GRID. However, the detailed morphological 
analysis of human pathological gut tissue revealed another possibility for the cause 
of GRID, i.e. that of increased bowel wall thickness, which is in keeping with the 
findings of a number of previous animal studies (Api et al., 2001, Correia-Pinto et 
al., 2002, Langer et al., 1989, Srinathan et al., 1995). The increased bowel wall 
thickening was found to be due to thickening of the outer bowel wall layers (serosa 
and muscularis externa) but sparing of the inner bowel wall layers (submucosa and 
mucosa). Of particular note the muscularis externa was found to be hyperplastic with 
deficiency of α-SMA within the outer longitudinal smooth muscle layer. Further, 
analysis of clinical data revealed increasing bowel wall thickness to be associated 
with prolonged GRID (measured as ENT). Together, these findings suggest that 
GRID may be caused by smooth muscle remodelling resulting in cell hyperplasia and 
possible bowel wall myopathy. However, bowel wall thickening was not present in 
AWD fetuses of the ACLP knockout mouse model, which is in keeping with the 
results reported by Danzer et al. This may be due to the externalised bowel being 
exposed to the exocoelomic fluid (an ultra-filtrate of the maternal serum) instead of 
the irritant amniotic fluid.  Table 9-1 summarises the previously held dogmas within 
the gastroschisis literature of bowel wall changes that may be the cause of GRID 
compared to the findings presented in this thesis.  
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Dogma within the Gastroschisis 
Literature  
Gastroschisis Findings 
Presented in this Thesis 
Animal 
Bowel wall ICC: 
-Immature architecture 
-Reduced numbers - 70% 
reduction of AWD ICC in ACLP 
model 
Bowel wall ICC: 
-Normal architecture 
- Slight reduction - 11% reduction 
of AWD ICC in ACLP model)  
Bowel wall enteric neurons: 
-Absent in AWD fetuses of ACLP 
model 
Bowel wall enteric neurons: 
-Normal architecture and numbers 
in AWD fetuses of ACLP model 
Bowel wall morphology: 
-Thickened bowel wall (not 
reported in ACLP model) 
Bowel wall morphology: 
-No bowel wall thickening in 
ACLP model 
Human 
Bowel wall ICC: 
-Immature architecture 
-Reduced numbers 
Bowel wall ICC: 
-Normal architecture 
-Normal numbers  
Bowel wall morphology: 
-Bowel appears grossly thickened 
at birth (no histological data) 
Bowel wall morphology: 
-Histological analysis shows 
bowel wall thickening involving 
serosa and muscularis externa 
-Muscularis externa hyperplastic 
-α-smooth muscle actin deficiency 
-Increased bowel wall thickening 
associated with prolonged ENT 
Table 9-1: Summary of the previously held dogmas within the gastroschisis literature of 
bowel wall changes that may be the cause of GRID compared to the findings presented in 
this thesis 
9.1.2 Impact of Inflammatory Modulation on Gastroschisis Bowel Wall 
Morphology 
Previous studies have shown that inflammation causes disruption to bowel wall ICC 
networks (Der et al., 2000, Wang et al., 2005) and thickening of the muscularis 
externa (Bettini et al., 2003, Blennerhassett et al., 1992). In-utero injection of IL-8, a 
pro-inflammatory cytokine, in the ACLP knockout mouse model resulted in 
  
310 
 
increased IL-8 exposure to the bowel serosal surface of AWD fetuses and the bowel 
mucosal surface of control fetuses. Results showed that bowel wall thickness was 
unaffected by IL-8 exposure in both groups, which could be due to the duration of 
IL-8 exposure being shorter than the time required for smooth muscle remodelling to 
occur. However, IL-8 exposure resulted in decreased ICC numbers without 
disrupting cell architecture which was most pronounced in the control group. This 
suggests that mucosal exposure to IL-8 has a greater negative impact on the 
myenteric ICC network than serosal exposure and morphological bowel wall changes 
in gastroschisis may occur from an additive effect of serosal and mucosal exposure to 
the pro-inflammatory amniotic fluid environment (Morrison et al., 1998). There was 
also a trend of reduced bowel contractility with increasing fetal manipulation. These 
results showed that IL-8 exposed bowel was more dysfunctional than the untreated 
counter-parts suggesting that bowel inflammation impairs intestinal motility.  
9.1.3 Impact of Clinical Antenatal Interventions on Infant Outcomes 
It has been hypothesised that prolonged serosal exposure to amniotic fluid negatively 
impacts bowel development (Morrison et al., 1998, Api et al., 2001) and that early 
delivery of gastroschisis pregnancies would improve bowel function and reduce the 
duration of GRID (Gelas et al., 2008, Serra et al., 2008, Moore et al., 1999, Moir et 
al., 2004). However, the International multi-centre retrospective cohort study 
presented in this thesis showed that although earlier delivery marginally reduced the 
corrected GA at time of ENT this did not translate into a faster time to achieve ENT 
and resulted in a prolonged hospital stay and increased risk of sepsis. Therefore, 
elective delivery at <37 weeks GA is not supported by these data as a strategy to 
improve infant outcomes. This conclusion is in keeping with several other published 
studies (Maramreddy et al., 2009, Youssef et al., 2015, Cain et al., 2014, Logghe et 
al., 2005, Charlesworth et al., 2007) (Table 9-2).  
Previous studies investigating antenatal administration of corticosteroids in surgical 
animal models of gastroschisis have shown a beneficial effect on bowel wall 
morphology and protein content (Guo et al., 1995, Yu et al., 2004, Bittencourt et al., 
2006). Antenatal corticosteroids could therefore have the potential to beneficially 
remodel the abnormal bowel wall of gastroschisis fetuses. However, the results of the 
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large International multi-centre retrospective study found no association between the 
administration of maternal antenatal corticosteroids and improved infant outcomes 
following multiple analysis strategies. Although results showed no positive benefit of 
maternal antenatal corticosteroids on infant outcomes, this may reflect the late 
administration of the corticosteroid or the need for repeated doses during pregnancy 
for a beneficial effect on bowel function to be apparent (Table 9-2). 
The ability to antenatally predict postnatal outcomes would aid the antenatal 
management of gastroschisis pregnancies. Antenatally detected bowel dilatation has 
previously been shown to be associated with complex gastroschisis (Huh et al., 2010, 
Houben et al., 2009, Ghionzoli et al., 2012, Nick et al., 2006, D'Antonio et al., 2015, 
Goetzinger et al., 2014, Contro et al., 2010) and hypothesised in simple gastroschisis 
fetuses to be associated with poorer intestinal function (Langer et al., 1993). The 
multi-centre retrospective study showed that although the absence of IABD or EABD 
is suggestive of simple gastroschisis the presence of either IABD or EABD is poorly 
predictive of complex gastroschisis and is not associated with prolonged ENT or 
LOS. However, the presence of combined IABD and EABD or IABD and collapsed 
extra-abdominal bowel before 30 weeks, although a rare finding, was highly 
predictive of complex gastroschisis. Therefore, overall antenatally detected bowel 
dilatation is a poor predictor of infant outcomes and could not be reliably used to 
identify fetuses that would benefit from antenatal intervention (Table 9-2).  
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 Dogma within the 
Gastroschisis Literature  
Gastroschisis Findings 
Presented in this Thesis 
Timing of delivery 
-Elective early delivery in 
the early preterm period 
improves infant outcomes  
-Earlier delivery associated 
with worse infant outcomes 
(ENT, LOS and sepsis) 
Antenatal maternal 
corticosteroids 
administration 
-In animals corticosteroids 
associated with improved 
bowel wall morphology and 
function 
-A small human study 
suggested corticosteroids 
may improve infant 
outcomes 
-No improvement in infant 
outcomes demonstrated 
from retrospective cohort 
study 
Antenatally 
detected bowel 
dilatation 
IABD predictive of: 
-Complex gastroschisis 
-Poorer infant outcomes 
EABD not predictive of: 
-Complex gastroschisis 
-Poorer infant outcomes 
(ENT and LOS) 
 
 
Absence of either IABD or 
EABD: 
-Suggestive of simple 
gastroschisis 
Presence of either IABD 
or EABD:  
-Poor predictor of complex 
gastroschisis 
-Not associated with 
prolonged ENT and LOS 
Combined IABD/EABD 
or IABD/collapsed extra-
abdominal bowel: 
-Highly predictive of 
complex gastroschisis 
Table 9-2: Summary of the previously held dogmas within the gastroschisis literature of 
timing of delivery, antenatal corticosteroid administration and predictive value of antenatally 
detected bowel dilatation compared to the findings presented in this thesis.  
9.1.4 Other Findings 
Animal models should closely reflect, structurally and functionally, the human 
disease (Klocke et al., 2007) in order to avoid the generation of misleading data and 
inaccurate conclusions (Chu et al., 2002, Klocke et al., 2007). Prior to starting this 
research two genetic mouse models of gastroschisis were described in the literature; 
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the Scribble knockout mouse model (Murdoch, 2003, Hartleben et al., 2012, Pearson 
et al., 2011) and the ACLP knockout mouse model (Layne et al., 2001, Danzer et al., 
2010). However, neither of these models had a detailed phenotypic description of the 
abdominal wall defect. A third model, the Alx-4 mutant mouse model, had previously 
been reported as having gastroschisis (Qu et al., 1997) but was later re-characterised 
as exomphalos (Matsumaru et al., 2011). Therefore, based on these published 
studies, detailed investigations of the abdominal wall defect and amniotic membrane 
anatomy was performed in both the Scribble and ACLP knockout mouse models. 
Detailed phenotyping of the Scribble knockout mouse model revealed AWD fetuses 
to have fine a membrane (intact or ruptured) covering the externalised viscera in 
keeping with an exomphalos. On the other hand, AWD fetuses of the ACLP 
knockout mouse model were found to have, as well as failed abdominal wall closure, 
failed umbilical cord formation whereby the amniotic membrane failed to adhere to 
the umbilical vessels and attached directly to the abdominal wall defect edge 
resulting in the externalised viscera lying within the exocoelomic fluid. The anatomy 
of this defect has never before been described in humans. However, if normal cord 
formation had occurred then the externalised viscera would have a membrane 
covering and the phenotype would be that of exomphalos. Given these results there 
are now no known genetic murine models of gastroschisis (Table 9-3).  
 Dogma within the 
Gastroschisis Literature  
Gastroschisis Findings 
Presented in this Thesis 
Scribble knockout 
mouse model 
Gastroschisis phenotype  Exomphalos phenotype 
ACLP Gastroschisis phenotype -Abdominal wall defect + 
failed umbilical cord 
formation 
-Externalised gut free 
floating in exocoelomic 
fluid  
-Not gastroschisis  
Table 9-3: Summary of the previously held dogmas within the gastroschisis literature of 
genetic gastroschisis mouse models compared to the findings presented in this thesis 
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9.2 Future Research 
The research presented in this thesis suggests that ICC defects may have less of a 
role in the cause of GRID than originally expected. However, bowel wall thickening 
and myopathy of the muscularis externa may be significant factors causing intestinal 
dysfunction. Further research is required to unravel the mechanisms underlying 
bowel wall thickening and smooth muscle remodeling, which might only be possible 
in an animal model due to the obvious difficulties in obtaining human gastroschisis 
gut tissue of an appropriate gestational age.  
The phenotypic analyses of the Scribble and ACLP knockout mouse models suggest 
that genetic murine models are of limited value in gastroschisis research. As such, if 
further animal research is to be carried out then an appropriate surgical model could 
be used. Given the high risk of fetal loss in the surgical rat model (Auber et al., 2013, 
Hakguder et al., 2011) and risk of operative induced inflammation, it would be of 
benefit to use a large animal model with a lower risk of fetal loss (Oyachi et al., 
2004, Krebs et al., 2014) and a longer gestational period reducing the impact of 
surgical induced inflammation on bowel development. Bowel wall thickening 
including the serosa and muscularis externa has previously been demonstrated both 
in the rabbit (Santos et al., 2003) and sheep (Krebs et al., 2014, Srinathan et al., 
1995) surgical models of gastroschisis making these models ideal for further 
gastroschisis research. However, the research design would need to take into 
consideration the expense of using large animals and the longer pregnancy duration. 
Key features of the gastroschisis bowel wall thickening found on analysis of the 
human pathological gut tissue included sparing of the inner bowel wall layers, 
hyperplasia of the muscularis externa and deficiency of α-SMA within the outer 
longitudinal smooth muscle layer. As previously discussed in chapter 6 of this thesis 
the trigger for deranged bowel wall morphology is likely external to the bowel wall 
and may include inflammation, reduced Hippo pathway signalling or growth factors. 
Further research investigating these possible triggers may help identify an antenatal 
therapy for the improvement of GRID. 
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9.2.1 Modulation of Inflammation 
The impact of inflammation on exposed bowel can be investigated through in-utero 
modulations of the amniotic fluid environment. In this thesis in-utero injection of the 
pro-inflammatory cytokine IL-8 was used to promote inflammation but further 
inflammatory modulations were not possible due to significant unforeseen 
experimental delays. However, investigations into the impact of inflammatory 
amelioration could be achieved using corticosteroids and/or amniotic fluid stem cells.  
Corticosteroids are well known for their potent anti-inflammatory action, which may 
have beneficial remodelling effects on the smooth muscle of the muscularis externa. 
Corticosteroids may also have a beneficial maturational effect on bowel motility 
(Morriss et al., 1986). Although the multi-centre retrospective study showed no 
association of administration of maternal antenatal corticosteroids on infant 
outcomes, the use of antenatal corticosteroids may still be beneficial in gastroschisis 
if optimisation of corticosteroid delivery and dosage could be achieved. 
Investigations in fetal animals could compare the effect of antenatal intramuscular 
maternal injection (as used in clinical practice) or direct intra-amniotic injection 
(which would enable direct serosal exposure to corticosteroid) on bowel wall 
morphology and motility. Additionally, varying dosages and number of injections 
could be performed to ascertain a dose-response curve based on recovery of bowel 
wall morphological changes and motility.  
Stem cell therapy has been investigated for the management of other inflammatory 
gastrointestinal conditions including inflammatory bowel disease (IBD) (Bamba et 
al., 2006, Legaki et al., 2016, Cassinotti et al., 2008, Ricart, 2012), graft versus host 
disease (Okamoto et al., 2002) and necrotising enterocolitis (NEC) (Zani et al., 2014) 
in which multifactorial therapeutic benefits have been found including anti-
inflammatory, immunomodulatory and tissue regenerative capabilities (Eaton et al., 
2013, Zani et al., 2014). Additionally, stem cells administered systemically in the 
form of a bone marrow transplant in humans (Okamoto et al., 2002) or topically into 
the intraperitoneal cavity in rats (Ghionzoli et al., 2010) has revealed that stem cells 
migrate and integrate into the bowel wall particularly homing to areas of intestinal 
injury (Zani et al., 2014, Srivastava et al., 2007). Therefore, stem cells have the 
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potential in gastroschisis to target dysfunctional bowel, reduce bowel wall 
inflammation and induce remodelling of abnormal smooth muscle providing a 
targeted therapy for GRID. Also, due to the integration of stem cells into the bowel 
wall the therapeutic effect could be long acting and therefore potentially only require 
a one off antenatal treatment. Stem cells could have significant benefits over a 
therapy such as antenatal corticosteroids, given that corticosteroids would have a 
systemic, not just local bowel effect, and are short acting therefore potentially 
requiring multiple injections in order to have a sustained and beneficial effect.  
The options for gastroschisis antenatal stem cell therapy could include intra-amniotic 
injection of (i) autologous amniotic fluid stem cells (harvested by amniocentesis at 
approximately 15 weeks gestation) (De Coppi et al., 2007), (ii) allogenic stem cells 
(amniotic fluid stem cells or mesenchymal stem cells derived from bone marrow) but 
only if administered early enough in gestation when the fetus is still immunologically 
immature (Loukogeorgakis and Flake, 2014), and (iii) conditioned medium 
(containing the secreted factors from stem cell culture) also known as cell free 
therapy  which would exert a paracrine effect on the bowel (Legaki et al., 2016). 
Animal investigations could involve intra-amniotic injections of labelled amniotic 
fluid stem cells, conditioned medium from amniotic fluid stem cells, labelled 
mesenchymal stem cells and conditioned medium from mesenchymal stem cells. 
Labelled stem cells would enable the assessment of stem cell integration and location 
of homing within the bowel. The experimental use of conditioned medium would 
determine whether the therapeutic effect of stem cell therapy was contingent on cell 
integration or could be achieved by a paracrine effect alone. 
9.2.2  Regulation of the Hippo Pathway 
The Hippo pathway closely regulates organ size during fetal development and is 
contingent on external mechanical pressure regulating molecular feedback through 
the YAP-TAZ pathway, which influences nuclear cues that prevent tissue 
overgrowth (Dupont et al., 2011, Low et al., 2014). During normal organogenesis the 
bowel is contained within the abdominal cavity which exerts an external mechanical 
pressure stimulating the YAP-TAZ pathway. However, in gastroschisis the bowel is 
free floating within the relatively large amniotic fluid cavity, which potentially exerts 
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a lower external mechanical pressure thus reducing YAP-TAZ activation resulting in 
smooth muscle hyperplasia of the muscularis externa. The effect of external 
mechanical pressure on bowel wall morphology and bowel wall nuclear YAP levels 
(Grijalva et al., 2014) could be investigated within a gastroschisis surgical large 
animal model whereby the externalised bowel could be surgically covered with 
varying sizes of membrane thus exerting differing degrees of external mechanical 
pressure. Given varying amounts of bowel may be externalised in each fetus the 
ability to measure the force exerted on the bowel wall by the membrane would 
greatly improve the validity and reproducibility of the data analysis. The use of a 
permeable membrane would enable the investigation of external mechanical pressure 
on the bowel whilst the serosal surface of the bowel remains in contact with the 
amniotic fluid thus enabling the investigation of only one variable at time.  
9.2.3 Growth Factors 
Growth factors are essential for fetal development and are ubiquitous in the amniotic 
fluid originating from the amniotic membranes (Underwood et al., 2005). The effect 
of mucosal bowel exposure to growth factors during fetal development has 
previously been investigated by ligation of the fetal rabbit oesophagus to prevent 
amniotic fluid swallowing followed by injection of amniotic fluid distal to the 
ligation (Mulvihill et al., 1986). A similar experimental design within a gastroschisis 
surgical large animal model could be coverage of the bowel with an impermeable 
membrane followed by injection of specific growth factors into the space between 
the bowel and the membrane. The difficulties with this experimental design are; the 
creation of a water tight seal may not be possible, the membrane coverage will also 
exclude all other amniotic fluid contents, and the pressure of the membrane on the 
bowel wall may also increase YAP-TAZ signalling resulting in a multi-factorial 
change that may be difficult to interrupt. Alternatively, intra-amniotic injection of a 
growth factor inhibitor or increased concentration of a growth factor could be 
undertaken but may have other systemic effects on the fetus, which could indirectly 
affect the development of the bowel. As such, investigating the effect of growth 
factors on bowel wall development may be challenging.  
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9.2.4 Prospective Cohort Study 
Although it is not possible to investigate the impact of potential triggers on bowel 
wall development in humans, other minimally-invasive research may be of benefit in 
understanding the pathophysiological cause of GRID and help develop reliable 
predictors of infant outcomes.  A large scale, multi-centre, prospective cohort study 
would be required in order to obtain enough data to accurately correlate potential 
biomarkers with prognosis and possibly uncover a therapeutic target for GRID. Such 
a study would ideally involve clinical data collection and collection of samples (such 
as amniotic fluid, blood and stool) both in the antenatal and postnatal period. The 
aim of the study would be to standardise obstetric monitoring, optimise antenatal and 
postnatal management and provide further insight into the pathophysiological cause 
of GRID.  
Antenatally a standardised study protocol would be required to ensure uniformity and 
reproducibility of antenatal ultrasound measurements such as bowel diameter, bowel 
wall thickness, stomach diameter, stomach position, amniotic fluid volume and fetal 
growth and Doppler assessment of umbilical cord and mesenteric perfusion. Clinical 
data such as maternal complications, administration of maternal antenatal 
corticosteroids, onset of labour, gestational age at delivery, mode of delivery and 
location of delivery would be essential. Collection of amniotic fluid, maternal blood 
and at birth fetal cord blood would provide a unique opportunity to perform 
biomarker discovery, identify trends between potential biomarkers and correlate 
markers with infant outcome data.  
Postnatally standardised outcome endpoints would be required to robustly define 
surrogate markers of gut function such as ENT and LOS. All infant outcome 
variables should be documented such as concomitant bowel pathology at birth, defect 
closure method, timing of defect closure, initiation of enteral feeds, duration of 
parenteral nutrition, number of operations, episodes of sepsis, bowel resection, 
mortality, etc. A photograph at birth would provide documented evidence of bowel 
appearance at birth and ultrasound could be used postnatally to measure bowel wall 
thickness. The collection of stool from gastroschisis and carefully selected control 
infants could provide invaluable insight into the ongoing role of bowel inflammation 
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and the impact of the bowel microbiome composition on GRID. Faecal calprotectin 
is being routinely measured to distinguish between inflammatory bowel disease and 
non-inflammatory bowel diseases in older children and adults (NICE, 2013). 
Therefore, the analysis of faecal calprotectin from stool collected from gastroschisis 
and control infants at regular intervals throughout their hospital admission could 
provide insight into whether ongoing bowel inflammation affects infant outcomes. 
Additionally, the microbiome plays an essential role in health influencing 
metabolism, nutrition and immune function and alteration to the microbiome 
population has been linked to several conditions including inflammatory bowel 
disease, irritable bowel disease, obesity, diabetes mellitus, neuropsychological 
conditions and allergies (Jandhyala et al., 2015). The microbiome begins to colonize 
the gut in-utero and alterations in the microbiota composition have been found in 
neonates that are delivered by caesarean section, premature or develop NEC 
(Torrazza and Neu, 2013, Slattery et al., 2016) and in animal studies the composition 
of the microbiome has been found to influence gut motility (Dey et al., 2015). As 
such, dysbiosis of the microbiome in gastroschisis infants may influence GRID and 
be associated with prolonged ENT and LOS.  
9.3 Concluding Statement 
The incidence of gastroschisis is increasing (Kilby, 2006) and although the advent of 
PN and improved surgical techniques have reduced the mortality rate from 90% to 3-
10% of live born gastroschisis neonates (Bradnock et al., 2011, McClellan et al., 
2011, Kassa and Lilja, 2011, Skarsgard et al., 2008) no improvements have been 
made in reducing the severity and duration of GRID. The most popular theory in the 
literature for the cause of GRID is deficiency and immaturity of ICC. However, the 
research presented in this thesis suggests that ICC may be less significant in the 
development of GRID than originally thought. Analysis of human pathological gut 
tissue suggests that bowel wall thickening with an element of smooth muscle 
myopathy may be another possibility for the cause of GRID. There are several 
hypothesised triggers for bowel wall thickening, all of which require further research 
in order to fully understand the pathophysiological basis of GRID. With this 
knowledge, it may be possible to develop targeted antenatal therapies that could 
improve postnatal outcomes for infants with gastroschisis.  
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